LEUKAEMIA & MYELOMA RESEARCH UK LTD

England & Wales · Charity number 1161622

Details

Status	Registered
Legal form	Charitable company
Company number	09481278
Registered	2015-05-12
Register	View on the Charity Commission register

Contact

Address	Unit 127 North Mersey Business Centre Woodward Road Knowsley Industrial Park Liverpool L33 7UY
Phone	08003687309
Email	info@leukaemiamyelomaresearchuk.org
Website	www.leukaemiamyelomaresearchuk.org

Activities

Objects: FOR THE BENEFIT OF THE PUBLIC TO PROTECT AND PROMOTE THE HEALTH OF THE PUBLIC IN PARTICULAR BY RESEARCH INTO THE NATURE, CAUSES, DIAGNOSIS, PREVENTION, TREATMENT AND CURE OF LEUKAEMIA & MYELOMA, INCLUDING THE DEVELOPMENT OF RESEARCH INTO PRACTICAL APPLICATIONS FOR THE PREVENTION, TREATMENT AND CURE OF LEUKAEMIA & MYELOMA AND TO PROVIDE INFORMATION AND RAISE PUBLIC UNDERSTANDING OF SUCH MATTERS.

Activities: Cord blood banking service.Sponsors of Research.

Downloaded from opencharities.uk/ew/1161622

Classification

- **How:** Sponsors Or Undertakes Research
- **What:** The Advancement Of Health Or Saving Of Lives
- **Who:** The General Public/mankind

Geography

- **Area of benefit:** NATIONALLY - ENGLAND, WALES AND SCOTLAND
- Scotland
- Throughout England And Wales

Finances

Period end	Income	Expenditure	Assets	Employees
2025-03-31	£553,937	£700,801	£243,340	4
2024-03-31	£360,331	£322,448	-	-
2023-03-31	£245,256	£209,782	-	-
2022-03-31	£206,609	£176,050	-	-
2021-03-31	£188,304	£138,386	-	-

Trustees

Name	Role	Appointed
SERGEJS VINOGRADOVS	Chair	2015-03-10
Julija Sidorika		2016-05-16
TATJANA VINOGRADOVA		2015-03-10
Victoria Kieran		2017-02-07

Downloaded from opencharities.uk/ew/1161622

LEUKAEMIA & MYELOMA RESEARCH UK LTD

England & Wales - Charity number 1161622

Accounts

Leukaemia & Myeloma Research UK

Together we can beat cancer

Annual Report 2024-25

Table of contents

About Us 3

Stem Cells 4

Charitable Activities..... 5

Chairman's Report 6

Operation Director's Report 7

MCB Service..... 9

Overview 9

Donate Clothes to Sammy 11

Research Priorities..... 12

Fundraising and Volunteers..... 13

Thanks..... 14

Trustees and Staff 14

Accounts 15



About Us

Leukaemia & Myeloma Research UK Ltd aims to prevent deaths from blood cancer through more effective treatments in the future. We are willing to fight blood cancer regardless of how long it might take.

Founded in 2015, our mission is to prevent people dying from blood cancer through prevention, research and more effective treatment.

Unfortunately, blood cancer affects a large number of people. Every 13 minutes, someone in the UK is told they have a blood cancer. That's around 110 people per day, 40,000 people per year. There are an estimated 4,700 leukaemia deaths every year, that's 13 every day!

We are aiming to become the UK's leading charity in supporting efforts to combat the three major types of blood cancer. The work we do helps fund vital stem cell research, raises awareness of stem cell therapies and helps families protect their children's future health by storing their cord blood stem cells at the time of birth.

There are 3 main types of cancers of the blood; they are lymphoma, leukaemia and myeloma.

The blood is made up of three different types of cells:

- Red blood cells which carry the oxygen around the body
- White blood cells which fight and stop infections
- Platelets which help the blood to clot

The course of treatment given will depend on the type of cancer. The most common treatments are chemotherapy, radiotherapy and in some instances, a stem cell transplant.

Leukaemia and Myeloma Research UK Ltd want to eradicate blood cancer once and for all. One of the ways we are aiming to achieve this is through advancing our understanding of stem cells and how we can use them to treat patients with blood cancer, particularly through stem cell transplants. We do this by:

- Actively supporting stem cell research into blood cancers
- Raising awareness of stem cell therapies
- Provide information about blood cancers and treatment options
- Protecting the vulnerable by offering qualifying expectant mothers, with a family history of cancer, the opportunity to store their baby's umbilical cord blood stem cells at the time of birth, in case they are needed in the future to treat that child or another member of the family if they are a suitable match.

This service is called Model Cell Biobank (MCB).

Stem Cells

In humans, there are two types of stem cells: embryonic stem cells and adult stem cells, which are found in various tissues.

Adult stem cells are the primary focus of the research that the Charity supports. They typically generate the cell types of the tissue in which they reside.

For example, a blood-forming adult stem cell in the bone marrow normally gives rise to the many types of blood cells. It is generally accepted that a blood-forming cell in the bone marrow—which is called a hematopoietic stem cell— cannot give rise to the cells of a very different tissue, such as nerve cells in the brain.

Where are stem cells found?

There are four known accessible sources of autologous adult stem cells in humans:

- Bone marrow which requires harvesting by drilling into bone (typically the femur or iliac crest). This is done under a general anesthetic.
- Blood, which requires extraction through apheresis, wherein blood is drawn from the donor (similar to a blood donation), and passed through a machine that extracts the stem cells and then returns the blood to the donor.
- Adipose tissue (lipid cells), which requires extraction by liposuction.

- Umbilical cord blood - these stem cells can be collected from the umbilical cord blood just after birth.

What can stem cells be used for today?

There are treatments where Hematopoietic Stem Cell Transplants (HSCT) - the transplantation of blood forming stem cells - is a standard treatment. For some diseases they are the only therapy, and in other diseases they are only employed when front-line therapies have failed or the disease is very aggressive.

There are other blood disorders that can be treated with stem cells that aren't cancers, such as sickle cell anaemia and aplastic anaemia.

For most types of blood cancers, for example: leukaemia, lymphoma and various anaemia's, the treatments use allogeneic stem cell transplants (someone else's stem cells). The reason for this is that the person may have a genetic predisposition to the disease; their genes have a defect that predisposes them to that disease.

However there are various types of cancers (some myelomas, plasma cell leukaemia, some anaemia's and solid tumours) that are treated using autologous stem cells (using your own stem cells).

Charitable Activities

Providing Information

Throughout the year we have shared facts about blood cancer, including the signs, symptoms and treatments. This has been achieved through our regular newsletter, social media channels, website, and our blood cancer booklet. This provides patients with clear and informative advice that would answer their questions, explain terminology, discuss treatments so they are better prepared and able to make informed choices.

We produce a monthly newsletter that shines a spotlight on our inspirational fundraisers and their stories; highlights our exciting plans for the future and provides information relating to blood cancer. It is available from our website free of charge.

Medical Research

Leukaemia & Myeloma Research UK Ltd allocate research grants to those who uphold our primary objectives. These are to benefit the public, in particular by research into the nature, causes, diagnosis, prevention, treatment and cure of leukaemia and myeloma. Our current funding priorities are to advance understanding of stem cells and how they can be used to treat blood cancer patients. All grant applications are reviewed by the Charity's Research and Review Committee, an independent panel of experts. The Charity is a member of the Association of Medical Research Charities, the AMRC.

Fundraising Activities

Over the last year, the Charity expanded its textile recycling project so it now includes local schools and nurseries based in the Merseyside and Greater Manchester areas. This is with the aim of raising awareness of both blood cancer and of the environmental benefits of recycling. It also continues to raise valuable funds for the charities work.

In conjunction with this, our fundraisers have been busy from running marathons, to organising golf days and completing sponsored bike rides. This has secured an amazing £88,766 of funding to support our services and help in the fight against cancer.

Model Cell Biobank Service

This service was established to support families who are on low income, have a history of cancer in the family, to store their babies cord blood stem cells at the time of birth. These cells are stored for 25 years in case that child, or another member of the family, needs them in the future to treat a disease.

The cord blood stem cells can be used today instead of bone marrow stem cells to treat blood cancer and genetic disorders. In fact, recent studies show that over 80 diseases could be treated using cord blood stem cells.

Chairman's Report



We started this busy year by participating in Acute Myeloid Leukaemia Awareness day, raising awareness about this rare form of cancer and the symptoms and treatments. We have also actively taken part in national awareness days including, Blood Cancer Awareness Month in September, World Cord Blood Day in November, and Myeloma Awareness Month in March. We have shared key facts and statistics, as well as stories from people directly impacted by blood cancer.

Our biggest awareness campaign is Blood Cancer Awareness Month in September. This year we produced a video sharing information about blood cancer to educate the charity's audience. We also shared 2 blood cancer patients stories highlighting the symptoms they first experienced, their diagnosis treatment and support they received.
In July, our Research Review Committee met and awarded grants for 2 research projects, one investigating why some patients relapse after chemotherapy and the other looking at improving the efficiency of treatment for blood cancers.

The Charity funded research in 2022 that has now led to a five-year Wellcome Postdoctoral Fellowship. The funding allows the researchers at the University of Oxford to continue the work and widen its investigations, with the potential to assist patients with other forms of cancer as well as AML. We are very proud to have been able to fund the initial work and to know that the continued work may have the potential to assist patients with other forms of cancer as well as AML.

At the beginning of April 2024 we launched the Sammy Project which aims to raise funds and awareness of our work whilst giving a second life to preloved clothing donated by the community. We have been working with schools, nurseries, dance schools and Scouts across the North West.

In 2025 the Charity turned 10. It has been fantastic to be able to review and reflect on the work that we have done as a Charity over the past 10 years. None of the work would be possible without the staff, volunteers and our incredible fundraisers. I would like to say a huge thank you to each and every one of them. Without them, we couldn't continue to offer the services that we do and fight blood cancer.

Sergejs Vinogradovs
Chair, Leukaemia and Myeloma Research UK Ltd

Operation Director's Report

Each year we receive fantastic support from our wonderful fundraisers. Around of 33% of the charity's funding comes from individual donations and fundraising events, highlighting the reliance on the generosity of supporters. From marathons and golf matches to sponsored walks, there has been a variety of fantastic fundraising events to celebrate. A few highlights from the year are below.

At the beginning of the year Kevin Pluck, a keen golfer, took over the captaincy of the Kingsway Golf Centre in Cambridge, pledged to run a series of events throughout the year on behalf of LMRUK. Kevin lost both his parents to blood cancer, he explained: "I was 11 years old when my father was diagnosed and was given just months to live...when you're a child your father is your idol, so it was pretty traumatic to be told he wouldn't be around for long." Throughout the year he raised over £2,100 which is fantastic.

In May, two sisters ran the Hackney half marathon in memory of their grandad. They raised an amazing £5,000 towards our research programme.

Hairdressing salon owner Rebecca Caraccio, from Whitstable, Kent, wanted to help others affected by the disease following the death of her 52-year-old brother, Michael Ingham. She raised just over £2,000 by running a half-marathon.

Another amazing runner is Rachel Handley who ran 10k following her mother's myeloma diagnosis. Or Jacob Riley and his girlfriend Lydia Heaton, who raised more than £1,500 after completing a 10k sponsored run following a blood cancer diagnosis for Jacob's sister.

Wendy Forrest has taken part in her second Kiltwalk to raise money for our charity in memory of her husband, Alan. Wendy and five friends braved one of the hottest days of the year for the picturesque 20 mile walk from St Andrew's to Slessor Gardens, Dundee. To date they have collected at least £2,225 for LMRUK.

A couple embarked on a gruelling challenge to complete 100 miles in a month to raise money for LMRUK – after one of their parents was diagnosed with life-threatening Multiple Myeloma. Jonny Turner and Nichola Harrower from Wigan walked, ran and cycled to clock up the 100 miles all within a month during the summer and collected an impressive £1,310 in sponsorship money. "We read the fundraising stories on the website, " Nichola said. "It saddened us to learn that LMRUK does not receive any government funding and so we decided a fundraising event would be an excellent place to start."

Staff, governors and parents from a primary school in County Durham have raised over £1,000 for LMRUK with a 13-mile sponsored walk after their Deputy Head was diagnosed with leukaemia.

In November, 4 friends successfully completed a 13-mile walk in memory of a colleague who passed away from a rare type of blood cancer securing over £1,800 towards our work.

Our fundraisers of the year were announced in December, for the 2nd time the restaurant founders Elaine and Peter Kinsella won the award having raised over £23,000 in total for our Charity.

We are incredibly grateful to each and every one of fundraisers and to those who make donations to the charity in memory of loved ones. Thank you so much for your wonderful support!

Dr Joanna Tilley

Operations Director, Leukaemia and Myeloma Research UK Ltd

MCB Service

Overview

The Model Cell Biobank (MCB) service allows the storage of a child's umbilical cord blood stem cells at the time of birth, in case they or another member of the family needs them in the future to help in the treatment of a disease. It may be possible to use the stem cells to treat blood cancers or in emerging therapies to treat diseases such as diabetes, cerebral palsy and Parkinson's disease. Clinical trials are being performed all over the world looking at the potential use of stem cells to treat new diseases and hopefully further breakthroughs.

When a baby is born and the umbilical cord is cut, the placenta and umbilical cord are normally thrown away. The blood that remains in the cord and the placenta contains stem cells. The Charity offers a service to collect these stem cells without any risk to the mother and baby, and to store them in case that child or another member of the family needs them in the future.

The cord blood stem cells are stored on behalf of the child for 25 years. The mother is the legal guardian of the cells until the child reaches the age of majority, at which point, ownership transfers to the child. After 25 years, the cells can be privately stored, donated for research, offered to a public bank, or destroyed. Consent from the child will be sought at this point and we would strongly encourage the donation of any remaining cells to public banks.

We now offer a fully funded cord blood banking service to families who are on universal credit, with a history of cancer in the family.

Alongside this, we also offer a part funded service to low income families.

Smart Cells Technical is our chosen partner to procure; process and store cord stem cells under its Human Tissue Authority licence. Smart Cells has a strong reputation for the high standards it applies to the storage and processing of stem cells derived from umbilical cord and peripheral blood, bone marrow, now extending to many types of tissues for human application or transplant.

Smart Cells not only works to the highest standards, it also has an ethical approach, which aligns with our charity, something we are proud of.

MODEL CELL BIOBANK
research that saves lives



Advantages of Cord Blood Stem Cells

Today, cord blood banking is changing lives and there have already been more than one million stem cell transplants around the world since the 1980s.

The stem cells in your baby's cord blood are fully developed adult stem cells, which are the building blocks of the blood immune system. These stem cells can be used instead of bone marrow stem cells to treat blood cancers and genetic disorders.

Cord blood stem cells have many advantages including:

- They are easily available, having already been harvested and stored;
- A new born baby has been exposed to fewer viruses and infections and so the stem cells are less likely to transmit infection and react with the patient;
- Cord blood stem cells offer the life-saving option of a transplant and avoids the invasive, painful and expensive procedures of other stem-cell collection, such as bone marrow;
- Cord blood stem cells can be stored for many years - the longevity of these cells has proved they are as good 30 years later as on as the day they were first extracted and stored.

Feedback from Clients

"I would really recommend storing stem cells from the umbilical cord blood to others. To use the service you have to have a history of cancer. It gives you a plan B should someone fall ill - and you never know what might happen in the future."

"Its like having a second plan in place if something should go wrong - an extra protection against ill-health. The procedure was very straight-forward and I would recommend it to others."

We didn't know anything about the procedure but having a friend die from Leukaemia and another diagnosed when I was pregnant, made me more aware and I found out about what was involved."

"I really don't know why we aren't storing babies' stem cells as a matter of course - it seems such a simple yet important thing to do."

"The team at LMRUK were so helpful and knowledgeable - they talked me through the whole process...they made the process straightforward from start to finish."

Donate Clothes to Sammy

The Sammy Project was launched in April 2024 with the aim generating additional income to support the mission and causes of LMRUK charity, and to raise awareness of our work.

The goal of the project is to raise extra funds by giving a second life to preloved clothing donated by the community via local schools, community centres, nurseries and other establishments.

Our recycling programme secures valuable funds for the charities projects fighting blood cancer and raising awareness of our work. It also promotes re-use and recycling and encourages sustainable practices.

According to The Times, British consumers spent £12.5 billion on clothing. The rising trend of “disposable” fashion has led to the dumping of 300,000 tonnes of textiles, exacerbating environmental pollution. Without significant changes in clothing production, usage, and disposal practices, projections suggest that global textile waste could reach 134 million tonnes by 2030.

Due to the success of the project in the North West, we are planning to expand our services in West Yorkshire and Shropshire areas.

We have had fantastic engagement from primary school and nurseries. The largest bag collection since the launch was from Farmworth Primary School with a total of 857kg, closely followed by Park View Primary school with 724kg, and St Bridget’s Primary school with 645kg. Thats 2.2 tonnes save from land fill!

The project is managed entirely by the charity’s team without involving commercial companies, ensuring that 100% of the proceeds go directly to the charity.

Research Priorities

Leukaemia & Myeloma Research UK Ltd offer research grants to those who uphold our primary objectives: to protect and promote the health of the public, in particular by research into the nature, causes, diagnosis, prevention, treatment and cure of leukaemia and myeloma.

The Trustees funding priorities are to advance understanding of stem cells and how they can be used to treat blood cancer patients, particularly through stem cell transplants.

In 2024-2025, to mark World Cancer Research day, LMRUK were pleased to have awarded £63,000 in grant funding to support two vital blood cancer projects.

Assistant Professor Sophie Kellaway at the University of Nottingham will be undertaking specialist research into the regrowth of cells that cause the cancer, and whether they can be neutralised with the use of two drugs already available to treat conditions to help prevent the return of blood cancers.

Professor Cristina Lo Celso and her PhD student Dr Germaine Chia of Imperial College London will be conducting a two year project that aims to improve the efficiency of treatment for blood cancers and reduce its toxicity.



Research Review Committee Members

Professor Joseph R. Slupsky: Reader in Department of Molecular and Clinical Cancer Medicine, University of Liverpool.

Dr Rhys Morgan: Lecturer in Biomedical Sciences in Department of Biochemistry & Biomedicine, at the University of Sussex.

Dr John Jones: Senior Clinical Lecturer – Brighton and Sussex Medical School, Honorary Consultant Haematologist – Kings College Hospital NHS Trust, London and Eastbourne District General Hospital.

Dr Simon Richardson: Senior Clinical Research Associate, University of Cambridge, Honorary Consultant Haematologist, Addenbrooke's Hospital.

Dr Ceri Bygrave: Consultant Haematologist and Myeloma Lead at the University Hospital of Wales and a member of the UK Myeloma Forum Executive Committee and the UK Myeloma Research Alliance.

Dr Paul Spencer Hole: Senior Research Scientist. Engaged in academic research at Cardiff University and extends his experience in a clinical-stage biopharmaceutical company.

Dr Claire Seedhouse: Associate Prof within Division of Cancer & Stem Cells & Principle Investigator & research group leader in Blood Cancer at the University of Nottingham.

Dr Sandeep Potluri: Consultant Paediatric Haematologist/Stem Cell Transplantation and Clinician-Scientist, University of Birmingham.

Fundraising and Volunteers

Founders of Lunya restaurant and deli, Elaine and Peter Kinsella have been named as our Fundraisers of the Year for their incredible work on behalf of our charity

This is the second time that the duo has been named winners of the award, after jointly receiving the title in 2022.

Elaine has been an innovator in finding new and effective ways to raise funds for our charity, enlisting the support of customers in the couple's Liverpool restaurants to contribute to the cost of research into blood cancers.

She and Peter, together with all their staff, raised £15,000 for LMRUK in 2022 by inviting customers of the Lunya and Lunyalita restaurants to add a pound to their bill every time they ate there. The initiative raised £7,500, generously matched by the couple themselves, making a total of £15,000.

The success of the scheme prompted them to keep going, adding a further £7,657 to the pot, which was presented to our charity earlier this year.

Elaine's fundraising journey began after she was diagnosed with Myeloma following a routine blood test in 2021.

She underwent initial treatment, then had a stem cell transplant in October of that year and came up with the fundraising idea while in recovery.

Elaine said: "Peter and I are really happy to have been given this recognition for raising funds for such a good cause. I am currently receiving second line treatment for Myeloma and so have personal experience of how challenging a blood cancer diagnosis can be, but I am convinced that research into developing more treatments is the best way forward – this gives me hope for the future.

"We could not have raised the money we have without the help of our wonderful customers at the two restaurants. It has been a real team effort with all our staff and very fitting in the year that our business became an Employee Owned Trust."

Dr Joanna Tilley, Operations Director at LMRUK, said that the award was in recognition of the money raised by Elaine – and the creative ways she had found to bring in funding for the charity.

She added: "Elaine is a star. Fundraising is challenging in the current economic climate with household budgets tight. To get this kind of support from Elaine, her husband, staff, and their restaurant customers is a real boost for LMRUK and we are so grateful for their efforts."

This is just one of the many fantastic fundraisers that have kindly supported LMRUK over the past year - we simply could not run these services without them!

Many thanks!

Thanks to Funders

- Dalgleish Trust
- Rainford Trust
- Ian Askew Charitable Trust
- Santa Barbara Heights
- Hilary Awdry Charitable Trust
- Stanley Grundy Foundation
- Carl Lewis Foundation
- Mackintosh Foundation
- Frank Litchfield General Charitable Trust
- The Dixie Rose Findlay Charitable Foundation
- Fort Foundationt
- Sir Donald and Lady Edna Wilson Charitable Trust
- Thomas Sivewright Catto Charitable Settlement
- Postcode neighbourhood Trust
- Stockwell Cliffe Charitable Trust
- Albert Hunt Trust
- LCVS Eli Lily and Elanco
- Awards for All
- N Smith Charitable Settlement
- The Family Rich Charities Trust
- Grace Trust
- Aviva
- John Raymond Tijou Charitable Trust
- Worcester Bosch
- Geoffrey and Pauline Martin trust
- Warburtons
- LCVS Resilience and Capacity One Knowsley
- Hospital Saturday Fund
- Stagecoach Giving
- Arnold Clark Community Fund
- M J C Stone Charitable Trust
- Co-op Community Fund
- Cecil and Hilda Lewis Charitable Trust

Staff and Trustees

Trustees 2024-2025

- Sergejs Vinogradovs (Chair)
- Tatjana Vinogradova
- Victoria Kieran
- Julija Sidorika

Staff Team

- Dr Joanna Tilley - Interim Operations Director
- Kate Williams - PT Fundraiser
- Karina Zaiceva - Department Manager
- Aleashia Marland - Office Assistant
- Richard Thompson - Call Centre

Thanks to Individuals and supporters

- Smart Cells International
- KOR Communications
- Research Review Committee
- Best Freelance Design Ltd
- Chester Handbooks
- Fundraising Support Ltd
- West Lancs & Merseyside Myeloma Support Group

Leukaemia & Myeloma Research UK

leukaemiamyelomaresearchuk.org

Registered charity number 1161622 (England & Wales), SC046106 (Scotland),
Company Limited by guarantee Registered number 09481278

ACCOUNTS 31 MARCH 2025





Leukaemia & Myeloma Research UK Ltd

Report and accounts for the year ended 31 March 2025

Contents

	Page
Charity information	1
Trustees' Annual Report	1
Statement of directors' responsibilities	5
Independent Examiner's Report	7
Funds Statements:-	
Statement of Financial Activities	9
Statement of Financial Activities - Prior Year statement	11
Movements in funds	13
Income and Expenditure account	14
Balance sheet	15
Notes to the accounts	17

Leukaemia & Myeloma Research UK Ltd

Company Registration Number - 09481278

Trustees' Annual Report for the year ended 31 March 2025

The Trustees present their Report and Accounts for the year ended 31 March 2025, which also comprises the Directors' Report required by the Companies Act 2006.

Reference and administrative details

The charity name.

The legal name of the charity is:- Leukaemia & Myeloma Research UK Ltd.

The charity is also known by its operating name, LMR UK Ltd .

The charity's areas operation and UK charitable registration.

The charity is registered in England & Wales with the Charity Commission in England & Wales (CCEW) with charity number 1161622.

The charity is also registered in Scotland, with charity number SC046106 as it has operations in Scotland.

The charity does not operate in any overseas jurisdictions.

Legal structure of the charity

The charity is constituted as a company limited by guarantee, registered under the Companies Acts . The governing document of the charity is the Memorandum and Articles of Association establishing the company under company legislation.
The governing document is dated 10 March 2015
There are no restrictions in the governing documents on the operation of the Charity or on its investment powers other than those imposed by Charity Law.

By operation of law all, trustees are directors under the Companies Act 2006 and all directors are trustees under Charities legislation and have responsibilities, as such, under both company and charity legislation.

The trustees are all individuals.

The principal operating address, telephone number, email and web addresses of the charity are:-

Unit 127, North Mersey Business Centre
Woodward Road, Liverpool
Merseyside, L33 7UY
Telephone 08003687309

Email Address info@leukaemiamyelomaresearchuk.org
Web address https://www.leukaemiamyelomaresearchuk.org/

The registered office of the charity for Companies Act purposes is the same as the operating address shown above.

Leukaemia & Myeloma Research UK Ltd

Company Registration Number - 09481278

Trustees' Annual Report for the year ended 31 March 2025

The Trustees in office on the date the report was approved were:-

Sergejs Vinogradovs
Tatjana Vinogradova

Julija Sidorika
Victoria Kieran

The following persons served as Trustees during the year ended 31 March 2025 :-

The trustees who served as a trustee in the reporting period were as shown above, and there were no changes during the year, or in the period between the year end and the approval of the accounts.

All the trustees are also members of the charity.

Objects and activities of the charity

The purposes of the charity as set out in its governing document.

The objectives of the charity are set out in the Memorandum of Association of 14 July 2015. They are:
1. to protect and promote the health of the public in particular by research into the nature, causes, diagnosis, prevention, treatment and cure of leukaemia and myeloma.
2. development of research into practical applications for the prevention. Treatment and cure leukaemia and myeloma and raise public understanding of such matters.

The main activities undertaken in relation to those purposes during the year.

Research grants are provided in order to promote the health of the public by research into the nature, cause, disnoses, preventon, treatment and cure of leukaemia and myeloma.

The main activities undertaken during the year to further the charity's purpose for the public benefit.

One research grant was provided this year totalling £39,959.58

Public awareness was a big focus this year with the charity undertaking the project of collecting clothes and selling these to raise funds.

The trustees have had regard to the Charity Commission's guidance on public benefit in managing the activities of the charity.

Leukaemia & Myeloma Research UK Ltd

Company Registration Number - 09481278

Trustees' Annual Report for the year ended 31 March 2025

The main achievements and performance of the charity during the year.

As advised, the charity have been able to provide one large grants for research purposes.

There was a large increase in awareness via the donation of clothes. More funds were in turn raised to support the charity.

The difference the charity's performance during the year has made to the beneficiaries of the charity and wider society.

The charity was able to raise more funds this year which in turn raised awareness of the disease. This has benefited the wider society with more people being aware of the effects and the importance of research to support those living with the disease.

Structure, governance and management of the charity

The methods used to recruit and appoint new charity trustees.

Proposals for new Trustees are made by the Chair after making appropriate enquiries. Appointments are then made by election by the existing board of Trustees.

The trustees' bankers and advisors

Accountants	KBH Accountants Ltd - 255 Poulton Road, Wallasey, CH44 4BT

Financial review

The charity's financial position at the end of the year ended 31 March 2025

The financial position of the charity at 31 March 2025 and comparatives for the prior period, as more fully detailed in the accounts, can be summarised as follows:-

	2025	2024
	£	£
Net income	(146,864)	37,883
Unrestricted Revenue Funds available for the general purposes of the charity	191,442	346,737
Restricted Revenue Funds	51,898	43,467
Total Restricted Funds	51,898	43,467
Total Funds	243,340	390,204

Leukaemia & Myeloma Research UK Ltd

Company Registration Number - 09481278

Trustees' Annual Report for the year ended 31 March 2025

Financial review of the position at the reporting date, 31 March 2025 .

Overall surplus stands at £243,340 and will be distributed in the following way: £150,000 for Reserves, £25,000 for Research Grants, and £68,340 for charity development, including MCB, e-shop, and the Donate Clothes 4 Sammy project.

The trustees consider the financial performance by the charity during the year to have been satisfactory.

Policies on reserves.

The trustees collectively aim to maintain free reserves in unrestricted funds within a range equivalent to twelve months of unrestricted charitable expenditure. This targeted level is deemed essential by the trustees to ensure an adequate financial cushion for covering support and governance costs. The Reserves Policy will undergo an annual review, aligning with the scrutiny of the charity's annual accounts.

In light of the events of the past year, marked by a significant surge in inflation, escalating living costs, and an increased risk of economic downturn, the trustees have determined that a prudent Reserves amount must be set at £150,000. This decision is reflective of the charity's commitment to financial resilience and its responsiveness to the evolving economic landscape.

Availability and adequacy of assets of each of the funds

The board of trustees is satisfied that the charity's assets in each fund are available and adequate to fulfil its obligations in respect of each fund.

Details of The Independent Examiner

Olivia Higgins FCCA

Member of Chartered Certified Accountants

255 Poulton Road

Wallasey

Wirral

CH44 4BT

Leukaemia & Myeloma Research UK Ltd

Company Registration Number - 09481278

Trustees' Annual Report for the year ended 31 March 2025

Statement of the Directors' and Trustees' Responsibilities

The charity's trustees are responsible for the preparation of the accounts in accordance with the terms of the Companies Act 2006, the Charities Act 2011 and the Charities (Accounts and Reports) Regulations 2008. Notwithstanding the explicit requirement in the extant statutory regulations,the Charities (Accounts and Reports) Regulations 2008, to prepare the financial statements in accordance with the SORP 2005, in view of the fact that the SORP 2005 has been withdrawn, the Trustees determined to interpret this responsibility as requiring them to follow current best practice and prepare the accounts according to the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2019, applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), .

In particular, the Companies Act 2006 and charity law require the Board of Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity as at the end of the financial year and of the surplus or deficit of the charity. In preparing those financial statements the Board is required to :-

- to prepare the accounts in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law).
- select suitable accounting policies and apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business;
- state whether applicable accounting standards and statements of recommended practice have been followed, subject to any material departures disclosed and explained in the financial statements;

The law requires that the trustees must not approve the accounts unless they are satisfied that they give a true and fair view of the state of affairs of the charity and of the surplus or deficit of the charity for the year.

The Trustees are also responsible for maintaining adequate accounting records which disclose with reasonable accuracy at any time the financial position of the charity and which are sufficient to show and explain the charity's transactions and enable them to ensure that the financial statements comply with the Companies Act 2006 and comply with regulations made under the Charities Act. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Trustees are also responsible for the contents of the Trustees' report, and the statutory responsibility of the Independent Examiner in relation to the Trustees' report is limited to examining the report and ensuring that , on the face of the report, there are no material inconsistencies with the figures disclosed in the financial statements.

Leukaemia & Myeloma Research UK Ltd

Company Registration Number - 09481278

Trustees' Annual Report for the year ended 31 March 2025

Method of preparation of accounts - Small company provisions

The financial statements are set out on pages 9 to 36.
The financial statements have been prepared implementing the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2019, applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), and in accordance with the Financial Reporting Standard 102, (effective 1st January 2016)
These financial statements have been prepared in accordance with the provisions in Part 15 of the Companies Act 2006. applicable to companies subject to the small companies regime.

This report was approved by the board of trustees on 12 December 2025.

TATJANA VINOGRADOVA
Director and Trustee

Leukaemia & Myeloma Research UK Ltd

Report of the Independent Examiner to the Trustees of the charitable company on the accounts for the year ended 31 March 2025

I report to the Trustees on my examination of the financial statements of the charitable company on pages 9 to 36 for the year ended 31 March 2025 which have been prepared in accordance with the Charities Act 2011 (the Act) and with the Financial Reporting Standard 102, (effective 1st January 2016) as modified by FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2019, applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), published by the Charity Commission in England & Wales (CCEW) , and under the historical cost convention and the accounting policies set out on page 17.

Respective responsibilities of the Trustees and the Independent Examiner and the basis of the report

As described on page 5, you, the charitable company's Trustees, who are also the Directors of the Company for the purposes of Company law, are responsible for the preparation of the financial statements in accordance with the Companies Act 2006, the Charities Act 2011 and all other applicable law and with United Kingdom Generally Accepted Accounting Practice, applicable to smaller entities, and for being satisfied that the financial statements give a true and fair view.

The Trustees consider that the audit requirement of Section 144(1) of the Charities Act 2011 (the Act) does not apply, and that there is no requirement in the memorandum and articles of the charity for the conducting of an audit, and that the accounts do not require an audit in accordance with Part 16 of the Companies Act 2006 and that no member or members have requested an audit pursuant to Section 476 of the Companies Act 2006. As a consequence, the Trustees have elected that the financial statements be subject to independent examination.

Having satisfied myself that the financial statements are not required to be audited under any legal provision, or otherwise, and are eligible for independent examination, it is my responsibility to:-

a) examine the financial statements of the charity under Section 145 of the Act;

b) follow the applicable procedures in the Directions given by the Charity Commission under section 145(5)(b) of the Act.

Basis of Independent Examiner's Statement and scope of work undertaken

Since the charitable company's gross income exceeded £250,000, the charitable company's examiner must be a member of a body listed in section 145 of the Act. I confirm that I am qualified to undertake the examination because I am an authorised member of Chartered Certified Accountants , which is one of the listed bodies.

I report in respect of my examination of the charity's financial statements carried out under s145 of the Act. In carrying out my examination, I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act setting out the duties of an independent examiner in relation to the conducting of an independent examination. An independent examination includes a review of the accounting records kept by the charitable company and of the accounting systems employed by the charitable company and a comparison of the financial statements presented with those records. It also includes consideration of any unusual items or disclosures in the financial statements, and seeking explanations from you, as Trustees, concerning such matters. The purpose of the examination is to establish as far as possible that there have been no breaches of charity legislation and that, on a test basis of evidence relevant to the amounts and disclosures made, the financial statements comply with the SORP.

The procedures undertaken do not provide all the evidence that would be required in an audit, and information supplied by the Trustees in the course of the examination is not subjected to audit tests or enquiries and does not cover all the matters that an auditor would consider in arriving at an opinion. The planning and conduct of an audit goes beyond the limited assurance that an independent examination can provide

Consequently, I do not express an audit opinion on the view given by the financial statements, and in particular, I express no opinion as to whether the financial statements give a true and fair view of the affairs of the charity, and my report is limited to the matters set out in the statement below.

I planned and performed my examination so as to satisfy myself that the objectives of the independent examination are achieved and before finalising the report I obtained written assurances from the Trustees of all material matters.

Independent Examiner's Statement, Report and Opinion

Attention is drawn to the accounting policy stating that, notwithstanding the explicit requirement in the extant statutory regulations, the Charities (Accounts and Reports) Regulations 2008, to prepare the financial statements in accordance with the SORP 2005, in view of the fact that the SORP 2005 has been withdrawn, and in order to accord with current best practice, the Trustees have determined to prepare the financial statements in accordance with the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2019, applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), . I concur with this approach, and any references in my report to the regulations should be read subject to this comment.

Subject to the limitations upon the scope of my work as detailed above, I have completed my examination: and can confirm that:-

The accounts of this charitable company are not required to be audited under Part 16 of the Companies Act 2006;

The gross income of the charitable company in the year ended 31 March 2025 appears to exceed the sum specified in Section 145(3) of the Act, namely £250000, and that I am qualified to act as Independent Examiner in accordance with that section by virtue of my being a qualified member of Chartered Certified Accountants ;

This is a report in respect of an examination carried out under 145 of the Act and in accordance with Directions given by the Charity Commission under section 145(5)(b) of the Act which may be applicable;

and that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:-

accounting records were not kept in respect of the charity as required by Section 386 of the Companies Act 2006 and Section 130 of The Charities Act 2011;

the financial statements do not accord with those records; or

the financial statements do not comply with the applicable requirements concerning the form and content of accounts set out in section 396 of the Companies Act 2006 other than any requirement that the accounts give a 'true and fair' view, which is not a matter considered as part of an independent examination;

have not been prepared in accordance with the methods and principles set out in the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2019, applicable to all accounting periods beginning on or after 1st January 2019), (The SORP).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.

Signed:- O Higgins

Olivia Higgins FCCA - Independent Examiner
Chartered Certified Accountants
255 Poulton Road
Wallasey
Wirral
CH44 4BT

This report was signed on 12/12/2025

Leukaemia & Myeloma Research UK Ltd - Statement of Financial Activities for the year ended 31 March 2025

Statement of Financial Activities (including the Income and Expenditure Account for the year ended 31 March 2025, as required by the Companies Act 2006)

	SORP Ref	Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
		2025	2025	2025	2024
		£	£	£	£
Income & Endowments from:					
Donations & Legacies	A1	164,964	55,505	**220,469**	242,837
Charitable activities	A2	279,394	-	**279,394**	63,177
Investments	A4	3,742	-	**3,742**	4,317
Other	A5	50,000	332	**50,332**	50,000
Total income	**A**	**498,100**	**55,837**	**553,937**	**360,331**
Expenditure on:					
Raising funds	B1	16,473	-	**16,473**	14,389
Charitable activities	B2	636,922	47,406	**684,328**	308,059
Total expenditure	**B**	**653,395**	**47,406**	**700,801**	**322,448**
Net income for the year		**(155,295)**	**8,431**	**(146,864)**	**37,883**
Net movement in funds		**(155,295)**	**8,431**	**(146,864)**	**37,883**
Total funds brought forward		346,737	43,467	**390,204**	352,321
Total funds carried forward		**191,442**	**51,898**	**243,340**	**390,204**

The 'SORP Ref' indicated above is the classification of income set out in the formal SORP documents. As required by paragraph 4.60 of the SORP, the brought forward and carried forward funds above have been agreed to the Balance Sheet.

A separate Statement of Total Recognised Gains and Losses is not required as this statement includes all recognised gains and losses.

All activities derive from continuing operations

The notes attached on pages 17 to 36 form an integral part of these accounts.

Leukaemia & Myeloma Research UK Ltd - Statement of Financial Activities for the year ended 31 March 2025

Leukaemia & Myeloma Research UK Ltd - Analysis of prior year total funds, as required by paragraph 4.2 of the SORP

Leukaemia & Myeloma Research UK Ltd - Analysis of prior year total funds, as required by paragraph 4.2 of the SORP

	SORP Ref	Prior Year Unrestricted Funds 2024 £	Prior Year Restricted Funds 2024 £		Prior Year Total Funds 2024 £
Donations & Legacies	A1	191,132	51,705		**242,837**
Charitable activities	A2	63,177	-		**63,177**
Investments	A4	4,317	-		**4,317**
Other	A5	50,000	-	-	**50,000**
Total income	**A**	308,626	51,705		**360,331**
Expenditure on:					
Raising funds	B1	14,389	-		**14,389**
Charitable activities	B2	259,235	48,824		**308,059**
Total expenditure	**B**	**273,624**	**48,824**		**322,448**
Net income for the year		35,002	2,881		37,883
Net movement in funds		**35,002**	**2,881**		**37,883**
Total funds brought forward		311,735	40,586		**352,321**
Total funds carried forward		**346,737**	**43,467**		**390,204**

All activities derive from continuing operations

A separate Statement of Total Recognised Gains and Losses is not required as this statement includes all recognised gains and losses.'

The notes attached on pages 17 to 36 form an integral part of these accounts.

Leukaemia & Myeloma Research UK Ltd - Statement of Financial Activities for the year ended 31 March 2025

Leukaemia & Myeloma Research UK Ltd - Resources applied in the year ended 31 March 2025 towards fixed assets for Charity use:-

	2025 £	2024 £
Funds generated in the year as detailed in the SOFA	-	-
Resources applied on functional fixed assets	(57,700)	(24,570)
Net resources available to fund charitable activities	**(57,700)**	**(24,570)**

The resources applied on fixed assets for charity use represents the cost of additions less proceeds of any disposals.

The notes attached on pages 17 to 36 form an integral part of these accounts.

Leukaemia & Myeloma Research UK Ltd - Statement of Financial Activities for the year ended 31 March 2025

Movements in revenue and capital funds for the year ended 31 March 2025

Revenue accumulated funds

	Unrestricted Funds 2025 £	Restricted Funds 2025 £	Total Funds 2025 £	Last year Total Funds 2024 £
Accumulated funds brought forward	346,737	43,467	390,204	**352,321**
Recognised gains and losses before transfers	(155,295)	8,431	(146,864)	37,883
	191,442	**51,898**	**243,340**	**390,204**
Closing revenue funds	**191,442**	**51,898**	**243,340**	**390,204**

Summary of funds	Unrestricted and Designated funds 2025 £	Restricted Funds 2025 £	Total Funds 2025 £	Last Year Total Funds 2024 £
Revenue accumulated funds	191,442	51,898	**243,340**	390,204
Total funds	**191,442**	**51,898**	**243,340**	**390,204**

The notes attached on pages 17 to 36 form an integral part of these accounts.

Leukaemia & Myeloma Research UK Ltd - Statement of Financial Activities for the year ended 31 March 2025

Leukaemia & Myeloma Research UK Ltd
Income and Expenditure Account for the year ended 31 March 2025 as required by the Companies Act 2006

	2025	2024
	£	£
Income		
Income from operations	499,857	306,014
Investment income		
Interest receivable	3,742	4,317
Other operating income	50,332	50,000
Gross income in the year before exceptional items	**553,937**	**360,331**
Gross income in the year including exceptional items	**553,937**	**360,331**
Expenditure		
Charitable expenditure, excluding depreciation and amortisation	663,361	300,892
Depreciation and amortisation	20,967	7,167
Fundraising costs	16,473	14,389
Total expenditure in the year	**700,801**	**322,448**
Net income before tax in the financial year	**(146,864)**	**37,883**
Retained surplus for the financial year	**(146,864)**	**37,883**

All activities derive from continuing operations

In accordance with the provisions of the Companies Act 2006, the headings and subheadings used in the Income and Expenditure account have been adapted to reflect the special nature of the charity's activities.

Leukaemia & Myeloma Research UK Ltd - Balance Sheet as at 31 March 2025

	Note	SORP Ref		2025		2024
				£		£
Fixed assets		A				
Tangible assets	6	A2		55,960		19,227
Total fixed assets				55,960		19,227
Current assets		B				
Stocks		B1	26,550		27,319	
Debtors	8	B2	12,036		12,326	
Cash at bank and in hand		B4	177,273		335,511	
Total current assets			215,859		375,156	
Creditors: amounts falling due within one year	9	C1	(28,479)		(4,179)	
Net current assets				187,380		370,977
The total net assets of the charity				**243,340**		**390,204**
The total net assets of the charity are funded by the funds of the charity, as follows:-						
Restricted funds						
Restricted Revenue Funds	11	D2	51,898		43,467	
				51,898		43,467
Unrestricted Funds						
Unrestricted Revenue Funds	11	D3	191,442		346,737	
				191,442		346,737
Total charity funds				**243,340**		**390,204**

The 'SORP Ref' indicated above is the classification of Balance Sheet items as set out in the formal SORP documents. As required by paragraph 4.60 of the SORP, the brought forward and carried forward funds above have been agreed to the SOFA..

The directors are satisfied that the company is entitled to exemption from the requirement to obtain an audit under section 477 of the Companies Act 2006.

The members have not required the company to obtain an audit in accordance with section 476 of the Act.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.

The charity is subject to Independent Examination under charity legislation, and the report of the Independent Examiner is on page 8.

The financial statements have been prepared in accordance with the provisions in Part 15 of the Companies Act 2006. applicable to companies subject to the small companies regime.

TATJANA VINOGRADOVA

Trustee

Approved by the board of trustees on 12 December 2025

The notes attached on pages 17 to 36 form an integral part of these accounts.

Leukaemia & Myeloma Research UK Ltd

Notes to the Accounts for the year ended 31 March 2025

1 Accounting policies

Policies relating to the production of the accounts.

Basis of preparation and accounting convention

The accounts have been prepared on the accruals basis, under the historical cost convention, and in accordance with the Financial Reporting Standard 102, (effective 1st January 2016) and 'FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2019, applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), published by the Charity Commission in England & Wales (CCEW) , and in accordance with all applicable law in the charity's jurisdiction of registration, except that the charity has prepared the financial statements in accordance with the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2019, applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), in preference to the previous SORP, the SORP 2005, which has been withdrawn, notwithstanding the fact that the extant statutory regulations, the Charities (Accounts and Reports) Regulations 2008 refer explicitly to the SORP 2005. This has been done to accord with current best practice.

Going Concern
The charitable activities are entirely dependent on continuing grant aid and voluntary donations as well as trading revenues. As a consequence, the going concern basis is dependent on the future flow of these uncertain funding streams. Accordingly, the Trustees have obtained forecasts and, after reviewing the financial forecasts for future periods, the Trustees are satisfied that, at the time of approving the financial statements, it is appropriate to adopt the going concern basis in preparing the financial statements. Other than these matters, the Trustees are not aware of any material uncertainites about the charity's ability to continue as a going concern.

Policies relating to categories of income and income recognition.

Nature of income

Gross income represents the value, net of value added tax and discounts, of goods provided to customers and work carried out in respect of services provided to customers.

Categories of Income

Income is categorised as income from exchange transactions (contract income) and income from non-exchange transactions (gifts), investment income and other income.

Income from exchange transactions is received by the charity for goods or services supplied under contract or where entitlement is subject to fulfilling performance related conditions. The income the charity receives is approximately equal in value to the goods or services supplied by the charity to the purchaser.

Income from a non-exchange transaction is where the charity receives value from the donor without providing equal value in exchange, and includes donations of money, goods and services freely given without giving equal value in exchange.

Income recognition

Income, whether from exchange or non exchange transactions, is recognised in the statement of financial activities (SOFA) on a receivable basis, when a transaction or other event results in an increase in the charity’s assets or a reduction in its liabilities and only when the charity has legal entitlement, the income is probable and can be measured reliably.

Dividends are accrued when the shareholder’s right to receive payment is established.

Income subject to terms and conditions which must be met before the charity is entitled to the resources is not recognised until the conditions have been met.

All income is accounted for gross, before deducting any related fees or costs.

Notes to the Accounts for the year ended 31 March 2025

Income from legacies

Income from legacies is recognised when the charity has sufficient evidence that a gift has been left to them, that where required, probate has been granted, the executor is satisfied that the property in question will not be required to satisfy claims in the estate, that it is probable that the amount will be received by the charity, and the amount to be received can be estimated with sufficient accuracy, and that any conditions attached to the legacy are either within the control of the charity or have been met.

Where a payment is received from an estate or is notified as receivable by the executors after the reporting date and before the accounts are authorised for issue but it is clear that the payment had been agreed by the executors prior to the end of the reporting period, then the amount concerned is treated as an adjusting event and accrued as income in the accounting period if receipt is probable.

Where the charity has established entitlement to a legacy but there is uncertainty as to the amount of the payment, details of the legacy aredisclosed as a contingent asset until the criteria for income recognition are met. Where a legacy is subject to the interest of a life tenant, the legacy is not recognised as income until the death of the life tenant.

If it is doubtful that full settlement of a legacy debtor will be received, then an adjustment is made to reduce the amount of the legacy debtor and legacy income rather than charging the adjustment as expenditure in the Statement of Financial Activities

Donated goods, facilities and services

Donated fixed assets are recognised at the current fair value. All such donations are recognised as donation income, and debited to fixed assets.

Donated goods that are not fixed assets are accounted for at a fair value, unless it is impractical to reliably measure the value of the donated items.

In the absence of any direct evidence of fair value of donated goods, then a value is derived from the cost of the item to the donor or, in the case of goods that are expected to be sold, the estimated resale value after deducting any anticipated costs of sales.

If it is impracticable to measure the fair value of goods donated for resale, or the costs of valuation outweigh the benefits, the donated goods are recognised as income when sold, with an equivalent amount being recognised as an expense.

The costs of goods donated for distribution to beneficiaries is deemed to be the fair value of those goods upon receipt. When the goods are distributed freely or for a nominal consideration, then the carrying amount is adjusted at the time of sale, to the value at the point of distribution and the adjustment is shown as a cost of donations made.

The carrying amount of any stock held for distribution is assessed for impairment at the reporting date. All donated goods are recognised as donation income, and debited to trading stock.When trading stock is subsequently sold, or appropriated to meet an expense, then the carrying value of the stock is recognised as an expense. In accordance with the SORP, goods donated for distribution to beneficiaries, or for consumption by the charity are included in ***'legacies and donations***'. Goods donated for resale are included in ***'Income from other trading activities'***

The cost of any stock of goods donated for distribution to beneficiaries is deemed to be the fair value of those gifts at the time of their receipt. If the goods held are to be distributed freely or for a nominal consideration, then the carrying amount is subsequently adjusted to reflect the lower of deemed cost adjusted for any loss of service potential and replacement cost. Replacement cost is the economic cost incurred if the charity was to replace the service potential of the donated goods at its own expense in the most economic manner.

Donated services and facilities (including seconded staff and use of property) are included in the accounts on the basis of the value of the gift to the charity.

All donated services and facilities are recognised as donation income when received,(provided the value of the gift can be measured reliably) and recognised as an expense with an equivalent value.

Leukaemia & Myeloma Research UK Ltd

Notes to the Accounts for the year ended 31 March 2025

Policies relating to expenditure on goods and services provided to the charity.

Recognition of liabilities and expenditure

A liability, and the related expenditure, is recognised when a legal or constructive obligation exists as a result of a past event, and when it is more likely than not that a transfer of economic benefits will be required in settlement, and when the amount of the obligation can be measured or reliably estimated..

Liabilities arising from future funding commitments and constructive obligations, including performance related grants, where the timing or the amount of the future expenditure required to settle the obligation are uncertain, give rise to a provision in the accounts, which is reviewed at the accounting year end. The provision is increased to reflect any increases in liabilities, and is decreased by the utilisation of any provision within the period, and reversed if any provision is no longer required. These movements are charged or credited to the respective funds and activities to which the provision relates.

Allocating costs to activities

Direct costs that are specifically related to an activity are allocated to that activity. Shared direct costs and support costs are apportioned between activities.

The basis for apportionment, which is consistently applied, and proportionate to the circumstances, is :-

Staffing - on the basis of time spent in connection with any particular activity.

Premises related costs - on the proportion of floor area occupied by a particular activity.

Non specific support costs - on the basis of the usage of resources, in terms of time taken, capacity used, request made or other measures

Policies relating to assets, liabilities and provisions and other matters.

Tangible fixed assets

Tangible fixed assets are measured at their original cost value, or subsequent revaluation, or if donated, as described above. Cost value includes all costs expended in bringing the asset into its intended working condition.

Depreciation has been provided at the following rates in order to write off the assets to their anticipated residual value over their estimated useful lives.

Plant and machinery	25 % straight line
Motor vehicles	25 % straight line

A regular annual review of the likelihood of asset impairment is undertaken.

Notes to the Accounts for the year ended 31 March 2025

Accounting for capital grants and fixed asset funds.

Gifts of tangible fixed assets or grants of a capital nature, given for the purposes of acquiring specific assets to be fully utilised in the furtherance of the objects of the charity, are credited to fixed asset funds after the donated asset has been received or sums have been properly expended on the restricted purpose.

Where the terms of the gift require the charity to hold the asset on an ongoing basis for a specific purpose, then the fixed asset fund so created is categorised as a restricted fixed asset fund, and the relevant restrictions are noted in the fixed asset note 6.

Where the terms of the gift are met once the asset is acquired, so allowing the charity to use the asset on an unrestricted basis, including the right to receive the proceeds of any future sale of the asset on an unrestricted basis, then the fixed asset fund so created is categorised as a designated fixed asset fund.

When assets are acquired for the furtherance of the charity's objects, utilising the charity's own unrestricted funds, a transfer is made from unrestricted funds to a designated fixed asset fund.

Whether acquired with unrestricted or restricted funds, the asset acquired is initially shown in the balance sheet at the full cost of acquisition or subsequent revaluation.

As the related assets are depreciated, in accordance with the depreciation policy,in order to reflect the dimunition in the asset,a transfer is made from the relevant fixed asset funds to either unrestricted or restricted revenue funds, as appropriate to the terms of the original gift, if any.

The effect of this policy is that the aggregate of all fixed asset funds shall equate to the net book value of fixed assets.

In the first year that this policy was adopted, a transfer to fixed asset funds was made equivalent to the net book value of the assets.

Any residual liability to the donor arising from, for example, the asset's future sale, is disclosed as a contingent liability unless the event that would trigger repayment of the grant becomes probable in which case a liability for repayment is recognised.

Insofar as this policy relates to Government grants and to the extent that it may be a departure from the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2019, applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), such departure is justified on the basis that it is in order to comply with the SORP.

Stocks and work in progress

Stock is valued at the lower of cost and net realisable value.

Debtors

Debtors are measured at their recoverable amounts at the balance sheet date.

Creditors and provisions

Liabilities are measured at their settlement amount. A liability is recognised for the the amount the Charity anticpates it will pay to settle the deb or the amount it has received as an advance payment for goods or services it must provide.

Financial instruments including cash and bank balances

Cash held by the charity is included at the amount actually held and counted at the year end. Bank balances, whether in credit or overdrawn, are shown at the amounts properly reconciled to the bank statements.

Fund Accounting

Unrestricted funds are available for use at the discretion of the trustees in furtherance of the general objectives of the charity.

There are no endowment funds.

Notes to the Accounts for the year ended 31 March 2025

2 Liability to taxation

The Trustees consider that the charity satisfies the tests set out in Paragraph 1 Schedule 6 of the Finance Act 2010 for UK corporation tax purposes. Accordingly, the Charity is potentially exempt from taxation in respect of income or capital gains received within categories covered by chapter 3 part 11 of the Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992, to the extent that such income or gains are applied exclusively on the specific charitable objects of the charity and for no other purpose.

3 Winding up or dissolution of the charity

If upon winding up or dissolution of the charity there remain any assets, after the satisfaction of all debts and liabilities, the assets represented by the accumulated fund shall be transferred to some other charitable body or bodies having similar objects to the charity.

4 Defined contribution pension schemes

Any liabilites and assets associated with the scheme are shown under debtors and creditors.

5 Remuneration and payments to Trustees and persons connected with them

The trustees received payments in the amount of £1,082 as travel expenses related to providing services for clothing collection.

6 Tangible fixed assets

Current Year	Land and Buildings	Plant & Machinery	Motor Vehicles	Total
	£	£	£	£
Cost				
At 1 April 2024	-	4,674	23,995	28,669
Additions	-	39,255	18,445	57,700
At 31 March 2025	**-**	**43,929**	**42,440**	**86,369**
Depreciation				
At 1 April 2024	-	3,443	5,999	9,442
Charge for the year	-	10,357	10,610	20,967
At 31 March 2025	**-**	**13,800**	**16,609**	**30,409**
Net book value				
At 31 March 2025	**-**	**30,129**	**25,831**	**55,960**
At 31 March 2024	**-**	**1,231**	**17,996**	**19,227**

Notes to the Accounts for the year ended 31 March 2025

7 Stocks & Work in Progress

	2025	2024
	£	£
Stocks before write downs	26,550	27,319
	26,550	27,319

8 Debtors

	2025	2024
	£	£
Trade debtors	840	6,000
Prepayments and accrued income	-	294
Other debtors	11,196	6,032
	12,036	**12,326**

9 Creditors: amounts falling due within one year

	2025	2024
	£	£
Bank loans and overdrafts	-	-
Accruals for grants payable	-	-
Trade creditors	11,125	3,099
Accruals	1,080	1,080
PAYE, NIC VAT and other taxes	7,697	-
Other creditors	8,577	-
	28,479	**4,179**

10 Particulars of how particular funds are represented by assets and liabilities

At 31 March 2025	Unrestricted funds	Designated funds	Restricted funds	Total Funds
	£	£	£	£
Tangible Fixed Assets	55,960	-	-	**55,960**
Current Assets	163,961		51,898	**215,859**
Current Liabilities	(28,479)	-	-	**(28,479)**
	191,442	**-**	**51,898**	**243,340**

At 1 April 2024	Unrestricted funds	Designated funds	Restricted funds	Total Funds
	£	£	£	£
Tangible Fixed Assets	19,227	-	-	**19,227**
Current Assets	331,689	-	43,467	**375,156**
Current Liabilities	(4,179)	-	-	**(4,179)**
	346,737	**-**	**43,467**	**390,204**

Leukaemia & Myeloma Research UK Ltd

Notes to the Accounts for the year ended 31 March 2025

11 Change in total funds over the year as shown in Note 10 , analysed by individual funds

	Funds brought forward from 2024	Movement in funds in 2025	Transfers between funds in 2025	Funds carried forward to 2026
		See Note 12		
	£	£	£	£
Unrestricted and designated funds:-				
Unrestricted Revenue Funds	346,737	(155,295)	-	**191,442**
Total unrestricted and designated funds	**346,737**	**(155,295)**	**-**	**191,442**
Restricted funds:-				
Research	1,350	3,540	-	**4,890**
Model Cell Biobank	42,117	4,559	-	**46,676**
Sundry other funds	-	332	-	**332**
Total restricted funds	**43,467**	**8,431**	**-**	**51,898**
Total charity funds	**390,204**	**(146,864)**	**-**	**243,340**

12 Analysis of movements in funds over the year as shown in Note 11

	Income	Expenditure	Other Gains & Losses	Movement in funds
	2025	2025	2025	2025
	£	£	£	£
Unrestricted and designated funds:-				
Unrestricted Revenue Funds	498,100	(653,395)	-	**(155,295)**
Restricted funds:-				
Research	43,500	(39,960)	-	**3,540**
Model Cell Biobank	12,005	(7,446)	-	**4,559**
Sundry other funds	332		-	**332**
	553,937	**(700,801)**	**-**	**(146,864)**

Notes to the Accounts for the year ended 31 March 2025

13 The purposes for which the funds as detailed in note 11 are held by the charity are:-

Unrestricted and designated funds:-	
Unrestricted Revenue Funds	These funds are held for the meeting the objectives of the charity, and to provide reserves for future activities, and , subject to charity legislation, are free from all restrictions on their use.
Restricted funds:-	
Research	The purpose of these funds is described under the accounting policy.
Model Cell Biobank	The purpose of these funds is described under the accounting policy.

14 Ultimate controlling party

The charity is under the control of its legal members.

For companies ltd by guarantee - Every member of the charity is obliged to contribute such amount as may be required to contribute to the assets of the company in the event of its being wound up while he or she is a member, or within one year after he or she ceases to be a member.

Leukaemia & Myeloma Research UK Ltd

Detailed analysis of income and expenditure for the year ended 31 March 2025 as required by the SORP 2015

This analysis is classsified by conventional nominal descriptions and not by activity.

15 Donations, Grants and Legacies

	Current year Unrestricted Funds 2025 £	Current year Restricted Funds 2025 £	Current year Total Funds 2025 £	Prior Year Total Funds 2024 £
Donations and gifts from individuals				
Small donations individually less than £1000	2,302	-	**2,302**	3,297
Refunds from HMRC on gift aided donations	6	-	**6**	-
Stripe Direct Donations	10,973	-	**10,973**	13,177
Charities Trust	4,784	-	**4,784**	-
Facebook	-	-	**-**	1,508
Just Giving	37,866	-	**37,866**	60,725
GC C1	1,646	-	**1,646**	-
In Memory	5,665	-	**5,665**	12,693
Unity Lottery	1,217	-	**1,217**	-
Muchloved	7,970	-	**7,970**	2,688
Sheila Puzey	1,450	-	**1,450**	-
Louise Bevan	1,703	-	**1,703**	-
Paypal Giving	1,557	-	**1,557**	8,605
CAF	1,208	-	**1,208**	**3,367**
Total donations and gifts from individuals	**78,347**	**-**	**78,347**	**106,060**

Donations and gifts from individuals (Include HMRC refunds on gift aided donations) - Prior Year analysis

	Prior Year Unrestricted Funds 2024 £	Prior Year Restricted Funds 2024 £	Prior Year Total Funds 2024 £
Prior year	**106,060**	**-**	**106,060**

Leukaemia & Myeloma Research UK Ltd

Detailed analysis of income and expenditure for the year ended 31 March 2025 as required by the SORP 2015

	Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
	2025	2025	2025	2024
	£	£	£	£
Legacies receivable				
Small legacies individually less than £1000	500	-	**500**	750
Holmes Mackillop	5,000	-	**5,000**	-
Oglethorpe & Broach	30,000	-	**30,000**	-
David C Taylor	-	-	**-**	3,000
Nick Glynne/Martin Glynne	-	-	**-**	5,000
Holmes & Hills LLP	-	-	**-**	44,843
Jackson Lees Group Ltd	3,431	-	**3,431**	3,750
Catherine Dunne and Rachel O'Mallet	-	-	**-**	10,000
Total legacies receivable	**38,931**	**-**	**38,931**	**67,343**

Legacies receivable - Prior Year analysis

	Prior Year Unrestricted Funds	Prior Year Restricted Funds	Prior Year Total Funds
	2024	2024	2024
	£	£	£
Prior year	67,343	-	**67,343**

Leukaemia & Myeloma Research UK Ltd

Detailed analysis of income and expenditure for the year ended 31 March 2025 as required by the SORP 2015

	Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
	2025	2025	2025	2024
	£	£	£	£
Revenue grants from government and public bodies				
Small grants individually less than £1000	1,680	65	**1,745**	2,890
Orange Tree Trust	-	-	**-**	2,500
Hilary Awdry Trust	-	-	**-**	2,000
Medicash Trust	-	-	**-**	3,000
John Mason Charitable Trust	-	-	**-**	3,500
The National Lottery Community Fund	8,880	-	**8,880**	-
Rathbone Investment Management	-	-	**-**	3,000
Michael Watson Charitable Trust	-	-	**-**	2,500
L & R Gilley Charitable Trust	-	-	**-**	2,500
The Sunset Charitable Trust	-	-	**-**	5,000
Total public sector revenue grants	**10,560**	**65**	**10,625**	**26,890**

All the grants in the prior year were unrestricted.

Revenue grants from government and public bodies - Prior Year analysis

	Prior Year Unrestricted Funds	Prior Year Restricted Funds	Prior Year Total Funds
	2024	2024	2024
	£	£	£
Prior Year	7,090	19,800	**26,890**

Leukaemia & Myeloma Research UK Ltd

Detailed analysis of income and expenditure for the year ended 31 March 2025 as required by the SORP 2015

	Current year Unrestricted Funds 2025 £	Current year Restricted Funds 2025 £	Current year Total Funds 2025 £	Prior Year Total Funds 2024 £
Revenue grants and donations from non public bodies				
Small grants individually less than £1000	741	640	**1,381**	4,652
Dalgleish Trust	-	2,000	**2,000**	-
Fundraising Support Ltd	-	2,300	**2,300**	2,650
Golders Green Foundation	-	-	**-**	2,000
The Rainford Trust	1,000	-	**1,000**	-
Prowting Charitable Foundation	-	-	**-**	10,000
Robert Luff Foundation	-	-	**-**	10,000
Albert Hunt Trust	5,000		**5,000**	
Barratt Development	-	-	**-**	2,000
Bognor Regis Golf Club	2,527	-	**2,527**	2,767
Cecil and Hilda Lewis Charitable Trust		2,000	**2,000**	
Charity Job Giving	10,000		**10,000**	
CBRE ASD	-	-	**-**	1,500
Frank Litchfield General Charitable Trust		10,000	**10,000**	
John Raymond TIJOU Charitable Trust		4,000	**4,000**	
Kiwanis London	-	-	**-**	2,000
Lunya Limited	7,658		**7,658**	
Markeyl International	-	-	**-**	2,975
Miss D.R Finlay Charitable Trust	-	3,000	**3,000**	
MJ C Stone Charitable Trust	2,200		**2,200**	
One Knowsley cancel alliance	2,000		**2,000**	
Postcode Neighbourho0d Trust	5,000		**5,000**	
Santa Barbara Heights Charitable Trust		1,000	**1,000**	
Sir Donald Trust	1,000		**1,000**	
The Carl Lewis Foundation		1,000	**1,000**	
The Family Rich Church Trust		5,000	**5,000**	
The Fort Foundation	-	2,000	**2,000**	

The Gaynor Cemlyn-Jones Trust		1,000	**1,000**	
The Geoofrey & Pauline Martin Trust		10,000	**10,000**	
The Grace Trust		2,000	**2,000**	
The Hospital Saturday Fund	-	2,000	**2,000**	**2,000**
The N Smith Charitable Settlement	-	1,000	**1,000**	
The Mackintosh Foundation	-	1,500	**1,500**	
The Stanley Grundy Fondation Ltd	-	1,000	**1,000**	
The Stockwell Clifee Charitable Trust	-	3,000	**3,000**	
The Thomas Sivewright Catto Charitable Settlement	-	1,000	**1,000**	
Total private sector revenue grants	**37,126**	**55,440**	**92,566**	**42,544**

All the grants in the prior year were unrestricted.

Revenue grants and donations from non public bodies (Include Gift Aid donations from subsidiaries) - Prior Year analysis

	Prior Year Unrestricted Funds 2024 £	Prior Year Restricted Funds 2024 £	Prior Year Total Funds 2024 £
Prior Year	10,639	31,905	**42,544**

Leukaemia & Myeloma Research UK Ltd

Detailed analysis of income and expenditure for the year ended 31 March 2025 as required by the SORP 2015

Total Donations, Grants and Legacies

Current year		Unrestricted Funds 2025 £	Restricted Funds 2025 £	Current Year Total Funds 2025 £	Prior Year Total Funds 2024 £
Total Donations, Grants and Legacies	**A1**	**164,964**	**55,505**	**220,469**	**242,837**

All the donations and gifts in the prior year were unrestricted.

Prior year		Unrestricted Funds 2024 £	Restricted Funds 2024 £	Prior Year Total Funds 2024 £
Total Donations, Grants and Legacies	**A1**	**191,132**	**51,705**	**242,837**

Detailed analysis of income and expenditure for the year ended 31 March 2025 as required by the SORP 2015

16 Income from charitable activities - Trading Activities

Current year

	Current year Unrestricted Funds 2025 £	Current year Restricted Funds 2025 £	Current year Total Funds 2025 £	Prior Year Total funds 2024 £
Primary purpose and ancillary trading				
Sale of goods and services in accordance with the charity's objects	279,394	-	**279,394**	63,177
Total Primary purpose and ancillary trading	**279,394**	**-**	**279,394**	**63,177**

Prior year

	Prior Year Unrestricted Funds 2024 £	Prior Year Restricted Funds 2024 £	Prior Year Total Funds 2024 £
Primary purpose and ancillary trading			
Sale of goods and services in accordance with the charity's objects	63,177	-	**63,177**
Total Primary purpose and ancillary trading	**63,177**	**-**	**63,177**

Detailed analysis of income and expenditure for the year ended 31 March 2025 as required by the SORP 2015

17 Total Income from charitable activities

Current year		Current year Unrestricted Funds 2025 £	Current year Restricted Funds 2025 £	Current year Total Funds 2025 £	Prior Year Total Funds 2024 £
Total income from charitable trading		279,394	-	**279,394**	63,177
Total from charitable activities	**A2**	**279,394**	**-**	**279,394**	**63,177**

Income from charitable activities - Prior Year analysis

Prior year	Prior Year Unrestricted Funds 2024 £	Prior Year Restricted Funds 2024 £	Prior Year Total Funds 2024 £
Total income from charitable trading	63,177	-	63,177
	63,177	**-**	**63,177**

18 Investment income

		Current year Unrestricted Funds 2025 £	Current year Restricted Funds 2025 £	Current year Total Funds 2025 £	Prior Year Total Funds 2024 £
Bank Interest Receivable		3,742	-	**3,742**	4,317
Total investment income	**A4**	**3,742**	**-**	**3,742**	**4,317**

Investment income - Prior Year analysis

	Unrestricted Funds	Restricted Funds	Total Funds
Prior Year	**4,317**	**-**	**4,317**

Detailed analysis of income and expenditure for the year ended 31 March 2025 as required by the SORP 2015

19 Other income and gains

Current year		Current year Unrestricted Funds 2025 £	Current year Restricted Funds 2025 £	Current year Total Funds 2025 £	Prior Year Total Funds 2024 £
Royalties from the exploitation of intellectual property rights		50,000	-	**50,000**	50,000
Sundry other income		-	332	**332**	-
Total other income	**A5**	**50,000**	**332**	**50,332**	**50,000**

Other income and gains - Prior year analysis

Prior Year		Prior Year Unrestricted Funds 2024 £	Prior Year Restricted Funds 2024 £	Prior Year Total Funds 2024 £
Royalties from the exploitation of intellectual property rights		50,000	-	**50,000**
Total other income	**A5**	**50,000**	**-**	**50,000**

20 Expenditure on charitable activities - Direct spending

Current Year		Current year Unrestricted Funds 2025 £	Current year Restricted Funds 2025 £	Current year Total Funds 2025 £	Prior Year Total Funds 2024 £
Travel and Subsistence - Charitable Activities		592	-	**592**	**470**
Costs of activities and events		16,161	5,927	**22,088**	**20,878**
Consultancy and professional support		47,968	-	**47,968**	**38,586**
Travel and Subsistence - Trustees Travel Expenses		-	-	**-**	**1,082**
Total direct spending	**B2a**	**64,721**	**5,927**	**70,648**	**61,016**

All the expenditure in the prior year was unrestricted.

Detailed analysis of income and expenditure for the year ended 31 March 2025 as required by the SORP 2015

Prior Year		Prior Year Unrestricted Funds 2024 £	Prior Year Restricted Funds 2024 £	Prior Year Total Funds 2024 £
Travel and Subsistence - Charitable Activities		470	-	**470**
Costs of activities and events		12,207	8,671	**20,878**
Consultancy and professional support		38,586	-	**38,586**
Travel and Subsistence - Trustees Travel Expenses		1,082		**1,082**
Total direct spending	**B2a**	**52,345**	**8,671**	**61,016**

21 Expenditure on charitable activities - Charitable trading

Current Year		Current year Unrestricted Funds 2025 £	Current year Restricted Funds 2025 £	Current year Total Funds 2025 £	Prior Year Total Funds 2024 £
Cost of goods for primary purpose trading - Including movement in stock		**200,590**	**-**	**200,590**	**54,307**
Cost of Shipping, Freigh and Delivery		**6,923**	**-**	**6,923**	**1,894**
Total charitable trading costs	**B2b**	**207,513**	**-**	**207,513**	**56,201**

Prior Year		Prior Year Unrestricted Funds 2024 £	Prior Year Restricted Funds 2024 £	Prior Year Total Funds 2024 £
Cost of goods for primary purpose trading - Including movement in stock		54,307	-	**54,307**
Cost of Shipping, Freigh and Delivery		1,894	-	**1,894**
Total charitable trading costs	**B2b**	**56,201**	**-**	**56,201**

22 Expenditure on charitable activities- Grant funding of activities

Current Year		Current year Unrestricted Funds 2025 £	Current year Restricted Funds 2025 £	Current year Total Funds 2025 £	Prior Year Total Funds 2024 £
Grants made to organisations		-	39,960	**39,960**	**57,500**
Total grantmaking costs	**B2c**	**-**	**39,960**	**39,960**	**57,500**

Detailed analysis of income and expenditure for the year ended 31 March 2025 as required by the SORP 2015

Breakdown of Grants made to organisations

Current Year	Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds
	2025	2025	2025
	£	£	£
Imperial Colleage of Science, Technology and Medicine		39,960	39,960
	-	**39,960**	**39,960**

Prior Year	Prior Year Unrestricted Funds	Prior Year Restricted Funds	Prior Year Total Funds
	2024	2024	2024
	£	£	£
Grants made to organisations	19,800	37,700	**57,500**
Total grantmaking costs **B2c**	**19,800**	**37,700**	**57,500**

23 Support costs for charitable activities

Current Year	Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
	2025	2025	2025	2024
	£	£	£	£
Employee costs not included in direct costs				
Salaries - Administrative staff	89,603	-	**89,603**	**-**
Employers' NI - Administrative staff	8,428	-	**8,428**	**-**
Defined contribution pension costs - Other salaries	1,469	-	**1,469**	**-**
Subcontractors	10,431	-	**10,431**	**1,328**
Premises Expenses				
Service charges payable	3,332	-	**3,332**	**-**
Rates and water charges	341	-	**341**	**397**
Room Hire	29,318	-	**29,318**	**24,607**
Light heat and power	674	-	**674**	**521**
Cleaning and waste management	1,714	-	**1,714**	**1,427**
Premises repairs, renewals and maintenance	1,220	-	**1,220**	**420**
Property insurance	581	-	**581**	**701**
Storage	13,484	-	**13,484**	**2,554**

Leukaemia & Myeloma Research UK Ltd

Detailed analysis of income and expenditure for the year ended 31 March 2025 as required by the SORP 2015

Administrative overheads				
Telephone, fax and internet	3,319	-	**3,319**	**1,921**
Postage	1,648	-	**1,648**	**1,053**
Stationery and printing	1,284	-	**1,284**	**1,608**
Membership subscriptions	11,015	-	**11,015**	**8,568**
Equipment expenses	4,314	-	**4,314**	**1,414**
Hire of equipment	4,163	-	**4,163**	**1,339**
Software licences and expenses	6,951	-	**6,951**	**3,968**
Advertising and marketing	84,343	1,519	**85,862**	**30,326**
Liabilty and contents insurance	381	-	**381**	**-**
Sundry expenses	1,848	-	**1,848**	**2,045**
Motor Expenses	20,714	-	**20,714**	**3,867**
Professional fees paid to advisors other than the auditor or examiner				
Accountancy fees other than examination or audit fees	1,830	-	**1,830**	**240**
Management fees	19,626	-	**19,626**	**32,638**
Other legal and professional	21,625	-	**21,625**	**5,121**
Financial costs				
Bank charges	65	-	**65**	**112**
Other costs				
Depreciation & Amortisation in total for the period	20,967	-	**20,967**	**7,167**
Support costs before reallocation	**364,688**	**1,519**	**366,207**	**133,342**
Total support costs - Current Year	**364,688**	**1,519**	**366,207**	**133,342**
				-
The basis of allocation of costs between activities is described under accounting policies				**-**
				-

Leukaemia & Myeloma Research UK Ltd

Detailed analysis of income and expenditure for the year ended 31 March 2025 as required by the SORP 2015

Prior Year	Prior Year Unrestricted Funds 2024	Prior Year Restricted Funds 2024	Prior Year Total Funds 2024
Employee costs not included in direct costs			
Subcontractors	1,328	-	**1,328**
Premises Expenses			
Rates and water charges	397	-	**397**
Room Hire	24,607	-	**24,607**
Light heat and power	521	-	**521**
Cleaning and waste management	1,427	-	**1,427**
Premises repairs, renewals and maintenance	420	-	**420**
Property insurance	701	-	**701**
Storage	2,554	-	**2,554**
Administrative overheads			
Telephone, fax and internet	1,921	-	**1,921**
Postage	1,053	-	**1,053**
Stationery and printing	1,608	-	**1,608**
Membership subscriptions	8,568	-	**8,568**
Equipment expenses	1,414	-	**1,414**
Hire of equipment	1,339	-	**1,339**
Software licences and expenses	3,968	-	**3,968**
Advertising and marketing	27,873	2,453	**30,326**
Sundry expenses	2,045	-	**2,045**
Motor Expenses	3,867	-	**3,867**
Professional fees paid to advisors			
Accountancy fees other than examination or audit fees	240	-	**240**
Management fees	32,638	-	**32,638**
Other legal and professional	5,121	-	**5,121**
Financial costs			
Bank charges	112	-	**112**
Other costs			
Depreciation & Amortisation in total for the period	7,167	-	**7,167**
Support costs before reallocation	**130,889**	**2,453**	**133,342**
Total support costs - Prior Year	**130,889**	**2,453**	**133,342**

The basis of allocation of costs between activities is described under accounting policies

Detailed analysis of income and expenditure for the year ended 31 March 2025 as required by the SORP 2015

24 Total Charitable expenditure

Current Year		Current year Unrestricted Funds 2025 £	Current year Restricted Funds 2025 £	Current year Total Funds 2025 £	Prior Year Total Funds 2024 £
Total direct spending	**B2a**	64,721	5,927	**70,648**	**61,016**
Total charitable trading costs	**B2b**	207,513	-	**207,513**	**56,201**
Total grantmaking costs	**B2c**	-	39,960	**39,960**	**57,500**
Total support costs	**B2d**	364,688	1,519	**366,207**	**133,342**
Total charitable expenditure	**B2**	**636,922**	**47,406**	**684,328**	**308,059**

Prior Year		Prior Year Unrestricted Funds 2024 £	Prior Year Restricted Funds 2024 £	Prior Year Total Funds 2024 £
Total direct spending	**B2a**	52,345	8,671	**61,016**
Total charitable trading costs	**B2b**	56,201	-	**56,201**
Total grantmaking costs	**B2c**	19,800	37,700	**57,500**
Total support costs	**B2d**	130,889	2,453	**133,342**
Total charitable expenditure	**B2**	**259,235**	**48,824**	**308,059**

25 Expenditure on raising funds and costs of investment management

Current Year		Current year Unrestricted Funds 2025 £	Current year Restricted Funds 2025 £	Current year Total Funds 2025 £	Prior Year Total Funds 2024 £
Agent's costs for fundraising		13,245	-	**13,245**	**7,080**
Cost of fundraising activities		2,507	-	**2,507**	**6,337**
Fundraising trading costs		721	-	**721**	**972**
Total fundraising costs	**B1**	**16,473**	**-**	**16,473**	**14,389**

All the expenditure in the prior year was unrestricted.

Prior Year		Prior Year Unrestricted Funds 2024 £	Prior Year Restricted Funds 2024 £	Prior Year Total Funds 2024 £
Agent's costs for fundraising		7,080	-	**7,080**
Cost of fundraising activities		6,337	-	**6,337**
Fundraising trading costs		972	-	**972**
Total fundraising costs	**B1**	**14,389**	**-**	**14,389**

LEUKAEMIA & MYELOMA RESEARCH UK LTD

England & Wales - Charity number 1161622

Accounts

Leukaemia & Myeloma Research UK

Report and Accounts

31 March 2024

Research That Saves Lives

leukaemiamyelomaresearchuk.org
Registered charity number 1161622 (England & Wales), SC046106 (Scotland),
Leukaemia and Myeloma Research UK Ltd
Company Limited by guarantee Registered number 09481278

Leukaemia & Myeloma Research UK

Research That Saves Lives

Leukaemia and Myeloma Research UK Ltd
Unit 127,
North Mersey Business Centre,
Woodward Rd,
Knowsley Industrial Park,
Liverpool,
Merseyside,
L33 7UY

Tel: 0800 368 7309

Web: www.leukaemiamyelomaresearchuk.org

Email: cs@leukaemiamyelomaresearchuk.org

Charity Number 1161622
Company Number 09481278



Follow us on Twitter: **https://twitter.com/lmruk_org**

Facebook: **https://www.facebook.com/leukaemiamyelomaresearchuk.org**

Leukaemia & Myeloma Research UK

Together we can beat cancer

Annual Report 2023-24

Table of contents

About Us 3

Stem Cells 4

Charitable Activities..... 5

Chairman's Report 6

Operation Director's Report 7

MCB Service..... 9

Overview 9

Donate Clothes to Sammy 11

Research Priorities.....12

Fundraising and Volunteers.....13

Thanks.....14

Trustees and Staff 14

Accounts 15



About Us

Leukaemia & Myeloma Research UK Ltd wants to prevent people dying from blood cancer through more effective treatment in the future. We are willing to fight blood cancer regardless of how long it might take.

Founded in 2015, our mission is to prevent people dying from blood cancer through prevention, research and more effective treatment.

Unfortunately, blood cancer affects a large number of people. Every 13 minutes, someone in the UK is told they have a blood cancer. That's around 110 people per day, 40,000 people per year. There are an estimated 4,700 leukaemia deaths every year, that's 13 every day!

We are aiming to become the UK's leading charity in supporting efforts to combat the three major types of blood cancer. The work we do helps fund vital stem cell research, raises awareness of stem cell therapies and helps families protect their children's future health by storing their cord blood stem cells at the time of birth.

There are 3 main types of cancers of the blood; they are lymphoma, leukaemia and myeloma.

The blood is made up of three different types of cells:

- Red blood cells which carry the oxygen around the body
- White blood cells which fight and stop infections
- Platelets which help the blood to clot

The course of treatment given will depend on the type of cancer. The most common treatments are chemotherapy, radiotherapy and in some instances, a stem cell transplant.

In essence, the Charity wants to eradicate blood cancer once and for all. One of the ways we are aiming to achieve that is through advancing our understanding of stem cells and how we can use them to treat patients with blood cancer, particularly through stem cell transplants. We do this by:

- Actively supporting stem cell research into blood cancers
- Raising awareness of stem cell therapies
- Provide information about blood cancers and treatment options
- Protecting the vulnerable by offering qualifying expectant mothers, with a family history of cancer, the opportunity to store their baby's umbilical cord blood stem cells at the time of birth, in case they are needed in the future to treat that child or another member of the family if they're a suitable match.

This service is called Model Cell Biobank (MCB).

Stem Cells

In humans, there are two types of stem cells: embryonic stem cells and adult stem cells, which are found in various tissues.

Adult stem cells are the primary focus of the research that the Charity supports. They typically generate the cell types of the tissue in which they reside.

For example, a blood-forming adult stem cell in the bone marrow normally gives rise to the many types of blood cells. It is generally accepted that a blood-forming cell in the bone marrow—which is called a hematopoietic stem cell— cannot give rise to the cells of a very different tissue, such as nerve cells in the brain.

Where are stem cells found?

There are four known accessible sources of autologous adult stem cells in humans:

- Bone marrow which requires harvesting by drilling into bone (typically the femur or iliac crest). This is done under a general anesthetic.
- Blood, which requires extraction through apheresis, wherein blood is drawn from the donor (similar to a blood donation), and passed through a machine that extracts the stem cells and then returns the blood to the donor.
- Adipose tissue (lipid cells), which requires extraction by liposuction.
- Umbilical cord blood - these stem cells can be collected from the umbilical cord blood just after birth.

What can stem cells be used for today?

There are treatments where Hematopoietic Stem Cell Transplants (HSCT) - the transplantation of blood forming stem cells - is a standard treatment. For some diseases they are the only therapy, and in other diseases they are only employed when front-line therapies have failed or the disease is very aggressive.

There are other blood disorders that can be treated with stem cells that aren't cancers, such as sickle cell anaemia and aplastic anaemia. For most types of blood cancers, for example: leukaemia, lymphoma and various anaemia's, the treatments use allogeneic stem cell transplants (someone else's stem cells). The reason for this is that the person may have a genetic predisposition to the disease; their genes have a defect that predisposes them to that disease.

However there are various types of cancers (some myelomas, plasma cell leukaemia, some anaemia's and solid tumours) that are treated using autologous stem cells (using your own stem cells).

Charitable Activities

Providing Information

Throughout the year we have shared facts about blood cancer, including the signs, symptoms and treatments. We have achieved this through our regular newsletter, social media channels, website, and our blood cancer booklet. This provides patients with clear and informative advice that would answer their questions, explain terminology, discuss treatments so they are better prepared and able to make informed choices.

We produce a monthly newsletter that shines a spotlight on our inspirational fundraisers and their stories; highlights our exciting plans for the future and provides information relating to blood cancer. It is available from our website free of charge.

Medical Research

Leukaemia & Myeloma Research UK Ltd allocate research grants to those who uphold our primary objectives. These are to benefit the public, in particular by research into the nature, causes, diagnosis, prevention, treatment and cure of leukaemia and myeloma. Our current funding priorities are to advance understanding of stem cells and how they can be used to treat blood cancer patients. All grant applications are reviewed by the Charity's Research and Review Committee, an independent panel of experts. The Charity is a member of the Association of Medical Research Charities, the AMRC.

Fundraising Activities

Over the last year, the Charity expanded its textile recycling project so it now includes local schools to the Merseyside and Greater Manchester areas. This is with the aim of raising awareness of both blood cancer and of the environmental benefits of recycling. It also continues to raise valuable funds for the charities work.

In conjunction with this, our fundraisers have been busy running events from cake sales to sky dives. This has secured £116,699 of funding to support our services and help in the fight against cancer.

Model Cell Biobank Service

This service was established to support families who are on low income, have a history of cancer in the family, to store their babies cord blood stem cells at the time of birth. These cells are stored for 25 years in case that child, or another member of the family, needs them in the future to treat a disease.

The cord blood stem cells can be used today instead of bone marrow stem cells to treat blood cancer and genetic disorders. In fact, recent studies show that over 80 diseases could be treated using cord blood stem cells.

Chairman's Report





It's been a busy year for Leukaemia & Myeloma Research UK Ltd (LMRUK) and we are celebrating the amazing support from staff, volunteers and fundraisers who enable our charity to continue our vital work.

Throughout the year we actively took part in national awareness days including Myeloma Awareness Month in March, Blood Cancer Awareness Month in September and World Cord Blood Day in November by sharing key facts and statistics, as well as stories from people directly impacted by blood cancer.

The biggest campaign is Blood Cancer Awareness Month and throughout September, charities across the country band together to shine a light on the three main types of cancer of the blood; Leukaemia, Myeloma and Lymphoma, which more than 240,000 people in the UK are living with.

But for our charity, this work goes on every day, 12 months a year. We are committed to educating people on the symptoms, so that the number of people diagnosed with the disease – currently over 40,000 a year – are diagnosed and begin treatment sooner. We have produced an informative downloadable poster for people to print and share with family, friends, colleagues, and local community groups.

At the end of 2023 we started working on the Donate Clothes 4 Sammy Project which launched at the beginning of April 2024. The aim of the project is to raise extra funds by giving a second life to preloved clothing donated by the community. Local schools, community centres, nurseries and other establishments will be involved in the project, by offering a clothing collection service.

The project will also offer a free "Book Collection" service and a "Donate Clothes by Post" option for the community, making it easy for people to donate their clothing to our charity and support our work.

We also want to be able to install clothing banks to make it easier to donate to the project.

I would like to thank all our incredible fundraisers, volunteers, their families and friends who have supported them and our Charity. Without them, we couldn't continue to offer the services that we do and fight blood cancer.

Sergejs Vinogradovs
Chair, Leukaemia and Myeloma Research UK Ltd

Operation Director's Report

This year we have once again been supported by some incredible fundraisers. From skydives to kiltwalks and marathons, there has been a variety of fantastic fundraising events this year, including the Margot family, who climbed the Yorkshire Three Peaks in memory of Graham Margot – a beloved husband, dad and grandad who passed away in 2022. The Margot family were named the charity's 'Fundraiser of the Year' for 2023 after raising a phenomenal £14,000 for LMRUK!

An average of 33% of the charity's funding comes from individual donations and fundraising events, highlighting the reliance on the generosity of supporters. We have so many incredible fundraisers, a few are highlighted below.

Tamara, a student at University of Leeds, ran the Leeds Half Marathon in May in support of her stepdad Richard Woods, who is currently receiving treatment for acute myeloid leukaemia (AML). She was supported by good friend, Alex Lewis, whose Grandad, is also undergoing treatment for blood cancer, as well as William Sudding and Lucas Heappey, both of whom wanted to support her and Alex in raising money for vital blood cancer research. They smashed their target and raised an incredible £3,700.

Another amazing fundraiser was Chris Cattrall, who took part in the Dorney Lakes 5km race, raising over £1,000 for the charity.

To mark a year since her husband's passing, Wendy Forrest from Broughty Ferry in Dundee and five of her closest friends, took on the Mighty Stride Kiltwalk in Dundee to raise money for LMRUK. Wendy, who works as a Civil Servant, was joined by Suzy, Morag, Lynne, Jade and Sarah to complete the 20-mile walk to raise awareness of blood cancer in memory of Alan. They raised an incredible £2,500 for the charity.

Ashleigh Harris from South Wales, ran the Cardiff Half Marathon in October in memory of her close friend and former colleague, Rachel Stickler, who passed away from Acute Myeloid Leukaemia (AML). Inspired by Rachel's passion for fitness and running, Ashleigh joined her local running group – Islwyn Running Club – and set herself a goal of completing the 13.1-mile race to raise money for LMRUK.

She raised an incredible £1,000, 335% more than her than her original target.

12 members of the Kiwanis London South East Group took to the streets to complete an 8-mile fundraising walk for LMRUK raising over £1,600 for the charity. Winston Mason, 61, helped organise the circular walk in memory of his mother, Olive Campbell, who passed away aged 84 after being diagnosed with myeloma.

We are incredibly grateful to each and every one of fundraisers and to those who make donations to the charity in memory of loved ones. As a result of the funds raised this year, we awarded our highest ever grant funding of £57,500 to support two projects exploring and examining the causes of Acute Myeloid Leukaemia and Myeloma to help in the fight against blood cancer.

I would like to say a huge 'thank you' to all our fundraisers for their hard work and to our dedicated staff team and partners who together have made 2023-24 such a huge success. All of our fundraisers are important - we simply would not be able to run these services without their help.

Dr Joanna Tilley

Operations Director, Leukaemia and Myeloma Research UK Ltd

MCB Service

Overview

The Model Cell Biobank (MCB) service allows the storage of a child's umbilical cord blood stem cells at the time of birth, in case they or another member of the family needs them in the future to help in the treatment of a disease. It may be possible to use the stem cells to treat blood cancers or in emerging therapies to treat diseases such as diabetes, cerebral palsy and Parkinson's disease. Clinical trials are being performed all over the world looking at the potential use of stem cells to treat new diseases and hopefully further breakthroughs.

When a baby is born and the umbilical cord is cut, the placenta and umbilical cord are normally thrown away. The blood that remains in the cord and the placenta contains stem cells. The Charity offers a service to collect these stem cells without any risk to the mother and baby, and to store them in case that child or another member of the family needs them in the future. The cord blood stem cells are stored on behalf of the child for 25 years.

The mother is the legal guardian of the cells until the child reaches the age of majority, at which point, ownership transfers to the child. After 25 years, the cells can be privately stored, donated for research, offered to a public bank, or destroyed.Consent from the child will be sought at this point and we would strongly encourage the donation of any remaining cells to public banks.

We now offer a fully funded cord blood banking service to families who are universal credit with a history of cancer in the family.

Alongside this, we also offer a part funded service to low income families.

Smart Cells Technical is our chosen partner to procure; process and store cord stem cells under its Human Tissue Authority licence. Smart Cells has a strong reputation for the high standards it applies to the storage and processing of stem cells derived from umbilical cord and peripheral blood, bone marrow, now extending to many types of tissues for human application or transplant.

Smart Cells not only works to the highest standards, it also has an ethical approach, which aligns with our charity, something we are proud of.

MODEL CELL BIOBANK
research that saves lives

Advantages of Cord Blood Stem Cells

Today, cord blood banking is changing lives and there have already been more than one million stem cell transplants around the world since the 1980s.

The stem cells in a baby's cord blood are fully developed adult stem cells, which are the building blocks of the blood immune system. These stem cells can be used instead of bone marrow stem cell to treat blood cancers and genetic disorders.

Cord blood stem cells have many advantages including:

- They are easily available, having already been harvested and stored;
- A new born baby has been exposed to fewer viruses and infections and so the stem cells are less likely to transmit infection and react with the patient;
- Cord blood stem cells offer the life-saving option of a transplant and avoids the invasive, painful and expensive procedures of other stem cell collection, such as bone marrow;
- Cord blood stem cells can be stored for many years - the longevity of these cells has proved they are as good 30 years later as on as the day they were first extracted and stored.

Feedback from Clients

"Cord blood stem cell storage and transplants are very costly so many cannot afford to use this potentially lifesaving service. This would certainly have been the case for us."

"Ever since my diagnosis I have felt an enormous sense of guilt about the chance of any of my children getting cancer – it is a mother's worst nightmare. I am incredibly grateful to have found out about this potentially lifesaving service, and even if we don't use the stored cord blood stem cells, it is reassuring to know that they will not go to waste."

"The whole process of retrieving the cord blood stem cells was very simple. When I was induced at the hospital we called the phlebotomist who arrived shortly after to take our baby daughter's cord blood stem cells. The collection was very quick –and within two hours of birth her cord blood stem cells had been collected from the hospital and taken back to Smart Cells Technical to be stored."

Donate Clothes to Sammy

To generate additional revenue to support the mission and causes of LMRUK charity, the trustees approved the launch in December 2023 of the newly expanded recycling project aptly called: Donate Clothes 4 Sammy. www.donateclothes4sammy.org

The goal of the project is to raise extra funds by giving a second life to preloved clothing donated by the community via local schools, community centres, nurseries and other establishments.

Our recycling programme secures valuable funds for the charities projects fighting blood cancer and raising awareness of our work. It also promotes re-use and recycling and encourages sustainable practices.

The project also offers a free 'Book Collection' service and a 'Donate Clothes by Post' option for the community, making it easy for people to donate their clothing to our charity and support our work. The project has received strong support and a great response from the public, which has enabled us to provide additional services, including the installation of Clothes Banks for convenient collection of pre-loved clothing.

We plan to reach out to 104 schools over the 24-25 financial year, enrolling 2 every week.

Combined with this we are hoping to purchase an additional 10 outdoor clothing banks which will be located in Liverpool and Manchester.

We expect the newly expanded recycling scheme to generate an extra £50,000 per year to allocate additional grants for research initiatives.

The project is managed entirely by the charity's team without involving commercial companies, ensuring that 100% of the proceeds go directly to the charity.

Research Priorities

Leukaemia & Myeloma Research UK Ltd offer research grants to those who uphold our primary objectives: to protect and promote the health of the public, in particular by research into the nature, causes, diagnosis, prevention, treatment and cure of leukaemia and myeloma.

The Trustees funding priorities are to advance understanding of stem cells and how they can be used to treat blood cancer patients, particularly through stem cell transplants.

In 23/24 Dr Rodrigues from the Europen Cancer Stem Cell Research Institute at Cardiff University, was awarded £35,000 to continue his ground breaking research into finding a more effective treatment for acute myeloid leukaemia (AML).

The project was initiated in 2016, and showed a gene was a master switch capable of activating 'flags' on leukaemia cells. Those flags are potential new theraputic targets in AML.

Dr Concetta Bubici from Brunel University in London, received funding to continue her work investigating treatment for myeloma, by starving

the disease of nutrients specifically sugar and fat.

She was awarded the Lister Wilder Research Grant of £22,500. If successful, their work will lead to the testing of new drugs in combination with current anti-myeloma medications in the laboratory and if deemed, in people.

Research Review Committee Members

Dr Paul Spencer Hole
Senior Research Scientist. Has been engaged in academic research at Cardiff University and extends his experience in a clinical-stage biopharmaceutical company.

Dr Claire Seedhouse
Associate Professor within Division of Cancer and Stem Cells, University of Nottingham. She is Principle Investigator and research group leader in Blood Cancer at the University of Nottingham.

Dr John Jones
Senior Clinical Lecturer – Brighton and Sussex Medical School, Honorary Consultant Haematologist – Kings College Hospital NHS Trust, London and Eastbourne District General Hospital.

Dr Rhys Morgan
Lecturer in Biomedical Sciences in Department of Biochemistry and Biomedicine, at the University of Sussex.

Professor Joseph R. Slupsky
Reader in Department of Molecular and Clinical Cancer Medicine, University of Liverpool. He is Principal Investigator of the Liverpool Blood Disease Biobank and Academic Lead University of Liverpool Technology Directorate Cell Sorting and Flow/Mass Cytometry Facility.

Dr Ceri Bygrave
A Consultant Haematologist and Myeloma Lead at the University Hospital of Wales and a member of the UK Myeloma Forum Executive Committee and the UK Myeloma Research Alliance.

Dr Salvatore Papa
An Associate Professor at Leeds University whose research speciality is in lymphoma and myeloma.

Fundraising and Volunteers

The Margot family were joined by close friends as they took on the Yorkshire Three Peaks challenge

The Margot family were joined by close friends as they took on the Yorkshire Three Peaks challenge at the end of the summer 2023.

The group climbed all three peaks in 12 hours and dedicated the 24.5 mile trek to Graham Margot – a wonderful husband, dad and grandfather - who passed away in August 2022.

Graham was diagnosed with Chronic Myelomonocytic Leukaemia (CMML), which meant that his body struggled to fight off the infection caused by a previous ailment – in this instance, diverticulitis. Due to the infection, his bowel perforated and he developed sepsis, a life-threatening reaction, and sadly passed away surrounded by his family.

Graham's daughter, Emily said: "After setting our fundraising target at £3,000, we can't quite believe that we've now raised almost £15,000 for LMRUK!

The group did incredibly well and we are all so proud that they've completed this mountain of a challenge to help support vital blood cancer research.

"My dad would have hated all the fuss that we've done in his memory, but we know he's looking down on us all and feeling very proud."

Dr Joanna Tilley, Operations Director at LMRUK added: "There are over 100 types of blood cancer, many of which are extremely rare. Our charity is committed to funding vital research into stem cell therapies as a more effective treatment, so we can help to protect the next generation.

So many people mistake the early signs and symptoms with something else, so we're encouraging people to educate themselves and others on what to look out for, and if something isn't right, go to your doctor to get checked out.

"None of our work would be possible without the support and tenacity of our fantastic fundraisers, including the Margot family, who have done such an incredible job of fundraising! We really can't thank them enough."

To read the Margot's story, visit https://bit.ly/45u1Spv

Furthermore, LMRUK were delighted to announce that our Fundraiser of the Year is.... the Margot family!

A huge congratulations to everyone involved and a massive thank you for their fantastic fundraising efforts.

The group who completed the challenge was Anna, Graham's wife, and Emily's brother, Oli, brother-in-law, Sam, and husband, Alex, as well as close friends; Charles, Jonny, Jamie, Julio, Emily, Robbo and Sharon.

This is just one of the many fantastic fundraisers that have kindly supported LMRUK over the past year - we simply could not run these services without them!

Thanks to Funders

- Lloyds Bank Staff
- N Smith Charitable Settlement
- Robert Luff Foundation
- Mackintosh Foundation
- Orange Tree Trust
- Hilary Awdry Charitable Trust
- The Medicash Foundation
- Hospital Saturday Fund
- Michael Watson Charitable Trust
- Marsland Mcadoo Charitable Settlement
- Hemby Charitable Trust
- Hudson Charitable trust
- Barratt Developments PLC
- CharitableFoundation
- John Mason Charitable trust
- Prowting Charitable Foundation
- Worcester Bosch
- L and R Gilley Charitable Trust
- LCVS Eli Lily and Co Speke Ops
- Golders green Foundation
- Belvedere Trust
- Dalgleish Trust
- Sunset Charitable Trust
- The James Dyson Foundation

Staff and Trustees

Trustees

- Sergejs Vinogradovs (Chair)
- Tatjana Vinogradova
- Victoria Kieran
- Julija Sidorika

Staff Team

- Dr Joanna Tilley - Interim Operations Director
- Lucy Heron - Office Manager
- Richard Thompson - Call Centre
- Kate Williams - PT Fundraiser
- Karina Zaiceva - Project Manager

Thanks to Individuals and supporters

- Best Freelance Design Ltd
- Smart Cells International
- West Lancs & Merseyside Myeloma Support Group
- Fundraising Support Ltd
- KOR Communications
- Phlebotomy UK Ltd
- Research Review Committee
- Lister Wilder

Leukaemia & Myeloma Research UK

leukaemiamyelomaresearchuk.org

Registered charity number 1161622 (England & Wales), SC046106 (Scotland),
Company Limited by guarantee Registered number 09481278

Accounts 31 March 2024





Leukaemia & Myeloma Research UK Ltd

Report and accounts for the year ended 31 March 2024

Contents

	Page
Charity information	1
Trustees' Annual Report	1
Statement of directors' responsibilities	5
Independent Examiner's Report	7
Funds Statements:-	
Statement of Financial Activities	10
Statement of Financial Activities - Prior Year statement	11
Movements in funds	13
Income and Expenditure account	14
Balance sheet	15
Notes to the accounts	17

Leukaemia & Myeloma Research UK Ltd

Company Registration Number - 09481278

Trustees' Annual Report for the year ended 31 March 2024

The Trustees present their Report and Accounts for the year ended 31 March 2024, which also comprises the Directors' Report required by the Companies Act 2006.

Reference and administrative details

The charity name.

The legal name of the charity is:- Leukaemia & Myeloma Research UK Ltd.

The charity is also known by its operating name, LMR UK Ltd .

The charity's areas operation and UK charitable registration.

The charity is registered in England & Wales with the Charity Commission in England & Wales (CCEW) with charity number 1161622.

The charity is also registered in Scotland, with charity number SC046106 as it has operations in Scotland.

The charity does not operate in any overseas jurisdictions.

Legal structure of the charity

The charity is constituted as a company limited by guarantee, registered under the Companies Acts . The governing document of the charity is the Memorandum and Articles of Association establishing the company under company legislation.

The governing document is dated 10 March 2015
There are no restrictions in the governing documents on the operation of the Charity or on its investment powers other than those imposed by Charity Law.

By operation of law all, trustees are directors under the Companies Act 2006 and all directors are trustees under Charities legislation and have responsibilities, as such, under both company and charity legislation.

The trustees are all individuals.

The principal operating address, telephone number, email and web addresses of the charity are:-

Unit 127, North Mersey Business Centre
Woodward Road, Liverpool
Merseyside, L33 7UY
Telephone 08003687309

Email Address info@leukaemiamyelomaresearchuk.org Web address https://www.leukaemiamyelomaresearc

The registered office of the charity for Companies Act purposes is the same as the operating address shown above.

Leukaemia & Myeloma Research UK Ltd

Company Registration Number - 09481278

Trustees' Annual Report for the year ended 31 March 2024

The Trustees in office on the date the report was approved were:-

Sergejs Vinogradovs
Tatjana Vinogradova

Julija Sidorika
Victoria Kieran

The following persons served as Trustees during the year ended 31 March 2024 :-

The trustees who served as a trustee in the reporting period were as shown above, and there were no changes during the year, or in the period between the year end and the approval of the accounts.

All the trustees are also members of the charity.

Objects and activities of the charity

The purposes of the charity as set out in its governing document.

The objectives of the charity are set out in the Memorandum of Association of 14 July 2015. They are:
1. to protect and promote the health of the public in particular by research into the nature, causes, diagnosis, prevention, treatment and cure of leukaemia and myeloma.
2. development of research into practical applications for the prevention. Treatment and cure leukaemia and myeloma and raise public understanding of such matters.

The main activities undertaken in relation to those purposes during the year.

Research grants are provided in order to promote the health of the public by research into the nature, cause, disnoses, preventon, treatment and cure of leukaemia and myeloma.

The main activities undertaken during the year to further the charity's purpose for the public benefit.

Two research grants were provided this year totalling £57,500.00

Public awareness was a big focus this year with the charity undertaking the project of collecting clothes and selling these to raise funds.

The trustees have had regard to the Charity Commission's guidance on public benefit in managing the activities of the charity.

Leukaemia & Myeloma Research UK Ltd

Company Registration Number - 09481278

Trustees' Annual Report for the year ended 31 March 2024

The main achievements and performance of the charity during the year.

As advised, the charity have been able to provide two large grants for research purposes.

There was a large increase in awareness via the donation of clothes. More funds were in turn raised to support the charity.

The difference the charity's performance during the year has made to the beneficiaries of the charity and wider society.

The charity was able to raise alot more funds this year which in turn raised awareness of the disease. This has benefited the wider society with more people being aware of the effects and the importance of research to support those living with the disease.

Structure, governance and management of the charity

The methods used to recruit and appoint new charity trustees.

Proposals for new Trustees are made by the Chair after making appropriate enquiries. Appointments are then made by election by the existing board of Trustees.

The trustees' bankers and advisors

Accountants	KBH Accountants Ltd - 255 Poulton Road, Wallasey, CH44 4BT

Financial review

The charity's financial position at the end of the year ended 31 March 2024

The financial position of the charity at 31 March 2024 and comparatives for the prior period, as more fully detailed in the accounts, can be summarised as follows:-

	2024	2023
	£	£
Net income	37,883	35,474
Unrestricted Revenue Funds available for the general purposes of the charity	346,737	311,735
Restricted Revenue Funds	43,467	40,586
Total Funds	390,204	352,321

Financial review of the position at the reporting date, 31 March 2024 .

Trustees' Annual Report for the year ended 31 March 2024

Overall surplus stands at £390,204 and will be distributed in the following way: £150,000 for the Reserves; £25,000 for Research Grants, and £215,204 for charity development, including MCB, e-shop, and the Donate Clothes 4 Sammy project.

The trustees consider the financial performance by the charity during the year to have been satisfactory.

Policies on reserves.

The trustees collectively aim to maintain free reserves in unrestricted funds within a range equivalent to twelve months of unrestricted charitable expenditure. This targeted level is deemed essential by the trustees to ensure an adequate financial cushion for covering support and governance costs. The Reserves Policy will undergo an annual review, aligning with the scrutiny of the charity's annual accounts.

In light of the events of the past year, marked by a significant surge in inflation, escalating living costs, and an increased risk of economic downturn, the trustees have determined that a prudent Reserves amount must be set at £150,000. This decision is reflective of the charity's commitment to financial resilience and its responsiveness to the evolving economic landscape.

Availability and adequacy of assets of each of the funds

The board of trustees is satisfied that the charity's assets in each fund are available and adequate to fulfil its obligations in respect of each fund.

Details of The Independent Examiner

Olivia Higgins FCCA

Member of Chartered Certified Acocuntants

255 Poulton Road

Wallasey

Wirral

CH44 4BT

Trustees' Annual Report for the year ended 31 March 2024

Statement of the Directors' and Trustees' Responsibilities

The charity's trustees are responsible for the preparation of the accounts in accordance with the terms of the Companies Act 2006, the Charities Act 2011 and the Charities (Accounts and Reports) Regulations 2008. Notwithstanding the explicit requirement in the extant statutory regulations,the Charities (Accounts and Reports) Regulations 2008, to prepare the financial statements in accordance with the SORP 2005, in view of the fact that the SORP 2005 has been withdrawn, the Trustees determined to interpret this responsibility as requiring them to follow current best practice and prepare the accounts according to the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2019, applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), .

In particular, the Companies Act 2006 and charity law require the Board of Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity as at the end of the financial year and of the surplus or deficit of the charity. In preparing those financial statements the Board is required to :-

- to prepare the accounts in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law).
- select suitable accounting policies and apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business;
- state whether applicable accounting standards and statements of recommended practice have been followed, subject to any material departures disclosed and explained in the financial statements;

The law requires that the trustees must not approve the accounts unless they are satisfied that they give a true and fair view of the state of affairs of the charity and of the surplus or deficit of the charity for the year.

The Trustees are also responsible for maintaining adequate accounting records which disclose with reasonable accuracy at any time the financial position of the charity and which are sufficient to show and explain the charity's transactions and enable them to ensure that the financial statements comply with the Companies Act 2006 and comply with regulations made under the Charities Act. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Trustees are also responsible for the contents of the Trustees' report, and the statutory responsibility of the Independent Examiner in relation to the Trustees' report is limited to examining the report and ensuring that , on the face of the report, there are no material inconsistencies with the figures disclosed in the financial statements.

Leukaemia & Myeloma Research UK Ltd

Company Registration Number - 09481278

Trustees' Annual Report for the year ended 31 March 2024

Method of preparation of accounts - Small company provisions

The financial statements are set out on pages 10 to 36.
The financial statements have been prepared implementing the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2019, applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), and in accordance with the Financial Reporting Standard 102 (effective 1st January 2016)
These financial statements have been prepared in accordance with the provisions in Part 15 of the Companies Act 2006. applicable to companies subject to the small companies regime.

This report was approved by the board of trustees on 11 December 2024.

TATJANA VINOGRADOVA
Director and Trustee

Leukaemia & Myeloma Research UK Ltd

Report of the Independent Examiner to the Trustees of the charitable company on the accounts for the year ended 31 March 2024

I report to the Trustees on my examination of the financial statements of the charitable company on pages 10 to 36 for the year ended 31 March 2024 which have been prepared in accordance with the Charities Act 2011 (the Act) and with the Financial Reporting Standard 102, (effective 1st January 2016) as modified by FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2019, applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), published by the Charity Commission in England & Wales (CCEW) , and under the historical cost convention and the accounting policies set out on page 17.

Respective responsibilities of the Trustees and the Independent Examiner and the basis of the report

As described on page 5, you, the charitable company's Trustees, who are also the Directors of the Company for the purposes of Company law, are responsible for the preparation of the financial statements in accordance with the Companies Act 2006, the Charities Act 2011 and all other applicable law and with United Kingdom Generally Accepted Accounting Practice, applicable to smaller entities, and for being satisfied that the financial statements give a true and fair view.

The Trustees consider that the audit requirement of Section 144(1) of the Charities Act 2011 (the Act) does not apply, and that there is no requirement in the memorandum and articles of the charity for the conducting of an audit, and that the accounts do not require an audit in accordance with Part 16 of the Companies Act 2006 and that no member or members have requested an audit pursuant to Section 476 of the Companies Act 2006. As a consequence, the Trustees have elected that the financial statements be subject to independent examination.

Having satisfied myself that the financial statements are not required to be audited under any legal provision, or otherwise, and are eligible for independent examination, it is my responsibility to:-

a) examine the financial statements of the charity under Section 145 of the Act;

b) follow the applicable procedures in the Directions given by the Charity Commission under section 145(5)(b) of the Act.

Basis of Independent Examiner's Statement and scope of work undertaken

Since the charitable company's gross income exceeded £250,000, the charitable company's examiner must be a member of a body listed in section 145 of the Act. I confirm that I am qualified to undertake the examination because I am an authorised member of Chartered Certified Acocuntants , which is one of the listed bodies.

I report in respect of my examination of the charity's financial statements carried out under s145 of the Act. In carrying out my examination, I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act setting out the duties of an independent examiner in relation to the conducting of an independent examination. An independent examination includes a review of the accounting records kept by the charitable company and of the accounting systems employed by the charitable company and a comparison of the financial statements presented with those records. It also includes consideration of any unusual items or disclosures in the financial statements, and seeking explanations from you, as Trustees, concerning such matters. The purpose of the examination is to establish as far as possible that there have been no breaches of charity legislation and that, on a test basis of evidence relevant to the amounts and disclosures made, the financial statements comply with the SORP.

The procedures undertaken do not provide all the evidence that would be required in an audit, and information supplied by the Trustees in the course of the examination is not subjected to audit tests or enquiries and does not cover all the matters that an auditor would consider in arriving at an opinion. The planning and conduct of an audit goes beyond the limited assurance that an independent examination can provide

Consequently, I do not express an audit opinion on the view given by the financial statements, and in particular, I express no opinion as to whether the financial statements give a true and fair view of the affairs of the charity, and my report is limited to the matters set out in the statement below.

I planned and performed my examination so as to satisfy myself that the objectives of the independent examination are achieved and before finalising the report I obtained written assurances from the Trustees of all material matters.

Independent Examiner's Statement, Report and Opinion

Attention is drawn to the accounting policy stating that, notwithstanding the explicit requirement in the extant statutory regulations, the Charities (Accounts and Reports) Regulations 2008, to prepare the financial statements in accordance with the SORP 2005, in view of the fact that the SORP 2005 has been withdrawn, and in order to accord with current best practice, the Trustees have determined to prepare the financial statements in accordance with the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2019, applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), . I concur with this approach, and any references in my report to the regulations should be read subject to this comment.

Subject to the limitations upon the scope of my work as detailed above, I have completed my examination: and can confirm that:-

The accounts of this charitable company are not required to be audited under Part 16 of the Companies Act 2006;

The gross income of the charitable company in the year ended 31 March 2024 appears to exceed the sum specified in Section 145(3) of the Act, namely £250000, and that I am qualified to act as Independent Examiner in accordance with that section by virtue of my being a qualified member of Chartered Certified Acocuntants ;

This is a report in respect of an examination carried out under 145 of the Act and in accordance with Directions given by the Charity Commission under section 145(5)(b) of the Act which may be applicable;

and that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:-

accounting records were not kept in respect of the charity as required by Section 386 of the Companies Act 2006 and Section 130 of The Charities Act 2011;

the financial statements do not accord with those records; or

the financial statements do not comply with the applicable requirements concerning the form and content of accounts set out in section 396 of the Companies Act 2006 other than any requirement that the accounts give a 'true and fair' view, which is not a matter considered as part of an independent examination;

have not been prepared in accordance with the methods and principles set out in the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2019, applicable to all accounting periods beginning on or after 1st January 2019), (The SORP).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.

Signed:-

Olivia Higgins FCCA - Independent Examiner
Chartered Certified Acocuntants
255 Poulton Road
Wallasey
Wirral
CH44 4BT

This report was signed on 11/12/2024

Leukaemia & Myeloma Research UK Ltd - Statement of Financial Activities for the year ended 31 March 2024

Statement of Financial Activities (including the Income and Expenditure Account for the year ended 31 March 2024, as required by the Companies Act 2006)

	SORP Ref	Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
		2024	2024	2024	2023
		£	£	£	£
Income & Endowments from:					
Donations & Legacies	A1	191,132	51,705	**242,837**	173,975
Charitable activities	A2	63,177	-	**63,177**	20,553
Investments	A4	4,317	-	**4,317**	665
Other	A5	50,000	-	**50,000**	50,063
Total income	**A**	**308,626**	**51,705**	**360,331**	**245,256**
Expenditure on:					
Raising funds	B1	14,389	-	**14,389**	19,100
Charitable activities	B2	259,235	48,824	**308,059**	190,682
Total expenditure	**B**	**273,624**	**48,824**	**322,448**	**209,782**
Net income for the year		**35,002**	**2,881**	**37,883**	**35,474**
Net movement in funds		**35,002**	**2,881**	**37,883**	**35,474**
Total funds brought forward		311,735	40,586	**352,321**	316,847
Total funds carried forward		**346,737**	**43,467**	**390,204**	**352,321**

The 'SORP Ref' indicated above is the classification of income set out in the formal SORP documents. As required by paragraph 4.60 of the SORP, the brought forward and carried forward funds above have been agreed to the Balance Sheet.

A separate Statement of Total Recognised Gains and Losses is not required as this statement includes all recognised gains and losses.

All the prior year transactions were unrestricted items, and no further analysis is required

All activities derive from continuing operations

The notes attached on pages 17 to 36 form an integral part of these accounts.

Leukaemia & Myeloma Research UK Ltd - Statement of Financial Activities for the year ended 31 March 2024

Leukaemia & Myeloma Research UK Ltd - Analysis of prior year total funds, as required by paragraph 4.2 of the SORP

	SORP Ref	Prior Year Unrestricted Funds 2023 £	Prior Year Restricted Funds 2023 £		Prior Year Total Funds 2023 £
Donations & Legacies	A1	173,975	-		**173,975**
Charitable activities	A2	20,553	-		**20,553**
Investments	A4	665	-		**665**
Other	A5	50,063	-	-	**50,063**
Total income	**A**	245,256	-		**245,256**
Expenditure on:					
Raising funds	B1	19,100	-		**19,100**
Charitable activities	B2	190,682	-		**190,682**
Total expenditure	**B**	**209,782**	-		**209,782**
Net income for the year		35,474	-		35,474
Net movement in funds		**35,474**	-		**35,474**
Total funds brought forward		285,330	31,517		**316,847**
Total funds carried forward		**320,804**	**31,517**		**352,321**

All activities derive from continuing operations

A separate Statement of Total Recognised Gains and Losses is not required as this statement includes all recognised gains and losses.'

The notes attached on pages 17 to 36 form an integral part of these accounts.

Leukaemia & Myeloma Research UK Ltd - Statement of Financial Activities for the year ended 31 March 2024

Leukaemia & Myeloma Research UK Ltd - Resources applied in the year ended 31 March 2024 towards fixed assets for Charity use:-

	2024 £	2023 £
Funds generated in the year as detailed in the SOFA	-	-
Resources applied on functional fixed assets	(24,570)	(1,599)
Net resources available to fund charitable activities	**(24,570)**	**(1,599)**

The resources applied on fixed assets for charity use represents the cost of additions less proceeds of any disposals.

The notes attached on pages 17 to 36 form an integral part of these accounts.

Leukaemia & Myeloma Research UK Ltd - Statement of Financial Activities for the year ended 31 March 2024

Movements in revenue and capital funds for the year ended 31 March 2024

Revenue accumulated funds

	Unrestricted Funds 2024 £	Restricted Funds 2024 £	Total Funds 2024 £	Last year Total Funds 2023 £
Accumulated funds brought forward	311,735	40,586	352,321	**316,847**
Recognised gains and losses before transfers	35,002	2,881	37,883	35,474
	346,737	**43,467**	**390,204**	**352,321**
(From)/To restricted revenue funds	-		-	-
Closing revenue funds	**346,737**	**43,467**	**390,204**	**352,321**

Summary of funds	Unrestricted and Designated funds 2024 £	Restricted Funds 2024 £	Total Funds 2024 £	Last Year Total Funds 2023 £
Revenue accumulated funds	346,737	43,467	**390,204**	352,321
Total funds	**346,737**	**43,467**	**390,204**	**352,321**

The notes attached on pages 17 to 36 form an integral part of these accounts.

Leukaemia & Myeloma Research UK Ltd - Statement of Financial Activities for the year ended 31 March 2024

Leukaemia & Myeloma Research UK Ltd
Income and Expenditure Account for the year ended 31 March 2024 as required by the Companies Act 2006

	2024	2023
	£	£
Income		
Income from operations	306,014	194,528
Investment income		
Interest receivable	4,317	665
Other operating income	50,000	50,063
Gross income in the year before exceptional items	**360,331**	**245,256**
Gross income in the year including exceptional items	**360,331**	**245,256**
Expenditure		
Charitable expenditure, excluding depreciation and amortisation	300,892	189,657
Depreciation and amortisation	7,167	1,025
Fundraising costs	14,389	19,100
Total expenditure in the year	**322,448**	**209,782**
Net income before tax in the financial year	**37,883**	**35,474**
Retained surplus for the financial year	**37,883**	**35,474**

All activities derive from continuing operations

In accordance with the provisions of the Companies Act 2006, the headings and subheadings used in the Income and Expenditure account have been adapted to reflect the special nature of the charity's activities.

Leukaemia & Myeloma Research UK Ltd - Balance Sheet as at 31 March 2024

	Note	SORP Ref		2024 £		2023 £
Fixed assets		A				
Tangible assets	6	A2		19,227		1,824
Total fixed assets				19,227		1,824
Current assets		B				
Stocks		B1	27,319		17,490	
Debtors	8	B2	12,326		5,060	
Cash at bank and in hand		B4	335,511		333,510	
Total current assets			375,156		356,060	
Creditors: amounts falling due within one year	9	C1	(4,179)		(5,563)	
Net current assets				370,977		350,497
The total net assets of the charity				**390,204**		**352,321**
The total net assets of the charity are funded by the funds of the charity, as follows:-						
Restricted funds						
Restricted Revenue Funds	11	D2	43,467		40,586	
				43,467		40,586
Unrestricted Funds						
Unrestricted Revenue Funds	11	D3	346,737		311,735	
				346,737		311,735
Total charity funds				**390,204**		**352,321**

The 'SORP Ref' indicated above is the classification of Balance Sheet items as set out in the formal SORP documents. As required by paragraph 4.60 of the SORP, the brought forward and carried forward funds above have been agreed to the SOFA..

The directors are satisfied that the company is entitled to exemption from the requirement to obtain an audit under section 477 of the Companies Act 2006.

The members have not required the company to obtain an audit in accordance with section 476 of the Act.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.

The charity is subject to Independent Examination under charity legislation, and the report of the Independent Examiner is on page 9.

The financial statements have been prepared in accordance with the provisions in Part 15 of the Companies Act 2006. applicable to companies subject to the small companies regime.

TATJANA VINOGRADOVA
Trustee
Approved by the board of trustees on 11 December 2024

The notes attached on pages 17 to 36 form an integral part of these accounts.

Notes to the Accounts for the year ended 31 March 2024

1 Accounting policies

Policies relating to the production of the accounts.

Basis of preparation and accounting convention

The accounts have been prepared on the accruals basis, under the historical cost convention, and in accordance with the Financial Reporting Standard 102, (effective 1st January 2016) and 'FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2019, applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), published by the Charity Commission in England & Wales (CCEW) , and in accordance with all applicable law in the charity's jurisdiction of registration, except that the charity has prepared the financial statements in accordance with the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2019, applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), in preference to the previous SORP, the SORP 2005, which has been withdrawn, notwithstanding the fact that the extant statutory regulations, the Charities (Accounts and Reports) Regulations 2008 refer explicitly to the SORP 2005. This has been done to accord with current best practice.

Going Concern

The charitable activities are entirely dependent on continuing grant aid and voluntary donations as well as trading revenues. As a consequence, the going concern basis is dependent on the future flow of these uncertain funding streams. Accordingly, the Trustees have obtained forecasts and, after reviewing the financial forecasts for future periods, the Trustees are satisfied that, at the time of approving the financial statements, it is appropriate to adopt the going concern basis in preparing the financial statements. Other than these matters, the Trustees are not aware of any material uncertainites about the charity's ability to continue as a going concern.

Policies relating to categories of income and income recognition.

Nature of income

Gross income represents the value, net of value added tax and discounts, of goods provided to customers and work carried out in respect of services provided to customers.

Categories of Income

Income is categorised as income from exchange transactions (contract income) and income from non-exchange transactions (gifts), investment income and other income.

Income from exchange transactions is received by the charity for goods or services supplied under contract or where entitlement is subject to fulfilling performance related conditions. The income the charity receives is approximately equal in value to the goods or services supplied by the charity to the purchaser.

Income from a non-exchange transaction is where the charity receives value from the donor without providing equal value in exchange, and includes donations of money, goods and services freely given without giving equal value in exchange.

Income recognition

Income, whether from exchange or non exchange transactions, is recognised in the statement of financial activities (SOFA) on a receivable basis, when a transaction or other event results in an increase in the charity's assets or a reduction in its liabilities and only when the charity has legal entitlement, the income is probable and can be measured reliably.

Dividends are accrued when the shareholder's right to receive payment is established.

Income subject to terms and conditions which must be met before the charity is entitled to the resources is not recognised until the conditions have been met.

All income is accounted for gross, before deducting any related fees or costs.

Notes to the Accounts for the year ended 31 March 2024

Income from legacies

Income from legacies is recognised when the charity has sufficient evidence that a gift has been left to them, that where required, probate has been granted, the executor is satisfied that the property in question will not be required to satisfy claims in the estate, that it is probable that the amount will be received by the charity, and the amount to be received can be estimated with sufficient accuracy, and that any conditions attached to the legacy are either within the control of the charity or have been met.

Where a payment is received from an estate or is notified as receivable by the executors after the reporting date and before the accounts are authorised for issue but it is clear that the payment had been agreed by the executors prior to the end of the reporting period, then the amount concerned is treated as an adjusting event and accrued as income in the accounting period if receipt is probable.

Where the charity has established entitlement to a legacy but there is uncertainty as to the amount of the payment, details of the legacy aredisclosed as a contingent asset until the criteria for income recognition are met. Where a legacy is subject to the interest of a life tenant, the legacy is not recognised as income until the death of the life tenant.

If it is doubtful that full settlement of a legacy debtor will be received, then an adjustment is made to reduce the amount of the legacy debtor and legacy income rather than charging the adjustment as expenditure in the Statement of Financial Activities

Donated goods, facilities and services

Donated fixed assets are recognised at the current fair value. All such donations are recognised as donation income, and debited to fixed assets.

Donated goods that are not fixed assets are accounted for at a fair value, unless it is impractical to reliably measure the value of the donated items.

In the absence of any direct evidence of fair value of donated goods, then a value is derived from the cost of the item to the donor or, in the case of goods that are expected to be sold, the estimated resale value after deducting any anticipated costs of sales.

If it is impracticable to measure the fair value of goods donated for resale, or the costs of valuation outweigh the benefits, the donated goods are recognised as income when sold, with an equivalent amount being recognised as an expense.

The costs of goods donated for distribution to beneficiaries is deemed to be the fair value of those goods upon receipt. When the goods are distributed freely or for a nominal consideration, then the carrying amount is adjusted at the time of sale, to the value at the point of distribution and the adjustment is shown as a cost of donations made.

The carrying amount of any stock held for distribution is assessed for impairment at the reporting date. All donated goods are recognised as donation income, and debited to trading stock.When trading stock is subsequently sold, or appropriated to meet an expense, then the carrying value of the stock is recognised as an expense. In accordance with the SORP, goods donated for distribution to beneficiaries, or for consumption by the charity are included in *'legacies and donations'*. Goods donated for resale are included in *'Income from other trading activities'*

The cost of any stock of goods donated for distribution to beneficiaries is deemed to be the fair value of those gifts at the time of their receipt. If the goods held are to be distributed freely or for a nominal consideration, then the carrying amount is subsequently adjusted to reflect the lower of deemed cost adjusted for any loss of service potential and replacement cost. Replacement cost is the economic cost incurred if the charity was to replace the service potential of the donated goods at its own expense in the most economic manner.

Donated services and facilities (including seconded staff and use of property) are included in the accounts on the basis of the value of the gift to the charity.

All donated services and facilities are recognised as donation income when received,(provided the value of the gift can be measured reliably) and recognised as an expense with an equivalent value.

Notes to the Accounts for the year ended 31 March 2024

Policies relating to expenditure on goods and services provided to the charity.

Recognition of liabilities and expenditure

A liability, and the related expenditure, is recognised when a legal or constructive obligation exists as a result of a past event, and when it is more likely than not that a transfer of economic benefits will be required in settlement, and when the amount of the obligation can be measured or reliably estimated..

Liabilities arising from future funding commitments and constructive obligations, including performance related grants, where the timing or the amount of the future expenditure required to settle the obligation are uncertain, give rise to a provision in the accounts, which is reviewed at the accounting year end. The provision is increased to reflect any increases in liabilities, and is decreased by the utilisation of any provision within the period, and reversed if any provision is no longer required. These movements are charged or credited to the respective funds and activities to which the provision relates.

Allocating costs to activities

Direct costs that are specifically related to an activity are allocated to that activity. Shared direct costs and support costs are apportioned between activities.

The basis for apportionment, which is consistently applied, and proportionate to the circumstances, is :-

Staffing - on the basis of time spent in connection with any particular activity.
Staffing - on a per capita basis, based on the number of of people employed within any partiular activity.
Premises related costs - on the proportion of floor area occupied by a particular activity.
Non specific support costs - on the basis of the usage of resources, in terms of time taken, capacity used, request made or other measures

Policies relating to assets, liabilities and provisions and other matters.

Tangible fixed assets

Tangible fixed assets are measured at their original cost value, or subsequent revaluation, or if donated, as described above. Cost value includes all costs expended in bringing the asset into its intended working condition.

Depreciation has been provided at the following rates in order to write off the assets to their anticipated residual value over their estimated useful lives.

Plant and machinery	25 % straight line
Motor vehicles	25 % straight line

A regular annual review of the likelihood of asset impairment is undertaken.

Notes to the Accounts for the year ended 31 March 2024

Accounting for capital grants and fixed asset funds.

Gifts of tangible fixed assets or grants of a capital nature, given for the purposes of acquiring specific assets to be fully utilised in the furtherance of the objects of the charity, are credited to fixed asset funds after the donated asset has been received or sums have been properly expended on the restricted purpose.

Where the terms of the gift require the charity to hold the asset on an ongoing basis for a specific purpose, then the fixed asset fund so created is categorised as a restricted fixed asset fund, and the relevant restrictions are noted in the fixed asset note 6.

Where the terms of the gift are met once the asset is acquired, so allowing the charity to use the asset on an unrestricted basis, including the right to receive the proceeds of any future sale of the asset on an unrestricted basis, then the fixed asset fund so created is categorised as a designated fixed asset fund.

When assets are acquired for the furtherance of the charity's objects, utilising the charity's own unrestricted funds, a transfer is made from unrestricted funds to a designated fixed asset fund.

Whether acquired with unrestricted or restricted funds, the asset acquired is initially shown in the balance sheet at the full cost of acquisition or subsequent revaluation.

As the related assets are depreciated, in accordance with the depreciation policy,in order to reflect the dimunition in the asset,a transfer is made from the relevant fixed asset funds to either unrestricted or restricted revenue funds, as appropriate to the terms of the original gift, if any.

The effect of this policy is that the aggregate of all fixed asset funds shall equate to the net book value of fixed assets.

In the first year that this policy was adopted, a transfer to fixed asset funds was made equivalent to the net book value of the assets.

Any residual liability to the donor arising from, for example, the asset's future sale, is disclosed as a contingent liability unless the event that would trigger repayment of the grant becomes probable in which case a liability for repayment is recognised.

Insofar as this policy relates to Government grants and to the extent that it may be a departure from the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2019, applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), such departure is justified on the basis that it is in order to comply with the SORP.

Stocks and work in progress

Stock is valued at the lower of cost and net realisable value.

Debtors

Debtors are measured at their recoverable amounts at the balance sheet date.

Creditors and provisions

Liabilities are measured at their settlement amount. A liability is recognised for the the amount the Charity anticpates it will pay to settle the deb or the amount it has received as an advance payment for goods or services it must provide.

Financial instruments including cash and bank balances

Cash held by the charity is included at the amount actually held and counted at the year end. Bank balances, whether in credit or overdrawn, are shown at the amounts properly reconciled to the bank statements.

Fund Accounting

Unrestricted funds are available for use at the discretion of the trustees in furtherance of the general objectives of the charity.

There are no endowment funds.

Notes to the Accounts for the year ended 31 March 2024

2 Liability to taxation

The Trustees consider that the charity satisfies the tests set out in Paragraph 1 Schedule 6 of the Finance Act 2010 for UK corporation tax purposes. Accordingly, the Charity is potentially exempt from taxation in respect of income or capital gains received within categories covered by chapter 3 part 11 of the Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992, to the extent that such income or gains are applied exclusively on the specific charitable objects of the charity and for no other purpose.

3 Winding up or dissolution of the charity

If upon winding up or dissolution of the charity there remain any assets, after the satisfaction of all debts and liabilities, the assets represented by the accumulated fund shall be transferred to some other charitable body or bodies having similar objects to the charity.

4 Defined contribution pension schemes

Any liabilites and assets associated with the scheme are shown under debtors and creditors.

5 Remuneration and payments to Trustees and persons connected with them

The trustees received payments in the amount of £1,082 as travel expenses related to providing services for clothing collection.

6 Tangible fixed assets

Current Year	Land and Buildings	Plant & Machinery	Motor Vehicles	Total
	£	£	£	£
Cost				
At 1 April 2023	-	4,099	-	4,099
Additions	-	575	23,995	24,570
At 31 March 2024	**-**	**4,674**	**23,995**	**28,669**
Depreciation				
At 1 April 2023	-	2,275	-	2,275
Charge for the year	-	1,168	5,999	7,167
At 31 March 2024	**-**	**3,443**	**5,999**	**9,442**
Net book value				
At 31 March 2024	**-**	**1,231**	**17,996**	**19,227**
At 31 March 2023	**-**	**1,824**	**-**	**1,824**

Notes to the Accounts for the year ended 31 March 2024

7 Stocks & Work in Progress

	2024	2023
	£	£
Stocks before write downs	27,319	17,490
	27,319	17,490

8 Debtors

	2024	2023
	£	£
Trade debtors	6,000	833
Prepayments and accrued income	294	280
Other debtors	6,032	3,947
	12,326	**5,060**

9 Creditors: amounts falling due within one year

	2024	2023
	£	£
Trade creditors	3,099	3,643
Accruals	1,080	1,920
	4,179	**5,563**

10 Particulars of how particular funds are represented by assets and liabilities

At 31 March 2024	Unrestricted funds	Designated funds	Restricted funds	Total Funds
	£	£	£	£
Tangible Fixed Assets	19,227	-	-	**19,227**
Current Assets	331,689		43,467	**375,156**
Current Liabilities	(4,179)	-	-	**(4,179)**
	346,737	**-**	**43,467**	**390,204**

At 1 April 2023	Unrestricted funds	Designated funds	Restricted funds	Total Funds
	£	£	£	£
Tangible Fixed Assets	1,824	-	-	**1,824**
Current Assets	315,474	-	40,586	**356,060**
Current Liabilities	(5,563)	-	-	**(5,563)**
	311,735	**-**	**40,586**	**352,321**

Notes to the Accounts for the year ended 31 March 2024

11 Change in total funds over the year as shown in Note 10 , analysed by individual funds

	Funds brought forward from 2023	Movement in funds in 2024	Transfers between funds in 2024	Funds carried forward to 2025
		See Note 12	See Note 13	
	£	£	£	£
Unrestricted and designated funds:-				
Unrestricted Revenue Funds	311,735	35,002	-	**346,737**
Total unrestricted and designated funds	**311,735**	**35,002**	**-**	**346,737**
Restricted funds:-				
Research	-	1,350	-	**1,350**
Model Cell Biobank	40,586	1,531	-	**42,117**
Total restricted funds	**40,586**	**2,881**	**-**	**43,467**
Total charity funds	**352,321**	**37,883**	**-**	**390,204**

12 Analysis of movements in funds over the year as shown in Note 11

	Income	Expenditure	Other Gains & Losses	Movement in funds
	2024	2024	2024	2024
	£	£	£	£
Unrestricted and designated funds:-				
Unrestricted Revenue Funds	308,626	(273,624)	-	**35,002**
Restricted funds:-				
Research	39,050	(37,700)	-	**1,350**
Model Cell Biobank	12,655	(11,124)	-	**1,531**
	360,331	**(322,448)**	**-**	**37,883**

Notes to the Accounts for the year ended 31 March 2024

13 The purposes for which the funds as detailed in note 11 are held by the charity are:-

Unrestricted and designated funds:-	
Unrestricted Revenue Funds	These funds are held for the meeting the objectives of the charity, and to provide reserves for future activities, and , subject to charity legislation, are free from all restrictions on their use.
Restricted funds:-	
Research	The purpose of these funds is described under the accounting policy.
Model Cell Biobank	The purpose of these funds is described under the accounting policy.

14 Ultimate controlling party

The charity is under the control of its legal members.

For companies ltd by guarantee - Every member of the charity is obliged to contribute such amount as may be required to contribute to the assets of the company in the event of its being wound up while he or she is a member, or within one year after he or she ceases to be a member.

Leukaemia & Myeloma Research UK Ltd

Detailed analysis of income and expenditure for the year ended 31 March 2024 as required by the SORP 2015

This analysis is classsified by conventional nominal descriptions and not by activity.

15 Donations, Grants and Legacies

	Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
	2024	2024	2024	2023
	£	£	£	£
Small donations individually less than £1000	3,297	-	**3,297**	8,415
Stripe Direct Donations	13,177	-	**13,177**	14,707
Holyhead Church	-	-	**-**	6,536
Facebook	1,508	-	**1,508**	2,523
Just Giving	60,725	-	**60,725**	47,846
Kiltwalk	-	-	**-**	2,880
In Memory	12,693	-	**12,693**	17,856
Muchloved	2,688	-	**2,688**	7,859
Giving.com	-	-	**-**	2,646
Paypal Giving	8,605	-	**8,605**	2,895
CAF	3,367	-	**3,367**	-
Total donations and gifts from individuals	**106,060**	**-**	**106,060**	**114,163**

Donations and gifts from individuals (Include HMRC refunds on gift aided donations) - Prior Year analysis

	Prior Year Unrestricted Funds	Prior Year Restricted Funds	Prior Year Total Funds
	2023	2023	2023
	£	£	£
Prior year	**114,163**	**-**	**114,163**

Leukaemia & Myeloma Research UK Ltd

Detailed analysis of income and expenditure for the year ended 31 March 2024 as required by the SORP 2015

	Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
	2024	2024	2024	2023
	£	£	£	£
Legacies receivable				
Small legacies individually less than £1000	750	-	**750**	-
Sylvia Allanson	-	-	**-**	1,500
Malcolm Squibb	-	-	**-**	5,000
David C Taylor	3,000	-	**3,000**	-
Nick Glynne/Martin Glynne	5,000	-	**5,000**	-
Holmes & Hills LLP	44,843	-	**44,843**	-
Jackson Lees Group Ltd	3,750	-	**3,750**	-
Catherine Dunne and Rachel O'Mallet	10,000	-	**10,000**	-
Total legacies receivable	**67,343**	**-**	**67,343**	**6,500**

Legacies receivable - Prior Year analysis

	Prior Year Unrestricted Funds	Prior Year Restricted Funds	Prior Year Total Funds
	2023	2023	2023
	£	£	£
Prior year	6,500	-	**6,500**

Leukaemia & Myeloma Research UK Ltd

Detailed analysis of income and expenditure for the year ended 31 March 2024 as required by the SORP 2015

	Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
	2024	2024	2024	2023
	£	£	£	£
Revenue grants from government and public bodies				
Small grants individually less than £1000	590	2,300	**2,890**	12,700
Orange Tree Trust	-	2,500	**2,500**	-
Hilary Awdry Trust	-	2,000	**2,000**	-
Medicash Trust	-	3,000	**3,000**	-
John Mason Charitable Trust	3,500	-	**3,500**	-
The Family Rich Charities Trust	-	-	**-**	5,000
Rathbone Investment Management	3,000	-	**3,000**	-
Michael Watson Charitable Trust	-	2,500	**2,500**	-
May Nearnshaw Charitable Trust	-	-	**-**	2,000
Ladbrokes Coral Trust	-	-	**-**	2,500
The Gledswood Charitable Trust	-	-	**-**	5,000
Dorothy Homes Charitable Trust	-	-	**-**	5,000
L & R Gilley Charitable Trust	-	2,500	**2,500**	-
The Sunset Charitable Trust	-	5,000	**5,000**	-
Total public sector revenue grants	**7,090**	**19,800**	**26,890**	**32,200**

Revenue grants from government and public bodies - Prior Year analysis

	Prior Year Unrestricted Funds	Prior Year Restricted Funds	Prior Year Total Funds
	2023	2023	2023
	£	£	£
Prior Year	32,200	-	**32,200**

Leukaemia & Myeloma Research UK Ltd

Detailed analysis of income and expenditure for the year ended 31 March 2024 as required by the SORP 2015

	Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
	2024	2024	2024	2023
	£	£	£	£
Revenue grants and donations from non public bodies				
Small grants individually less than £1000	1,397	3,255	**4,652**	427
Lunya Limited	-	-	**-**	7,685
Fundraising Support Ltd	**-**	2,650	**2,650**	10,000
Golders Green Foundation	**-**	2,000	**2,000**	-
Theatrical Society	-	-	**-**	3,000
Prowting Charitable Foundation	**-**	10,000	**10,000**	-
Robert Luff Foundation	-	10,000	**10,000**	-
Barratt Development	-	2,000	**2,000**	**-**
Bognor Regis Golf Club	2,767	**-**	**2,767**	**-**
CBRE ASD	1,500	**-**	**1,500**	**-**
Kiwanis London	2,000	**-**	**2,000**	**-**
Markeyl International	2,975	**-**	**2,975**	-
The Hospital Saturday Fund	-	2,000	**2,000**	**-**
Total private sector revenue grants	**10,639**	**31,905**	**42,544**	**21,112**

Revenue grants and donations from non public bodies (Include Gift Aid donations from subsidiaries) **-**

Prior Year analysis

	Prior Year Unrestricted Funds	Prior Year Restricted Funds	Prior Year Total Funds
	2023	2023	2023
	£	£	£
Prior Year	21,112	**-**	**21,112**

Detailed analysis of income and expenditure for the year ended 31 March 2024 as required by the SORP 2015

Total Donations, Grants and Legacies

Current year

		Unrestricted Funds 2024 £	Restricted Funds 2024 £	Current Year Total Funds 2024 £	Prior Year Total Funds 2023 £
Total Donations, Grants and Legacies	A1	**191,132**	**51,705**	**242,837**	**173,975**

Prior year

		Unrestricted Funds 2023 £	Restricted Funds 2023 £	Prior Year Total Funds 2023 £
Total Donations, Grants and Legacies	A1	**173,975**	**-**	**173,975**

16 Income from charitable activities - Trading Activities

Current year

	Current year Unrestricted Funds 2024 £	Current year Restricted Funds 2024 £	Current year Total Funds 2024 £	Prior Year Total funds 2023 £
Primary purpose and ancillary trading				
Sale of goods and services in accordance with the charity's objects	63,177	-	**63,177**	20,553
Total Primary purpose and ancillary trading	**63,177**	**-**	**63,177**	**20,553**

Prior year

	Prior Year Unrestricted Funds 2023 £	Prior Year Restricted Funds 2023 £	Prior Year Total Funds 2023 £
Primary purpose and ancillary trading			
Sale of goods and services in accordance with the charity's objects	20,553	-	**20,553**
Total Primary purpose and ancillary trading	**20,553**	**-**	**20,553**

Leukaemia & Myeloma Research UK Ltd

Detailed analysis of income and expenditure for the year ended 31 March 2024 as required by the SORP 2015

17 Total Income from charitable activities

Current year		Current year Unrestricted Funds 2024 £	Current year Restricted Funds 2024 £	Current year Total Funds 2024 £	Prior Year Total Funds 2023 £
Total income from charitable trading		63,177	-	**63,177**	20,553
Total from charitable activities	**A2**	**63,177**	**-**	**63,177**	**20,553**

Income from charitable activities - Prior Year analysis

Prior year	Prior Year Unrestricted Funds 2023 £	Prior Year Restricted Funds 2023 £	Prior Year Total Funds 2023 £
Total income from charitable trading	20,553	-	20,553
	20,553	**-**	**20,553**

Leukaemia & Myeloma Research UK Ltd

Detailed analysis of income and expenditure for the year ended 31 March 2024 as required by the SORP 2015

18 Investment income

		Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
		2024	2024	2024	2023
		£	£	£	£
Bank Interest Receivable		4,317	-	**4,317**	665
Total investment income	**A4**	**4,317**	**-**	**4,317**	**665**

Investment income - Prior Year analysis

	Unrestricted Funds	Restricted Funds	Total Funds
Prior Year	**665**	**-**	**665**

19 Other income and gains

Current year		Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
		2024	2024	2024	2023
		£	£	£	£
Royalties from the exploitation of intellectual property rights		50,000	-	**50,000**	50,063
Total other income	**A5**	**50,000**	**-**	**50,000**	**50,063**

Other income and gains - Prior year analysis

Prior Year		Prior Year Unrestricted Funds	Prior Year Restricted Funds	Prior Year Total Funds
		2023	2023	2023
		£	£	£
Royalties from the exploitation of intellectual property rights		50,063	-	**50,063**
Total other income	**A5**	**50,063**	**-**	**50,063**

Leukaemia & Myeloma Research UK Ltd

Detailed analysis of income and expenditure for the year ended 31 March 2024 as required by the SORP 2015

20 Expenditure on charitable activities - Direct spending

Current Year		Current year Unrestricted Funds 2024 £	Current year Restricted Funds 2024 £	Current year Total Funds 2024 £	Prior Year Total Funds 2023 £
Travel and Subsistence - Charitable Activities		470	-	**470**	**218**
Costs of activities and events		12,207	8,671	**20,878**	**36,661**
Consultancy and professional support		38,586	-	**38,586**	**33,333**
Travel and Subsistence - Trustees Travel Expenses		1,082	-	**1,082**	**1,292**
Total direct spending	**B2a**	**52,345**	**8,671**	**61,016**	**71,504**

Prior Year		Prior Year Unrestricted Funds 2023 £	Prior Year Restricted Funds 2023 £	Prior Year Total Funds 2023 £
Travel and Subsistence - Charitable Activities		218	-	**218**
Costs of activities and events		36,661	-	**36,661**
Consultancy and professional support		33,333	-	**33,333**
Travel and Subsistence - Trustees		1,292		**1,292**
Total direct spending	**B2a**	**71,504**	**-**	**71,504**

Leukaemia & Myeloma Research UK Ltd

Detailed analysis of income and expenditure for the year ended 31 March 2024 as required by the SORP 2015

21 Expenditure on charitable activities - Charitable trading

Current Year		Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
		2024	2024	2024	2023
		£	£	£	£
Cost of goods for primary purpose trading - Including movement in stock		54,307	-	54,307	7,874
Cost of Shipping, Freigh and Delivery		1,894	-	1,894	-
Total charitable trading costs	**B2b**	56,201	-	56,201	7,874

Prior Year		Prior Year Unrestricted Funds	Prior Year Restricted Funds	Prior Year Total Funds
		2023	2023	2023
		£	£	£
Cost of goods for primary purpose trading - Including movement in stock		7,874	-	7,874
Total charitable trading costs	**B2b**	7,874	-	7,874

22 Expenditure on charitable activities- Grant funding of activities

Current Year		Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
		2024	2024	2024	2023
		£	£	£	£
Grants made to organisations		19,800	37,700	57,500	25,000
Total grantmaking costs	**B2c**	19,800	37,700	57,500	25,000

Leukaemia & Myeloma Research UK Ltd

Detailed analysis of income and expenditure for the year ended 31 March 2024 as required by the SORP 2015

Breakdown of Grants made to organisations

Current Year		Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds
		2024	2024	2024
		£	£	£
Cardiff University		-	35,000	35,000
Brunel University		19,800	2,700	22,500
		19,800	**37,700**	**57,500**

Prior Year		Prior Year Unrestricted Funds	Prior Year Restricted Funds	Prior Year Total Funds
		2023	2023	2023
		£	£	£
Grants made to organisations		25,000	-	**25,000**
Total grantmaking costs	**B2c**	**25,000**	**-**	**25,000**

Leukaemia & Myeloma Research UK Ltd

Detailed analysis of income and expenditure for the year ended 31 March 2024 as required by the SORP 2015

23 Support costs for charitable activities

Current Year	Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
	2024	2024	2024	2023
	£	£	£	£
Employee costs not included in direct costs				
Subcontractors	1,328	-	**1,328**	-
Premises Expenses				
Rates and water charges	397	-	**397**	**219**
Room Hire	24,607	-	**24,607**	**24,212**
Light heat and power	521	-	**521**	**17**
Cleaning and waste management	1,427	-	**1,427**	-
Premises repairs, renewals and maintenance	420	-	**420**	**686**
Property insurance	701	-	**701**	**596**
Storage	2,554	-	**2,554**	-
Administrative overheads				
Telephone, fax and internet	1,921	-	**1,921**	**2,184**
Postage	1,053	-	**1,053**	**698**
Stationery and printing	1,608	-	**1,608**	**1,480**
Membership subscriptions	8,568	-	**8,568**	**7,895**
Equipment expenses	1,414	-	**1,414**	**2,199**
Hire of equipment	1,339	-	**1,339**	**1,099**
Software licences and expenses	3,968	-	**3,968**	**4,098**
Advertising and marketing	27,873	2,453	**30,326**	**11,746**
Sundry expenses	2,045	-	**2,045**	-
Motor Expenses	3,867	-	**3,867**	-
Professional fees paid to advisors other than the auditor or examiner				
Accountancy fees other than examination or audit fees	240	-	**240**	**710**
Management fees	32,638	-	**32,638**	**26,745**
Other legal and professional	5,121	-	**5,121**	**660**
Financial costs				
Bank charges	112	-	**112**	**35**
Depreciation & Amortisation in total for	7,167	-	**7,167**	**1,025**
Support costs before reallocation	**130,889**	**2,453**	133,342	**86,304**
Total support costs - Current Year	**130,889**	**2,453**	**133,342**	**86,304**

-

The basis of allocation of costs between activities is described under accounting policies -

-

All the expenditure in the prior year was unrestricted.

Leukaemia & Myeloma Research UK Ltd

Detailed analysis of income and expenditure for the year ended 31 March 2024 as required by the SORP 2015

Prior Year	Prior Year Unrestricted Funds 2023	Prior Year Restricted Funds 2023	Prior Year Total Funds 2023
Premises Expenses			
Rates and water charges	219	-	**219**
Room Hire	24,212	-	**24,212**
Light heat and power	17	-	**17**
Premises repairs, renewals and maintenance	686	-	**686**
Property insurance	596	-	**596**
Administrative overheads			
Telephone, fax and internet	2,184	-	**2,184**
Postage	698	-	**698**
Stationery and printing	1,480	-	**1,480**
Membership subscriptions	7,895	-	**7,895**
Equipment expenses	2,199	-	**2,199**
Hire of equipment	1,099	-	**1,099**
Software licences and expenses	4,098	-	**4,098**
Advertising and marketing	11,746	-	**11,746**
Professional fees paid to advisors			
Accountancy fees other than examination or audit fees	710	-	**710**
Management fees	26,745	-	**26,745**
Other legal and professional	660	-	**660**
Financial costs			
Bank charges	35	-	**35**
Depreciation & Amortisation in total for	1,025	-	**1,025**
Support costs before reallocation	**86,304**	**-**	**86,304**
Total support costs - Prior Year	**86,304**	**-**	**86,304**

The basis of allocation of costs between activities is described under accounting policies

Leukaemia & Myeloma Research UK Ltd

Detailed analysis of income and expenditure for the year ended 31 March 2024 as required by the SORP 2015

24 Total Charitable expenditure

Current Year		Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
		2024	2024	2024	2023
		£	£	£	£
Total direct spending	B2a	52,345	8,671	**61,016**	**71,504**
Total charitable trading costs	B2b	56,201	-	**56,201**	**7,874**
Total grantmaking costs	B2c	19,800	37,700	**57,500**	**25,000**
Total support costs	B2d	130,889	2,453	**133,342**	**86,304**
Total charitable expenditure	**B2**	**259,235**	**48,824**	**308,059**	**190,682**

All the expenditure in the prior year was unrestricted.

Prior Year		Prior Year Unrestricted Funds	Prior Year Restricted Funds	Prior Year Total Funds
		2023	2023	2023
		£	£	£
Total direct spending	B2a	71,504	-	**71,504**
Total charitable trading costs	B2b	7,874	-	**7,874**
Total grantmaking costs	B2c	25,000	-	**25,000**
Total support costs	B2d	86,304	-	**86,304**
Total charitable expenditure	**B2**	**190,682**	**-**	**190,682**

25 Expenditure on raising funds and costs of investment management

Current Year		Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
		2024	2024	2024	2023
		£	£	£	£
Agent's costs for fundraising		7,080	-	**7,080**	**6,450**
Cost of fundraising activities		6,337	-	**6,337**	**11,996**
Fundraising trading costs		972	-	**972**	**654**
Total fundraising costs	**B1**	**14,389**	**-**	**14,389**	**19,100**

All the expenditure in the prior year was unrestricted.

Prior Year		Prior Year Unrestricted Funds	Prior Year Restricted Funds	Prior Year Total Funds
		2023	2023	2023
		£	£	£
Agent's costs for fundraising		6,450	-	**6,450**
Cost of fundraising activities		11,996	-	**11,996**
Fundraising trading costs		654	-	**654**
Total fundraising costs	**B1**	**19,100**	**-**	**19,100**

LEUKAEMIA & MYELOMA RESEARCH UK LTD

England & Wales - Charity number 1161622

Accounts

Leukaemia & Myeloma Research UK

Report and Accounts

31 March 2023

Research That Saves Lives

leukaemiamyelomaresearchuk.org
Registered charity number 1161622 (England & Wales), SC046106 (Scotland),
Leukaemia and Myeloma Research UK Ltd
Company Limited by guarantee Registered number 09481278

Leukaemia & Myeloma Research UK

Research That Saves Lives

Leukaemia and Myeloma Research UK Ltd
Unit 127,
North Mersey Business Centre,
Woodward Rd,
Knowsley Industrial Park,
Liverpool,
Merseyside,
L33 7UY

Tel: 0800 368 7309

Web: www.leukaemiamyelomaresearchuk.org

Email: cs@leukaemiamyelomaresearchuk.org

Charity Number 1161622
Company Number 09481278



Follow us on Twitter: **https://twitter.com/lmruk_org**

Facebook: **https://www.facebook.com/leukaemiamyelomaresearchuk.org**

MODEL CELL BIOBANK
research that saves lives

Together we can beat cancer

Annual Report 2023

Table of contents

About Us 3

Stem Cells 4

Charitable Activities..... 5

Chairman's Report 6

Operation Director's Report 7

MCB Service..... 9

Overview 9

Case Study..... 11

Research Priorities..... 12

Fundraising and Volunteers..... 13

Thanks..... 14

Trustees and Staff 14

Accounts 15



About Us

Leukaemia & Myeloma Research UK Ltd wants to prevent people dying from blood cancer through more effective treatment in the future. We are willing to fight blood cancer regardless of how long it might take.

Founded in 2015, our mission is to prevent people dying from blood cancer through prevention, research and more effective treatment.

Unfortunately, blood cancer affects a large number of people. Every 13 minutes, someone in the UK is told they have a blood cancer. That's around 110 people per day, 40,000 people per year. There are an estimated 4,700 leukaemia deaths every year, that's 13 every day!

We are aiming to become the UK's leading charity in supporting efforts to combat the three major types of blood cancer. The work we do helps fund vital stem cell research, raises awareness of stem cell therapies and helps families protect their children's future health by storing their cord blood stem cells at the time of birth.

There are 3 main types of cancers of the blood; they are lymphoma, leukaemia and myeloma.

The blood is made up of three different types of cells:

- Red blood cells which carry the oxygen around the body
- White blood cells which fight and stop infections
- Platelets which help the blood to clot

The course of treatment given will depend on the type of cancer. The most common treatments are chemotherapy, radiotherapy and in some instances, a stem cell transplant.

In essence, the Charity wants to eradicate blood cancer once and for all. One of the ways we are aiming to achieve that is through advancing our understanding of stem cells and how we can use them to treat patients with blood cancer, particularly through stem cell transplants. We do this by:

- Actively supporting stem cell research into blood cancers
- Raising awareness of stem cell therapies
- Provide information about blood cancers and treatment options
- Protecting the vulnerable by offering qualifying expectant mothers, with a family history of cancer, the opportunity to store their baby's umbilical cord blood stem cells at the time of birth, in case they are needed in the future to treat that child or another member of the family if they're a suitable match.

This service is called Model Cell Biobank (MCB).

Stem Cells

In humans, there are two types of stem cells: embryonic stem cells and adult stem cells, which are found in various tissues.

Adult stem cells are the primary focus of the research that the Charity supports. They typically generate the cell types of the tissue in which they reside.

For example, a blood-forming adult stem cell in the bone marrow normally gives rise to the many types of blood cells. It is generally accepted that a blood-forming cell in the bone marrow—which is called a hematopoietic stem cell—cannot give rise to the cells of a very different tissue, such as nerve cells in the brain.

Where are stem cells found?
There are four known accessible sources of autologous adult stem cells in humans:

- Bone marrow which requires harvesting by drilling into bone (typically the femur or iliac crest). This is done under a general anesthetic.
- Blood, which requires extraction through apheresis, wherein blood is drawn from the donor (similar to a blood donation), and passed through a machine that extracts the stem cells and then returns the blood to the donor.
- Adipose tissue (lipid cells), which requires extraction by liposuction
- Umbilical cord blood - these stem cells can be collected from the umbilical cord blood just after birth.

What can stem cells be used for today?
There are treatments where Hematopoietic Stem Cell Transplants (HSCT) - the transplantation of blood forming stem cells - is a standard treatment. For some diseases they are the only therapy, and in other diseases they are only employed when front-line therapies have failed or the disease is very aggressive.

There are other blood disorders that can be treated with stem cells that aren't cancers, such as sickle cell anaemia and aplastic anaemia.

For most types of blood cancers, for example: leukaemia, lymphoma and various anaemia's, the treatments use allogeneic stem cell transplants (someone else's stem cells). The reason for this is that the person may have a genetic predisposition to the disease; their genes have a defect that predisposes them to that disease.

However there are various types of cancers (some myelomas, plasma cell leukaemia, some anaemia's and solid tumours) that are treated using autologous stem cells (using your own stem cells).

Charitable Activities

Providing Information

Throughout the year we have shared facts about blood cancer, including the signs, symptoms and treatments. We have achieved this through our regular newsletter, social media channels, website, and our blood cancer booklet. This provides patients with clear and informative advice that would answer their questions, explain terminology, discuss treatments so they are better prepared and able to make informed choices.

We produce a quarterly newsletter that shines a spotlight on our inspirational fundraisers and their stories; highlights our exciting plans for the future and provides information relating to blood cancer. It is available from our website free of charge.

Medical Research

Leukaemia & Myeloma Research UK Ltd allocate research grants to those who uphold our primary objectives. These are to benefit the public, in particular by research into the nature, causes, diagnosis, prevention, treatment and cure of leukaemia and myeloma.

Our current funding priorities are to advance understanding of stem cells and how they can be used to treat blood cancer patients. All grant applications are reviewed by the Charity's Research and Review Committee, an independent panel of experts. The Charity is a member of the Association of Medical Research Charities, the AMRC.

Fundraising Activities

Over the last year, the Charity expanded its textile recycling project so it now includes local schools to the Merseyside and Greater Manchester areas. This is with the aim of raising awareness of both blood cancer and of the environmental benefits of recycling. It also continues to raise valuable funds for the charities work.

In conjunction with this, our fundraisers have been busy running events from cake sales to sky dives. This has secured £127,500 of funding to support our services and help in the fight against cancer.

Model Cell Biobank Service

This service was established to support families who are on low income, have a history of cancer in the family, to store their babies cord blood stem cells at the time of birth. These cells are stored for 25 years in case that child, or another member of the family, needs them in the future to treat a disease.

The cord blood stem cells can be used today instead of bone marrow stem cells to treat blood cancer and genetic disorders. In fact, recent studies show that over 80 diseases could be treated using cord blood stem cells.

Chairman's Report

It remains one of our key focuses, to widen awareness of blood cancer. We have achieved this in a number of ways.

In May, the Charity engaged in World Blood Cancer Day, sharing informative posts on social media and producing an article for Charity Today. Following this, in June we marked National Myeloma Awareness week, where we shared our informative blog 'What is Myeloma?' to help raise awareness of the signs and symptoms.

A poll carried out by leading charities found that out of 2,000 participants only 1% were able to name the 4 main symptoms of leukaemia. This highlighted the urgent need to raise public awareness of the symptoms of this type of blood cancer. In response, during Blood Cancer Awareness Month in September we helped people identify common symptoms and also raised awareness of the different treatment options available, particularly cord blood banking and its many benefits.

In November, we celebrated World Cord Blood Day, sharing information and networking with like minded bodies.

In January, we launched the School Textile Recycling Scheme in the Liverpool and Greater Manchester areas. The team have been working hard to engage with schools and spread the message.

In March we celebrated Myeloma Awareness Month by educating people about this form of blood cancer and the common symptoms to look out for. We teamed up with former NHS worker and myeloma survivor, Jan Cashen (pictured above) and the West Lancs & Merseyside Myeloma Support Group, to promote the importance of funding blood cancer research and the value of support groups to those being treated or recovering from the disease.

I would like to take this opportunity to thank all our volunteers and fundraisers without their support we wouldn't be able to continue to offer the services that we do.

Sergejs Vinogradovs Chair, Leukaemia and Myeloma Research UK Ltd

Operation Director's Report

I would like to start by celebrating our inaugural winners of the charities Fundraiser of the Year award, Elaine and Peter Kinsella. They raised an incredible £8,000 for three charities.

We have had some fantastic fundraising efforts this year from walking and cycling to skydives! To give a few examples, 21-year-old Ben Saunders (pictured below) took part in an epic skydiving challenge to raise money for Leukaemia & Myeloma Research UK Ltd in memory of childhood friend, William Pearce.

For the first time ever we secured places in the London to Brighton Charity Bike Ride in September 2022. We were incredulous at the response - with 74 riders taking part, including 50 employees from professional machinery and service provider Lister Wilder. The Lister Wilder Team raised £22,250 which LMRUK are honoured to have allocated to a grant named the Lister Wilder Research Grant (pictured right). Someone who knows the importance of our research work is Research Review Committee member, Dr Rhys Morgan. Dr Morgan raised more than £1,400 in the ride, which he completed in memory of his younger brother David.

Further support came from members of the congregation at a church in Coventry have helped to raise over £5,000 for blood cancer research in memory of a much-loved member of their congregation who passed away from the disease.

We were fortunate to be awarded some corporate support including becoming Charity of the Year for Bognor Regis Golf Club. Ladies Captain, Heather Tidy, kindly secured £2,767 over the year.

A Scottish recruitment company celebrated its 35th birthday in business with a £3,000 donation.

We were fortunate to be one of the 20 good causes the Orion Group, headquartered in Inverness, who donated a total of £35,000 to, as a way of marking its anniversary.

Our cord blood banking service continues to grow from strength to strength. At the turn of the year we began a partnership with Smart Cells

WORLD CORD BLOOD DAY

International to procure, process and store cord blood stem cells through LMRUK's cord blood banking service, which we call MCB.

We are extremely grateful to the generous funding received from Fundraising Support Ltd who have helped this service support even more families.

Much Loved is a special memorial website in tribute to loved ones, where people can share thoughts and stories with family and friends. Through this scheme, donations can be made to charity. We are incredibly grateful to all the donations we have received this year in memory of loved ones.

I would like to say a huge 'thank you' to all our fundraisers for their hard work and to our dedicated staff team and partners who have pulled together to make 2022-23 such a huge success. All of our fundraisers are important - we simply would not be able to run these services without their help.

Dr Joanna Tilley
Operations Director,
Leukaemia and Myeloma Research UK Ltd

MCB Service

Overview

The Model Cell Biobank (MCB) service allows the storage of a child's umbilical cord blood stem cells at the time of birth, in case they or another member of the family needs them in the future to help in the treatment of a disease. It may be possible to use the stem cells to treat blood cancers or in emerging therapies to treat diseases such as diabetes, cerebral palsy and Parkinson's disease. Clinical trials are being performed all over the world looking at the potential use of stem cells to treat new diseases and hopefully further breakthroughs.

When a baby is born and the umbilical cord is cut, the placenta and umbilical cord are normally thrown away. The blood that remains in the cord and the placenta contains stem cells. The Charity offers a service to collect these stem cells without any risk to the mother and baby, and to store them in case that child or another member of the family needs them in the future.

The cord blood stem cells are stored on behalf of the child for 25 years. The mother is the legal guardian of the cells until the child reaches the age of majority, at which point, ownership transfers to the child. After 25 years, the cells can be privately stored, donated for research, offered to a public bank, or destroyed. Consent from the child will be sought at this point and we would strongly encourage the donation of any remaining cells to public banks.

The cord blood banking service is available to qualifying expectant mothers who live in the UK. They must be in receipt of Housing Benefit, Council tax or Universal Credit (at least one of these) and must meet the following criteria:

- The stem cells will be used to treat the child, or another member of the family, for a medically attested treatment;
- There is a history of cancer in the immediate family.

We recently extended the project to support low-income families by implementing a part funded service for those who have medical history, but are not on benefits.

Smart Cells Technical is our chosen partner to procure; process and store cord stem cells under its Human Tissue Authority licence.

Smart Cells has a strong reputation for standards it applies to the storage and processing of stem cells derived from umbilical cord and peripheral blood, bone marrow, now extending to many types of tissues for human application or transplant.

Smart Cells not only works to the highest standards, it also has an ethical approach, which aligns with our charity, something we are proud of.

MODEL CELL BIOBANK
research that saves lives



Advantages of Cord Blood Stem Cells

Today, cord blood banking is changing lives and there have already been more than one million stem cell transplants around the world since the 1980s.

The stem cells in your baby's cord blood are fully developed adult stem cells, which are the building blocks of the blood immune system. These stem cells can be used instead of bone marrow stem cells to treat blood cancers and genetic disorders.
Cord blood stem cells have many advantages including:

- They are easily available, having already been harvested and stored;
- A new born baby has been exposed to fewer viruses and infections and so the stem cells are less likely to transmit infection and react with the patient;
- Cord blood stem cells offer the life-saving option of a transplant and avoids the invasive, painful and expensive procedures of other stem-cell collection, such as bone marrow;
- Cord blood stem cells can be stored for many years - the longevity of these cells has proved they are as good 30 years later as on as the day they were first extracted and stored.

Future Plans

There are now a number of stem cells banks in the UK and interest in private storage has grown considerably over the last few years.

However, this is hugely expensive and means many people cannot take advantage of this service as the cost is too prohibitive.

There is also a huge shortage of stem cells being collected from BME communities - leaving them vulnerable and without a choice of treatment should they fall ill with blood cancer or another disease. Those from a minority ethnic background have only a 37% chance of finding a bone marrow match from an unrelated donor, whereas someone from a white Caucasian background has a 72% chance.

For this reason, over the next financial year we are promoting our funded stem cell collection and storage service to BME communities to increase awareness of stem cell treatments and encourage donations from this sector.

Case Study – Natalia's Story

The Cord Blood Stem Cell Pilot project was launched in 2017 and since this time we have received nearly 300 enquiries – which far exceeded our expectations. To date, this has resulted in 36 successful cord blood stem cell extractions.

Our very first client was Natalia and this is her story:
I am 24 years old and have 3 children aged six, three, and six months old. Whilst pregnant with my third child, I was diagnosed with lymphoma cancer in my neck. When I found out that I had cancer I was filled with guilt for my children – I was so worried that this could be hereditary and passed onto them. After doing some research into my family, I found out that my auntie had been diagnosed with cancer and that my grandfather had died from it. I had to do something to protect my children.

Cord blood stem cell storage and transplants are very costly so many cannot afford to use this potentially lifesaving service. This would certainly have been the case for us, however Leukaemia & Myeloma Research UK Ltd's Model Cell Biobank offers a fully-funded service to qualifying families. If it wasn't for this service we would never have been able to afford to store our baby's cord blood stem cells.
The process was really straightforward, we were sent a kit which contained all the information that we needed for the cord blood storage and collection.

When I went into labour, a phlebotomist came to the hospital and waited until the baby was delivered. Then they took a sample of cord blood to collect the stem cells, which caused no harm or pain to our baby or myself, and packaged it safely and securely.

My reason for storing my son's cord blood stem cells is not for my use but for my children, all of whom should be a strong match should any of them ever need it.

Ever since my diagnosis I have felt an enormous sense of guilt about the chance of any of my children getting cancer – it is a mother's worst nightmare.

I am incredibly grateful to have found out about this potentially lifesaving service, and even if we don't use the stored cord blood stem cells, it is reassuring to know that they will not go to waste.

Research Priorities

Leukaemia & Myeloma Research UK Ltd offer research grants to those who uphold our primary objectives: to protect and promote the health of the public, in particular by research into the nature, causes, diagnosis, prevention, treatment and cure of leukaemia and myeloma.

The Trustees funding priorities are to advance understanding of stem cells and how they can be used to treat blood cancer patients, particularly through stem cell transplants.
In July 2022 we awarded Dr Ricardo Fernandes and his team at the Department of Medicine at the University of Oxford £25,000 to engineer and screen different antibodies to find a way to stop mutations in the FLT3 protein from causing Acute Myeloid Leukaemia (AML) in patients.

"On average less than 15% of AML patients will survive longer than five years. FLT3 is a significant contributory factor, it's really pushing this disease and we have to shut it down," said Dr Fernandes.

The grant money will help the team move the research forward more quickly and

allow them to focus all their attention over the next year on tackling the FLT3 receptor problem.

It will ultimately help in the development of a prototype for a drug that can be used as an effective treatment in the future. Dr Ricardo Fernandes hopes that moving forward, this type of research could be applicable to other types of cancer as well.

Dr Paul Spencer Hole
Senior Research Scientist. Has been engaged in academic research at Cardiff University and extends his experience in a clinical-stage biopharmaceutical company.

Dr Claire Seedhouse
Associate Professor within Division of Cancer and Stem Cells, University of Nottingham. She is Principle Investigator and research group leader in Blood Cancer at the University of Nottingham.

Dr John Jones
Senior Clinical Lecturer – Brighton and Sussex Medical School, Honorary Consultant Haematologist – Kings College Hospital NHS Trust, London and Eastbourne District General Hospital.

Dr Rhys Morgan
Lecturer in Biomedical Sciences in Department of Biochemistry and Biomedicine, at the University of Sussex.

Professor Joseph R. Slupsky
Reader in Department of Molecular and Clinical Cancer Medicine, University of Liverpool. He is Principal Investigator of the Liverpool Blood Disease Biobank and Academic Lead University of Liverpool Technology Directorate Cell Sorting and Flow/Mass Cytometry Facility.

Dr Ceri Bygrave
A Consultant Haematologist and Myeloma Lead at the University Hospital of Wales and a member of the UK Myeloma Forum Executive Committee and the UK Myeloma Research Alliance.

Dr Salvatore Papa
An Associate Professor at Leeds University whose research speciality is in lymphoma and myeloma.

Fundraising and Volunteers

Churchgoers fundraising campaign in memory of a much-loved friend and wife.

Members of the congregation at a church in Coventry have helped to raise over £5,000 for blood cancer research charity, Leukaemia & Myeloma Research UK Ltd (LMRUK) in memory of a much-loved member of their congregation who passed away from the disease.

Pat Elliman from Coventry was about to begin a round of stronger chemotherapy treatment for Acute Myeloid Leukaemia (AML) in hospital in December 2020 when she passed away in the arms of her devoted husband Malcolm. Well known for her generous and kind nature, as well as a talent for baking, Pat was an active member of Holyhead Road United Reformed Church in the city for many years. Since her death, other members of the church have been holding a range of fundraising events after selecting LMRUK as its chosen charity for 2022.

The fundraising effort has been coordinated by Karen Adams, supported by her mum, Sue Adams and Malcolm. It was August 2020 and Pat had just given her 97th donation of blood when she arrived back home feeling very tired. Within a few days, blood tests and a bone marrow analysis revealed she had incurable AML FLT3 WILD.

During the Covid-19 pandemic she endured three courses of chemotherapy over several months, much of which had to take place at her home because of lockdown restrictions. But she also had to endure many visits to hospital for treatment, including two emergency admissions for infections. It was only two days before her death that she was told her condition was worsening and she chose to undertake the stronger chemotherapy treatment. Malcom says “I could write a book about Pat’s trials and bravery during those five months but also understand that many people have the same experience. The haematology staff were incredibly kind and caring throughout and I can’t thank them enough. “I am grateful that the church Pat loved so much is raising money for LMRUK in memory of her, but also to help other sufferers. I will do everything I can to support this fundraising,”

Malcom has already been part of the fundraising effort by doing a sponsored walk from Coventry to Kenilworth, a walk he and Pat would often do. Other fundraising events have included quiz and bingo evenings, a sponsored spell event by members of the 7th Coventry Girls’ Brigade Company, a second-hand book sale at a local shopping centre, craft and cake sales.

Karen and fellow family members completed a sponsored step challenge while on holiday in Devon. They set themselves a target of 600,000 in eight days and managed over 900,000.

“We were originally aiming to raise £4,000, but our current total is over £5,000 – the highest amount we have raised for a chosen project”, said Karen. The cheque was presented to LMRUK in January 2023.

Thanks to Funders

- Chamifealion Charitable Trust
- Boden
- Albert Hunt Trust
- Tesco Groundworks
- Ambergate Charitable Trust
- Ladbrokes Coral
- May Hearnshaw Charitable Trust
- T K Maxx and Homesense
- Santa Barbara Heights Charitable Trust
- LPC Group
- Thomas Sivewright Catto Charitable
- Settlement
- Ian Askew Charitable Trust
- Grace Trust
- Henhurst Trust
- The Tony Bramall Charitable Trust
- Family Rich Charities Trust
- Gisela Graham Foundation
- Stella Symons
- Gledswood Charitable Trust
- Marsland Mcadoo
- Dorothy Holmes Charitable Trust
- Orion Group (see photo)
- Arnold Clark Community Fund

Staff and Committee Members

Trustees 2022-2023

- Sergejs Vinogradovs (Chair)
- Tatjana Vinogradova
- Victoria Kieran
- Julija Sidorika

Staff Team

- Dr Joanna Tilley - Interim Operations Director
- Lucy Heron - Office Manager / Senior MCB Call Centre Manager
- Richard Thompson - Call Centre
- Kate Williams - PT Fundraiser

Thanks to Individuals and supporters

- Best Freelance Design Ltd
- Smart Cells International
- Dr Hannah Hunter – Consultant Haematologist
- Fundraising Support Ltd
- KOR Communications Limited
- Phlebotomy UK Ltd
- Research Review Committee

Accounts

Leukaemia & Myeloma Research UK

leukaemiamyelomaresearchuk.org

Registered charity number 1161622 (England & Wales), SC046106 (Scotland),
Company Limited by guarantee Registered number 09481278

Accounts 31 March 2023



Leukaemia & Myeloma Research UK Ltd

Report and accounts for the year ended 31 March 2023

Contents

	Page
Charity information	1
Trustees' Annual Report	1
Statement of directors' responsibilities	5
Independent Examiner's Report	7
Funds Statements:-	
Statement of Financial Activities	9
Statement of Financial Activities - Prior Year statement	10
Movements in funds	12
Income and Expenditure account	13
Balance sheet	14
Notes to the accounts	15

Leukaemia & Myeloma Research UK Ltd

Company Registration Number - 09481278

Trustees' Annual Report for the year ended 31 March 2023

The Trustees present their Report and Accounts for the year ended 31 March 2023, which also comprises the Directors' Report required by the Companies Act 2006.

Reference and administrative details

The charity name.

The legal name of the charity is:- Leukaemia & Myeloma Research UK Ltd.

The charity is also known by its operating name, LMR UK Ltd.

The charity's areas operation and UK charitable registration.

The charity is registered in England & Wales with the Charity Commission in England & Wales (CCEW) with charity number 1161622.

The charity is also registered in Scotland, with charity number SC046106 as it has operations in Scotland.

The charity does not operate in any overseas jurisdictions.

Legal structure of the charity

The charity is constituted as a company limited by guarantee, registered under the Companies Acts . The governing document of the charity is the Memorandum and Articles of Association establishing the company under company legislation.

The governing document is dated 10 March 2015

There are no restrictions in the governing documents on the operation of the Charity or on its investment powers other than those imposed by Charity Law.

By operation of law all, trustees are directors under the Companies Act 2006 and all directors are trustees under Charities legislation and have responsibilities, as such, under both company and charity legislation.

The trustees are all individuals.

Leukaemia & Myeloma Research UK Ltd

Company Registration Number - 09481278

Trustees' Annual Report for the year ended 31 March 2023

The principal operating address, telephone number, email and web addresses of the charity

Unit 127, North Mersey Business Centre
Woodward Road, Liverpool
Merseyside, L33 7UY
Telephone 08003687309

Email Address info@leukaemiamyelomaresearchuk.org Web address https://www.leukaemiamyelomaresearchuk.org/

The registered office of the charity for Companies Act purposes is the same as the operating address shown above.

The Trustees in office on the date the report was approved were:-

Sergejs Vinogradovs
Tatjana Vinogradova
Julija Sidorika
Victoria Kieran

The following persons served as Trustees during the year ended 31 March 2023 :-

The trustees who served as a trustee in the reporting period were as shown above, and there were no changes during the year, or in the period between the year end and the approval of the accounts.

All the trustees are also members of the charity.

Objects and activities of the charity

The purposes of the charity as set out in its governing document.

The objectives of the charity are set out in the Memorandum of Association of 14 July 2015. They are:
1. to protect and promote the health of the public in particular by research into the nature, causes, diagnosis, prevention, treatment and cure of leukaemia and myeloma.
2. development of research into practical applications for the prevention. Treatment and cure leukaemia and myeloma and raise public understanding of such matters.

Leukaemia & Myeloma Research UK Ltd

Company Registration Number - 09481278

Trustees' Annual Report for the year ended 31 March 2023

Structure, governance and management of the charity

The methods used to recruit and appoint new charity trustees.

Proposals for new Trustees are made by the Chair after making appropriate enquiries. Appointments are then made by election by the existing board of Trustees.

Accountants	KBH Accountants Ltd - 255 Poulton Road, Wallasey, CH44 4BT

Leukaemia & Myeloma Research UK Ltd

Company Registration Number - 09481278

Trustees' Annual Report for the year ended 31 March 2023

Financial review

	2023	2022
	£	£
Net income	35,474	30,559
Unrestricted Revenue Funds available for the general purposes of the charity	311,735	285,330
Restricted Revenue Funds	40,586	31,517
Total Funds	352,321	316,847

Financial review of the position at the reporting date, 31 March 2023 .

Overall surplus stands at £352,321 and will be distributed in following way: £150,000 for the Reserves; £65,000 for Research grants, and £137,321 for charity development, including MCB and the e-shop.
The trustees consider the financial performance by the charity during the year to have been satisfactory.

Policies on reserves.

The trustees collectively aim to maintain free reserves in unrestricted funds within a range equivalent to twelve months of unrestricted charitable expenditure. This targeted level is deemed essential by the trustees to ensure an adequate financial cushion for covering support and governance costs. The Reserves Policy will undergo an annual review, aligning with the scrutiny of the charity's annual accounts.

In light of the events of the past year, marked by a significant surge in inflation, escalating living costs, and an increased risk of economic downturn, the trustees have determined that a prudent Reserves amount must be set at £150,000. This decision is reflective of the charity's commitment to financial resilience and its responsiveness to the evolving economic landscape.

Availability and adequacy of assets of each of the funds

The board of trustees is satisfied that the charity's assets in each fund are available and adequate to fulfil its obligations in respect of each fund.

Details of The Independent Examiner

Olivia Higgins FCCA

Member of Chartered Certified Accountants

255 Poulton Road

Wallasey

Wirral

CH44 4BT

Leukaemia & Myeloma Research UK Ltd

Company Registration Number - 09481278

Trustees' Annual Report for the year ended 31 March 2023

Statement of the Directors Trustees' Responsibilities

The charity's trustees are responsible for the preparation of the accounts in accordance with the terms of the Companies Act 2006, the Charities Act 2011 and the Charities (Accounts and Reports) Regulations 2008. Notwithstanding the explicit requirement in the extant statutory regulations,the Charities (Accounts and Reports) Regulations 2008, to prepare the financial statements in accordance with the SORP 2005, in view of the fact that the SORP 2005 has been withdrawn, the Trustees determined to interpret this responsibility as requiring them to follow current best practice and prepare the accounts according to the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), .

In particular, the Companies Act 2006 and charity law require the Board of Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity as at the end of the financial year and of the surplus or deficit of the charity. In preparing those financial statements the Board is required to :-

- to prepare the accounts in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law).
- select suitable accounting policies and apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business;
- state whether applicable accounting standards and statements of recommended practice have been followed, subject to any material departures disclosed and explained in the financial statements;

The law requires that the trustees must not approve the accounts unless they are satisfied that they give a true and fair view of the state of affairs of the charity and of the surplus or deficit of the charity for the year.
The Trustees are also responsible for maintaining adequate accounting records which disclose with reasonable accuracy at any time the financial position of the charity and which are sufficient to show and explain the charity's transactions and enable them to ensure that the financial statements comply with the Companies Act 2006 and comply with regulations made under the Charities Act. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Trustees are also responsible for the contents of the Trustees' report, and the statutory responsibility of the Independent Examiner in relation to the Trustees' report is limited to examining the report and ensuring that , on the face of the report, there are no material inconsistencies with the figures disclosed in the financial statements.

Trustees' Annual Report for the year ended 31 March 2023

Method of preparation of accounts - Small company provisions

The financial statements are set out on pages 9 to 33.
The financial statements have been prepared implementing the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), and in accordance with the Financial Reporting Standard 102, (effective 1st January 2016)
These financial statements have been prepared in accordance with the provisions in Part 15 of the Companies Act 2006. applicable to companies subject to the small companies regime.

This report was approved by the board of trustees on 14 December 2023.

TATJANA VINOGRADOVA
Director and Trustee

Leukaemia & Myeloma Research UK Ltd

Report of the Independent Examiner to the Trustees of the charitable company on the accounts for the year ended 31 March 2023

I report to the Trustees on my examination of the financial statements of the charitable company on pages 9 to 33 for the year ended 31 March 2023 which have been prepared in accordance with the Charities Act 2011 (the Act) and with the Financial Reporting Standard 102, (effective 1st January 2016) as modified by FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), published by the Charity Commission in England & Wales (CCEW) , and under the historical cost convention and the accounting policies set out on page 15.

Respective responsibilities of the Trustees and the Independent Examiner and the basis of the report

As described on page 5, you, the charitable company's Trustees, who are also the Directors of the Company for the purposes of Company law, are responsible for the preparation of the financial statements in accordance with the Companies Act 2006, the Charities Act 2011 and all other applicable law and with United Kingdom Generally Accepted Accounting Practice, applicable to smaller entities, and for being satisfied that the financial statements give a true and fair view.

The Trustees consider that the audit requirement of Section 144(1) of the Charities Act 2011 (the Act) does not apply, and that there is no requirement in the memorandum and articles of the charity for the conducting of an audit, and that the accounts do not require an audit in accordance with Part 16 of the Companies Act 2006 and that no member or members have requested an audit pursuant to Section 476 of the Companies Act 2006. As a consequence, the Trustees have elected that the financial statements be subject to independent examination.

Having satisfied myself that the financial statements are not required to be audited under any legal provision, or otherwise, and are eligible for independent examination, it is my responsibility to:-

a) examine the financial statements of the charity under Section 145 of the Act;

b) follow the applicable procedures in the Directions given by the Charity Commission under section 145(5)(b) of the Act.

Basis of Independent Examiner's Statement and scope of work undertaken

Since the charitable company's gross income exceeded £250,000, the charitable company's examiner must be a member of a body listed in section 145 of the Act. I confirm that I am qualified to undertake the examination because I am an authorised member of Chartered Certified Accountants , which is one of the listed bodies.

I report in respect of my examination of the charity's financial statements carried out under s145 of the Act. In carrying out my examination, I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act setting out the duties of an independent examiner in relation to the conducting of an independent examination. An independent examination includes a review of the accounting records kept by the charitable company and of the accounting systems employed by the charitable company and a comparison of the financial statements presented with those records. It also includes consideration of any unusual items or disclosures in the financial statements, and seeking explanations from you, as Trustees, concerning such matters. The purpose of the examination is to establish as far as possible that there have been no breaches of charity legislation and that, on a test basis of evidence relevant to the amounts and disclosures made, the financial statements comply with the SORP.

The procedures undertaken do not provide all the evidence that would be required in an audit, and information supplied by the Trustees in the course of the examination is not subjected to audit tests or enquiries and does not cover all the matters that an auditor would consider in arriving at an opinion. The planning and conduct of an audit goes beyond the limited assurance that an independent examination can provide

Consequently, I do not express an audit opinion on the view given by the financial statements, and in particular, I express no opinion as to whether the financial statements give a true and fair view of the affairs of the charity, and my report is limited to the matters set out in the statement below.

I planned and performed my examination so as to satisfy myself that the objectives of the independent examination are achieved and before finalising the report I obtained written assurances from the Trustees of all material matters.

Independent Examiner's Statement, Report and Opinion

Subject to the limitations upon the scope of my work as detailed above, I have completed my examination: and can confirm that:-

The accounts of this charitable company are not required to be audited under Part 16 of the Companies Act 2006;

This is a report in respect of an examination carried out under 145 of the Act and in accordance with Directions given by the Charity Commission under section 145(5)(b) of the Act which may be applicable;

and that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:-

accounting records were not kept in respect of the charity as required by Section 386 of the Companies Act 2006 and Section 130 of The Charities Act 2011;

the financial statements do not accord with those records; or

the financial statements do not comply with the applicable requirements concerning the form and content of accounts set out in section 396 of the Companies Act 2006 other than any requirement that the accounts give a 'true and fair' view, which is not a matter considered as part of an independent examination;

have not been prepared in accordance with the methods and principles set out in the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.

Signed:-

O. Higgins

Olivia Higgins FCCA - Independent Examiner

KBH Accountants Ltd

Chartered Certified Accountants

255 Poulton Road

Wallasey

Wirral

CH44 4BT

This report was signed on 14/12/ 2023

Leukaemia & Myeloma Research UK Ltd - Statement of Financial Activities for the year ended 31 March 2023

Statement of Financial Activities (including the Income and Expenditure Account for the year ended 31 March 2023, as required by the Companies Act 2006)

	SORP Ref	Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
		2023	2023	2023	2022
		£	£	£	£
Income & Endowments from:					
Donations & Legacies	A1	138,590	35,385	**173,975**	138,627
Charitable activities	A2	18,635	1,918	**20,553**	17,846
Investments	A4	665	-	**665**	27
Other	A5	50,063	-	**50,063**	50,109
Total income	**A**	**207,953**	**37,303**	**245,256**	**206,609**
Expenditure on:					
Raising funds	B1	19,100	-	**19,100**	9,095
Charitable activities	B2	162,448	28,234	**190,682**	166,955
Total expenditure	**B**	**181,548**	**28,234**	**209,782**	**176,050**
Net income for the year		**26,405**	**9,069**	**35,474**	**30,559**
Transfers between funds	**C**	-	-	**-**	-
Net income after transfers	**A-B-C**	**26,405**	**9,069**	**35,474**	**30,559**
Net movement in funds		**26,405**	**9,069**	**35,474**	**30,559**
Reconciliation of funds:-	**E**				
Total funds brought forward		285,330	31,517	**316,847**	286,288
Total funds carried forward		**311,735**	**40,586**	**352,321**	**316,847**

The 'SORP Ref' indicated above is the classification of income set out in the formal SORP documents. As required by paragraph 4.60 of the SORP, the brought forward and carried forward funds above have been agreed to the Balance Sheet.

A separate Statement of Total Recognised Gains and Losses is not required as this statement includes all recognised gains and losses.

All activities derive from continuing operations

The notes attached on pages 15 to 33 form an integral part of these accounts.

Leukaemia & Myeloma Research UK Ltd - Statement of Financial Activities for the year ended 31 March 2023

Leukaemia & Myeloma Research UK Ltd - Analysis of prior year total funds, as required by paragraph 4.2 of the SORP

	SORP Ref	Prior Year Unrestricted Funds 2022 £	Prior Year Restricted Funds 2022 £		Prior Year Total Funds 2022 £
Income & Endowments from:					
Donations & Legacies	A1	126,387	12,240		**138,627**
Charitable activities	A2	17,846	-		**17,846**
Investments	A4	27	-		**27**
Other	A5	50,109	-	-	**50,109**
Total income	**A**	194,369	12,240		**206,609**
Expenditure on:					
Raising funds	B1	9,095	-		**9,095**
Charitable activities	B2	153,973	12,982		**166,955**
Total expenditure	**B**	**163,068**	**12,982**		**176,050**
Net income for the year		31,301	(742)		30,559
Net income after transfers		31,301	(742)		30,559
Net movement in funds		**31,301**	**(742)**		**30,559**
Reconciliation of funds:-	**E**				
Total funds brought forward		258,527	27,761		**286,288**
Total funds carried forward		**289,828**	**27,019**		**316,847**

All activities derive from continuing operations

A separate Statement of Total Recognised Gains and Losses is not required as this statement includes all recognised gains and losses.'

The notes attached on pages 15 to 33 form an integral part of these accounts.

Leukaemia & Myeloma Research UK Ltd - Statement of Financial Activities for the year ended 31 March 2023

Leukaemia & Myeloma Research UK Ltd - Resources applied in the year ended 31 March 2023 towards fixed assets for Charity use:-

	2023 £	2022 £
Funds generated in the year as detailed in the SOFA	35,474	30,559
Resources applied on functional fixed assets	(1,599)	-
Net resources available to fund charitable activities	**33,875**	**30,559**

The resources applied on fixed assets for charity use represents the cost of additions less proceeds of any disposals.

The notes attached on pages 15 to 33 form an integral part of these accounts.

Leukaemia & Myeloma Research UK Ltd - Statement of Financial Activities for the year ended 31 March 2023

Movements in revenue and capital funds for the year ended 31 March 2023

Revenue accumulated funds

	Unrestricted Funds 2023 £	Restricted Funds 2023 £	Total Funds 2023 £	Last year Total Funds 2022 £
Accumulated funds brought forward	285,330	31,517	316,847	**286,288**
Recognised gains and losses before transfers	26,405	9,069	35,474	30,559
	311,735	**40,586**	**352,321**	**316,847**
(From)/To unrestricted revenue funds	-	-	-	-
Closing revenue funds	**311,735**	**40,586**	**352,321**	**316,847**

Summary of funds	Unrestricted and Designated funds 2023 £	Restricted Funds 2023 £	Total Funds 2023 £	Last Year Total Funds 2022 £
Revenue accumulated funds	311,735	40,586	**352,321**	316,847

The notes attached on pages 15 to 33 form an integral part of these accounts.

Leukaemia & Myeloma Research UK Ltd - Statement of Financial Activities for the year ended 31 March 2023

Leukaemia & Myeloma Research UK Ltd
Income and Expenditure Account for the year ended 31 March 2023 as required by the Companies Act 2006

	2023 £	2022 £
Income		
Income from operations	194,528	156,405
Interest receivable	665	27
Other operating income	50,063	50,109
Gross income in the year before exceptional items	**245,256**	**206,609**
Gross income in the year including exceptional items	**245,256**	**206,609**
Expenditure		
Charitable expenditure, excluding depreciation and amortisation	189,657	165,910
Depreciation and amortisation	1,025	625
Fundraising costs	19,100	9,095
Governance costs	-	420
Total expenditure in the year	**209,782**	**176,050**
Net income before tax in the financial year	**35,474**	**30,559**
Tax on surplus on ordinary activities	-	-
Net income after tax in the financial year	**35,474**	**30,559**
Retained surplus for the financial year	**35,474**	**30,559**

All activities derive from continuing operations

In accordance with the provisions of the Companies Act 2006, the headings and subheadings used in the Income and Expenditure account have been adapted to reflect the special nature of the charity's activities.

The notes attached on pages 15 to 33 form an integral part of these accounts.

Leukaemia & Myeloma Research UK Ltd - Balance Sheet as at 31 March 2023

	Note	SORP Ref		2023		2022
				£		£
Fixed assets		A				
Tangible assets	7	A2		1,824		1,250
Total fixed assets				1,824		1,250
Current assets		B				
Stocks		B1	17,490		17,507	
Debtors	9	B2	5,060		4,432	
Cash at bank and in hand		B4	333,510		299,864	
Total current assets			356,060		321,803	
Creditors: amounts falling due within one year	10	C1	(5,563)		(6,206)	
Net current assets				350,497		315,597
The total net assets of the charity				**352,321**		**316,847**
The total net assets of the charity are funded by the funds of the charity, as follows:-						
Restricted funds						
Restricted Revenue Funds	13	D2	40,586		31,517	
				40,586		31,517
Unrestricted Funds						
Unrestricted Revenue Funds	13	D3	311,735		285,330	
				311,735		285,330
Designated Funds						
Total charity funds				**352,321**		**316,847**

The 'SORP Ref' indicated above is the classification of Balance Sheet items as set out in the formal SORP documents. As required by paragraph 4.60 of the SORP, the brought forward and carried forward funds above have been agreed to the SOFA..

The directors are satisfied that the company is entitled to exemption from the requirement to obtain an audit under section 477 of the Companies Act 2006.

The members have not required the company to obtain an audit in accordance with section 476 of the Act.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.

The charity is subject to Independent Examination under charity legislation, and the report of the Independent Examiner is on page 8.

The financial statements have been prepared in accordance with the provisions in Part 15 of the Companies Act 2006. applicable to companies subject to the small companies regime.

TATJANA VINOGRADOVA

Trustee

Approved by the board of trustees on 14 December 2023

The notes attached on pages 15 to 33 form an integral part of these accounts.

Leukaemia & Myeloma Research UK Ltd

Notes to the Accounts for the year ended 31 March 2023

1 Accounting policies

Policies relating to the production of the accounts.

Basis of preparation and accounting convention

The accounts have been prepared on the accruals basis, under the historical cost convention, and in accordance with the Financial Reporting Standard 102, (effective 1st January 2016) and 'FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), published by the Charity Commission in England & Wales (CCEW) , effective January 2016, , and in accordance with all applicable law in the charity's jurisdiction of registration, except that the charity has prepared the financial statements in accordance with the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), in preference to the previous SORP, the SORP 2005, which has been withdrawn, notwithstanding the fact that the extant statutory regulations, the Charities (Accounts and Reports) Regulations 2008 refer explicitly to the SORP 2005. This has been done to accord with current best practice.

Risks and future assumptions

The charity is a public benefit entity.
This policy is a formal acknowledgement that LMRUK is committed to maintaining a strong risk management framework and making every effort to manage risk appropriately by maximising potential opportunities whilst minimising the adverse effects of risks. It should be used to support the internal control systems of the charity, enabling LMRUK to respond to operational, strategic and financial risks regardless of whether they are internally or externally driven.

Policies relating to categories of income and income recognition.

Nature of income

Gross income represents the value, net of value added tax and discounts, of goods provided to customers and work carried out in respect of services provided to customers.

Categories of Income

Income is categorised as income from exchange transactions (contract income) and income from non-exchange transactions (gifts), investment income and other income.

Income from exchange transactions is received by the charity for goods or services supplied under contract or where entitlement is subject to fulfilling performance related conditions. The income the charity receives is approximately equal in value to the goods or services supplied by the charity to the purchaser.

Income from a non-exchange transaction is where the charity receives value from the donor without providing equal value in exchange, and includes donations of money, goods and services freely given without giving equal value in exchange.

Income recognition

Income, whether from exchange or non exchange transactions, is recognised in the statement of financial activities (SOFA) on a receivable basis, when a transaction or other event results in an increase in the charity's assets or a reduction in its liabilities and only when the charity has legal entitlement, the income is probable and can be measured reliably.

Dividends are accrued when the shareholder's right to receive payment is established.

Income subject to terms and conditions which must be met before the charity is entitled to the resources is not recognised until the conditions have been met.

All income is accounted for gross, before deducting any related fees or costs.

Income from legacies

Income from legacies is recognised when the charity has sufficient evidence that a gift has been left to them, that where required, probate has been granted, the executor is satisfied that the property in question will not be required to satisfy claims in the estate, that it is probable that the amount will be received by the charity, and the amount to be received can be estimated with sufficient accuracy, and that any conditions attached to the legacy are either within the control of the charity or have been met.

Where a payment is received from an estate or is notified as receivable by the executors after the reporting date and before the accounts are authorised for issue but it is clear that the payment had been agreed by the executors prior to the end of the reporting period, then the amount concerned is treated as an adjusting event and accrued as income in the accounting period if receipt is probable.

Where the charity has established entitlement to a legacy but there is uncertainty as to the amount of the payment, details of the legacy are disclosed as a contingent asset until the criteria for income recognition are met. Where a legacy is subject to the interest of a life tenant, the legacy is not recognised as income until the death of the life tenant.

If it is doubtful that full settlement of a legacy debtor will be received, then an adjustment is made to reduce the amount of the legacy debtor and legacy income rather than charging the adjustment as expenditure in the Statement of Financial Activities

Notes to the Accounts for the year ended 31 March 2023

Donated goods, facilities and services

Donated fixed assets are recognised at the current fair value. All such donations are recognised as donation income, and debited to fixed assets.

Donated goods that are not fixed assets are accounted for at a fair value, unless it is impractical to reliably measure the value of the donated items.

In the absence of any direct evidence of fair value of donated goods, then a value is derived from the cost of the item to the donor or, in the case of goods that are expected to be sold, the estimated resale value after deducting any anticipated costs of sales.

If it is impracticable to measure the fair value of goods donated for resale, or the costs of valuation outweigh the benefits, the donated goods are recognised as income when sold, with an equivalent amount being recognised as an expense.

The costs of goods donated for distribution to beneficiaries is deemed to be the fair value of those goods upon receipt. When the goods are distributed freely or for a nominal consideration, then the carrying amount is adjusted at the time of sale, to the value at the point of distribution and the adjustment is shown as a cost of donations made.

The carrying amount of any stock held for distribution is assessed for impairment at the reporting date. All donated goods are recognised as donation income, and debited to trading stock.When trading stock is subsequently sold, or appropriated to meet an expense, then the carrying value of the stock is recognised as an expense. In accordance with the SORP, goods donated for distribution to beneficiaries, or for consumption by the charity are included in ***'legacies and donations***'. Goods donated for resale are included in ***'Income from other trading activities'***

The cost of any stock of goods donated for distribution to beneficiaries is deemed to be the fair value of those gifts at the time of their receipt. If the goods held are to be distributed freely or for a nominal consideration, then the carrying amount is subsequently adjusted to reflect the lower of deemed cost adjusted for any loss of service potential and replacement cost. Replacement cost is the economic cost incurred if the charity was to replace the service potential of the donated goods at its own expense in the most economic manner.

Donated services and facilities (including seconded staff and use of property) are included in the accounts on the basis of the value of the gift to the charity.

All donated services and facilities are recognised as donation income when received,(provided the value of the gift can be measured reliably) and recognised as an expense with an equivalent value.

Policies relating to expenditure on goods and services provided to the charity.

Allocating costs to activities

Direct costs that are specifically related to an activity are allocated to that activity. Shared direct costs and support costs are apportioned between activities.

The basis for apportionment, which is consistently applied, and proportionate to the circumstances, is :-

Staffing - on the basis of time spent in connection with any particular activity.
Staffing - on a per capita basis, based on the number of of people employed within any partiular activity.
Premises related costs - on the proportion of floor area occupied by a particular activity.
Non specific support costs - on the basis of the usage of resources, in terms of time taken, capacity used, request made or other measures
Estimation techniques used in apportioning costs - give details

Notes to the Accounts for the year ended 31 March 2023

Policies relating to assets, liabilities and provisions and other matters.

Stocks and work in progress

Stock is valued at the lower of cost and net realisable value.

Debtors

Debtors are measured at their recoverable amounts at the balance sheet date.

Creditors and provisions

Liabilities are measured at their settlement amount. A liability is recognised for the amount the Charity anticpates it will pay to settle the debt or the amount it has received as an advance payment for goods or services it must provide.

2 Liability to taxation

The Trustees consider that the charity satisfies the tests set out in Paragraph 1 Schedule 6 of the Finance Act 2010 for UK corporation tax purposes. Accordingly, the Charity is potentially exempt from taxation in respect of income or capital gains received within categories covered by chapter 3 part 11 of the Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992, to the extent that such income or gains are applied exclusively on the specific charitable objects of the charity and for no other purpose. Value Added Tax is not recoverable by the charity, and is therefore included in the relevant costs in the Statement of Financial Activities.

3 Winding up or dissolution of the charity

If upon winding up or dissolution of the charity there remain any assets, after the satisfaction of all debts and liabilities, the assets represented by the accumulated fund shall be transferred to some other charitable body or bodies having similar objects to the charity.

No employees received emoluments (excluding pension costs) in excess of £60,000 per annum.

4 Defined contribution pension schemes

Any liabilites and assets associated with the scheme are shown under debtors and creditors.

5 Remuneration and payments to Trustees and persons connected with them

The trustees received payments in the amount of £1,292 as travel expenses related to providing services for clothing collection.

No persons connected with the trustees received any remuneration from the charity, or any related entity.

6 Trustees' expenses

There were no Trustees' expenses in the year and in the prior year.

7 Tangible fixed assets

Current Year	Land and Buildings	Plant & Machinery	Motor Vehicles	Total	Total
	£	£	£	£	£
Cost					
At 1 April 2022	-	2,500	-	2,500	2,500
Additions	-	1,599	-	1,599	1,599
At 31 March 2023	**-**	**4,099**	**-**	**4,099**	**4,099**
Depreciation					
At 1 April 2022	-	1,250	-	1,250	1,250
Charge for the year	-	1,025	-	1,025	1,025
At 31 March 2023	**-**	**2,275**	**-**	**2,275**	**2,275**
Net book value					
At 31 March 2023	**-**	**1,824**	**-**	**1,824**	**1,824**
At 31 March 2022	**-**	**1,250**	**-**	**1,250**	**1,250**

8 Stocks & Work in Progress

	2023	2022
	£	£
Stocks before write downs	17,490	17,507
	17,490	17,507

9 Debtors

	2023	2022
	£	£
Prepayments and accrued income	280	485
Other debtors	3,947	3,947
	5,060	**4,432**

Notes to the Accounts for the year ended 31 March 2023

10 Creditors: amounts falling due within one year

	2023	2022
	£	£
Trade creditors	3,643	3,916
Accruals	1,920	2,290
	5,563	**6,206**

11 Income and Expenditure account summary

	2023	2022
	£	£
At 1 April 2022	316,847	286,288
Surplus after tax for the year	35,474	30,559
At 31 March 2023	**352,321**	**316,847**

12 Particulars of how particular funds are represented by assets and liabilities

At 31 March 2023	**Unrestricted funds**	**Designated funds**	**Restricted funds**	**Total Funds**	**Total Funds**
	£	**£**	**£**	**£**	**£**
Tangible Fixed Assets	1,824	-	-	**1,824**	**1,824**
Current Assets	315,474		40,586	**356,060**	**356,060**
Current Liabilities	(5,563)	-	-	**(5,563)**	**(5,563)**
	311,735	**-**	**40,586**	**352,321**	**352,321**

At 1 April 2022	**Unrestricted funds**	**Designated funds**	**Restricted funds**	**Total Funds**	**Total Funds**
	£	**£**	**£**	**£**	**£**
Tangible Fixed Assets	1,250	-	-	**1,250**	**1,250**
Current Assets	290,286	-	31,517	**321,803**	**321,803**
Current Liabilities	(6,206)	-	-	**(6,206)**	**(6,206)**
	285,330	**-**	**31,517**	**316,847**	**316,847**

Leukaemia & Myeloma Research UK Ltd

Notes to the Accounts for the year ended 31 March 2023

13 Change in total funds over the year as shown in Note 12 , analysed by individual funds

	Funds brought forward from 2022	Movement in funds in 2023	Transfers between funds in 2023	Funds carried forward to 2024	Funds carried forward to 2024
		See Note 14			
	£	£	£	£	£
Unrestricted and designated funds:-					
Unrestricted Revenue Funds	285,330	26,405	-	**311,735**	**311,735**
Total unrestricted and designated funds	**285,330**	**26,405**	**-**	**311,735**	**311,735**
Restricted funds:-					
Model Cell Biobank	31,517	9,069	-	**40,586**	**40,586**
Total restricted funds	**31,517**	**9,069**	**-**	**40,586**	**40,586**
Total charity funds	**316,847**	**35,474**	**-**	**352,321**	**352,321**

14 Analysis of movements in funds over the year as shown in Note 13

	Income	Expenditure	Gains & Losses	Movement in funds	Movement in funds
	2023	2023	2023	2023	2023
	£	£	£	£	£
Unrestricted and designated funds:-					
Unrestricted Revenue Funds	207,953	(181,548)	-	**26,405**	**26,405**
Restricted funds:-					
Model Cell Biobank	37,303	(28,234)	-	**9,069**	**9,069**
	245,256	**(209,782)**	**-**	**35,474**	**35,474**

15 The purposes for which the funds

Unrestricted and designated funds:-

Unrestricted Revenue Funds	These funds are held for the meeting the objectives of the charity, and to provide reserves for future activities, research grants, and, subject to charity legislation, are free from all restrictions on their use.

Restricted funds:-

Model Cell Biobank	The purpose of these funds is described under the accounting policy.

16 Ultimate controlling party

The charity is under the control of its legal members.
Every member of the charity is obliged to contribute such amount as may be required not exceeding £10 to the assets of the company in the event of its being wound up while he or she is a member, or within one year after he or she ceases to be a member.

Leukaemia & Myeloma Research UK Ltd

Detailed analysis of income and expenditure for the year ended 31 March 2023 as required by the SORP 2015

This analysis is classsified by conventional nominal descriptions and not by activity.

17 Donations, Grants and Legacies

	Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
	2023	2023	2023	2022
	£	£	£	£
Donations and gifts from individuals				
Small donations individually less than £1000	8,415	-	**8,415**	7,410
Refunds from HMRC on gift aided donations	-	-	**-**	68
Stripe direct donations	14,707	-	**14,707**	7,995
Holyhead Road Unit Holyhead Church	6,536	-	**6,536**	-
Facebook	2,523	-	**2,523**	3,782
Just Giving	47,846	-	**47,846**	17,827
Kiltwalk	2,880	-	**2,880**	1,193
In Memory	17,856	-	**17,856**	9,028
Fundraising Support	-	-	**-**	-
Muchloved	7,859	-	**7,859**	3,545
Virgin Money Giving	-	-	**-**	2,453
Giving.com	2,646	-	**2,646**	2,379
Paypal Giving	2,895	-	**2,895**	1,066
Total donations and gifts from individuals	**114,163**	**-**	**114,163**	**56,746**

All the donations and gifts in the prior year were unrestricted.

Donations and gifts from individuals (Include HMRC refunds on gift aided donations) - Prior Year analysis

	Prior Year Unrestricted Funds	Prior Year Restricted Funds	Prior Year Total Funds
	2022	2022	2022
	£	£	£
Prior year	**44,506**	**12,240**	**56,746**

Leukaemia & Myeloma Research UK Ltd

Detailed analysis of income and expenditure for the year ended 31 March 2023 as required by the SORP 2015

Legacies receivable

	Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
	2023	2023	2023	2022
	£	£	£	£
Legacies receivable				
Small legacies individually less than £1000	-	-	**-**	-
Mrs Mary Dallas	-	-	**-**	100
Mrs Beryl Mary Round	-	-	**-**	40,784
Mayo Wynne Baxter Solicitors	-	-	**-**	64
Sylvia Allanson	1,500	-	**1,500**	-
Malcolm Squibb	5,000	-	**5,000**	-
Total legacies receivable	**6,500**	**-**	**6,500**	**40,948**

Legacies receivable - Prior Year analysis

	Prior Year Unrestricted Funds	Prior Year Restricted Funds	Prior Year Total Funds
	2022	2022	2022
	£	£	£
Prior year	40,948	-	**40,948**

Leukaemia & Myeloma Research UK Ltd

Detailed analysis of income and expenditure for the year ended 31 March 2023 as required by the SORP 2015

Revenue grants from government and public bodies

	Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
	2023	2023	2023	2022
	£	£	£	£
Revenue grants from government and public bodies				
Small grants individually less than £1000	2,500	200	**2,700**	1,240
Irwin Mitchell LLP / Ambergate	-	2,000	**2,000**	-
Santa Barabara Heights Cjaritable Trust	-	1,000	**1,000**	-
Thomas Sivewright Catto Charitable Trust	-	1,000	**1,000**	-
The Tony Bramall Charitable Trust	-	1,000	**1,000**	-
The Family Rich Charities Trust	-	5,000	**5,000**	-
L&R Gilley Charitable Trust	-	-	**-**	2,500
Gisela Graham Foundation	-	2,000	**2,000**	-
The Constance Paterson Charitable Trust	-	-	**-**	2,500
The Ian Askew Charitable Trust	-	1,000	**1,000**	1,000
Charities Trust AVIVA	-	-	**-**	3,268
Crowdfunder	-	-	**-**	247
The Caron Keating Foundation	-	-	**-**	3,000
The Hospital Saturday Fund	-	-	**-**	2,000
May Nearnshaw Charitbale Trust		2,000	**2,000**	
Ladbrokes Coral Trust		2,500	**2,500**	
The Gledswood Charitable Trust		5,000	**5,000**	
Dorothy Homes Charitable Trust		5,000	**5,000**	
CAF/Box Power Foundation	-	-	**-**	10,000
The Thomas Sivewright Catto Charitable Trust	-	-	**-**	1,000
Sir Cliff Richard	-	-	**-**	1,000
Albert Hunt	1,000		**1,000**	
Arnold Clark	1,000	-	**1,000**	1,000
Total public sector revenue grants	**4,500**	**27,700**	**32,200**	**28,755**

Revenue grants from government and public bodies - Prior Year analysis

	Prior Year Unrestricted Funds	Prior Year Restricted Funds	Prior Year Total Funds
	2022	2022	2022
	£	£	£
Prior Year	28,755	-	**28,755**

Leukaemia & Myeloma Research UK Ltd

Detailed analysis of income and expenditure for the year ended 31 March 2023 as required by the SORP 2015

	Current year Unrestricted Funds 2023 £	Current year Restricted Funds 2023 £	Current year Total Funds 2023 £	Prior Year Total Funds 2022 £
Revenue grants and donations from non public bodies				
Lunya Limited	-	-	**-**	8,000
Fundraising Support Ltd	-	7,685	**7,685**	4,178
LPC Group	10,000	-	**10,000**	-
Theatrical Society	427	-	**427**	-
Orion Engineering	3,000	-	**3,000**	-
Total private sector revenue grants	**13,427**	**7,685**	**21,112**	**12,178**

Revenue grants and donations from non public bodies (Include Gift Aid donations from subsidiaries) - Prior Year analysis

	Prior Year Unrestricted Funds 2022 £	Prior Year Restricted Funds 2022 £	Prior Year Total Funds 2022 £
Prior Year	12,178	-	**12,178**

Leukaemia & Myeloma Research UK Ltd

Detailed analysis of income and expenditure for the year ended 31 March 2023 as required by the SORP 2015

Total Donations, Grants and Legacies

Current year		Unrestricted Funds	Restricted Funds	Current Year Total Funds	Prior Year Total Funds
		2023	2023	2023	2022
		£	£	£	£
Total Donations, Grants and Legacies	**A1**	**138,590**	**35,385**	**173,975**	**138,627**

All the donations and gifts in the prior year were unrestricted.

Prior year		Unrestricted Funds	Restricted Funds	Prior Year Total Funds
		2022	2022	2022
		£	£	£
Total Donations, Grants and Legacies	**A1**	**126,387**	**12,240**	**138,627**

Leukaemia & Myeloma Research UK Ltd

Detailed analysis of income and expenditure for the year ended 31 March 2023 as required by the SORP 2015

18 Income from charitable activities - Trading Activities

Current year

	Current year Unrestricted Funds 2023 £	Current year Restricted Funds 2023 £	Current year Total Funds 2023 £	Prior Year Total funds 2022 £
Primary purpose and ancillary trading				
Sale of goods and services in accordance with the charity's objects	18,635	1,918	**20,553**	17,846
Total Primary purpose and ancillary trading	**18,635**	**1,918**	**20,553**	**17,846**

Prior year

	Prior Year Unrestricted Funds 2022 £	Prior Year Restricted Funds 2022 £	Prior Year Total Funds 2022 £
Primary purpose and ancillary trading			
Sale of goods and services in accordance with the charity's objects	17,846	-	**17,846**
Total Primary purpose and ancillary trading	**17,846**	**-**	**17,846**

19 Total Income from charitable activities

Current year	Current year Unrestricted Funds 2023 £	Current year Restricted Funds 2023 £	Current year Total Funds 2023 £	Prior Year Total Funds 2022 £
Total income from charitable trading	18,635	1,918	**20,553**	17,846
Total from charitable activities **A2**	**18,635**	**1,918**	**20,553**	**17,846**

Income from charitable activities - Prior Year analysis

Prior year	Prior Year Unrestricted Funds 2022 £	Prior Year Restricted Funds 2022 £	Prior Year Total Funds 2022 £
Total income from charitable trading	17,846	-	17,846
	17,846	**-**	**17,846**

Leukaemia & Myeloma Research UK Ltd

Detailed analysis of income and expenditure for the year ended 31 March 2023 as required by the SORP 2015

20 Investment income

		Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
		2023	2023	2023	2022
		£	£	£	£
Bank Interest Receivable		665	-	**665**	27
Total investment income	**A4**	**665**	**-**	**665**	**27**

21 Other income and gains

Current year		Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
		2023	2023	2023	2022
		£	£	£	£
Royalties from the exploitation of intellectual property rights		50,063	-	**50,063**	50,000
Sundry other income		-	-	**-**	109
Total other income	**A5**	**50,063**	**-**	**50,063**	**50,109**

Other income and gains - Prior year analysis

Prior Year		Prior Year Unrestricted Funds	Prior Year Restricted Funds	Prior Year Total Funds
		2022	2022	2022
		£	£	£
Royalties from the exploitation of intellectual property rights		50,000	-	**50,000**
Sundry other income		109	-	**109**
Total other income	**A5**	**50,109**	**-**	**50,109**

Leukaemia & Myeloma Research UK Ltd

Detailed analysis of income and expenditure for the year ended 31 March 2023 as required by the SORP 2015

22 Expenditure on charitable activities - Direct spending

Current Year		Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
		2023	2023	2023	2022
		£	£	£	£
Travel and Subsistence - Charitable Activities		218	-	**218**	**1,931**
Costs of activities and events		11,559	25,102	**36,661**	**20,683**
Consultancy and professional support		33,333	-	**33,333**	**24,636**
Travel and Subsistence - Trustees Travel Expenses		1,292	-	**1,292**	**-**
Total direct spending	**B2a**	**46,402**	**25,102**	**71,504**	**47,250**

Prior Year		Prior Year Unrestricted Funds	Prior Year Restricted Funds	Prior Year Total Funds
		2022	2022	2022
		£	£	£
Travel and Subsistence - Charitable Activities		1,931	-	**1,931**
Costs of activities and events		10,098	10,585	**20,683**
Consultancy and professional support		24,636	-	**24,636**
Total direct spending	**B2a**	**36,665**	**10,585**	**47,250**

Leukaemia & Myeloma Research UK Ltd

Detailed analysis of income and expenditure for the year ended 31 March 2023 as required by the SORP 2015

23 Expenditure on charitable activities - Charitable trading

Current Year		Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
		2023	2023	2023	2022
		£	£	£	£
Cost of goods for primary purpose trading - Including movement in stock for goods made by beneficiaries		**7,874**	**-**	**7,874**	**11,198**
Total charitable trading costs	**B2b**	**7,874**	**-**	**7,874**	**11,198**

24 Expenditure on charitable activities- Grant funding of activities

Current Year		Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
		2023	2023	2023	2022
		£	£	£	£
Grants made to organisations		25,000	-	**25,000**	**24,251**
Total grantmaking costs	**B2c**	**25,000**	**-**	**25,000**	**24,251**

Detailed analysis of income and expenditure for the year ended 31 March 2023 as required by the SORP 2015

25 Support costs for charitable activities

Current Year	Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
	2023	2023	2023	2022
	£	£	£	£
Premises Expenses				
Rates and water charges	219	-	**219**	**249**
Rent and rates	24,212	-	**24,212**	**23,206**
Light heat and power	17	-	**17**	**414**
Cleaning and waste management	-	-	**-**	**216**
Premises repairs, renewals and maintenance	686	-	**686**	**4,098**
Property insurance	596	-	**596**	**428**
Administrative overheads				
Telephone, fax and internet	2,184	-	**2,184**	**2,365**
Postage	698	-	**698**	**582**
Stationery and printing	1,480	-	**1,480**	**416**
Shipping, freight and delivery	-	-	**-**	**840**
Membership subscriptions	7,895	-	**7,895**	**7,381**
Equipment expenses	2,199	-	**2,199**	**3,167**
Hire of equipment	1,099	-	**1,099**	**1,058**
Software licences and expenses	2,119	1,979	**4,098**	**2,332**
Advertising and marketing	10,603	1,143	**11,746**	**13,502**
Equipment repairs,expenses and maintenance	-	-	**-**	**325**
Professional fees paid to advisors other than the auditor or examiner				
Accountancy fees other than examination or audit fees	710	-	**710**	**1,080**
Management fees	26,735	10	**26,745**	**21,528**
Other legal and professional	660	-	**660**	**-**
Financial costs				
Bank charges	35	-	**35**	**24**
Depreciation & Amortisation in total for	1,025	-	**1,025**	**625**
Support costs before reallocation	**83,172**	**3,132**	**86,304**	**83,836**
Total support costs - Current Year	**83,172**	**3,132**	**86,304**	**83,836**

The basis of allocation of costs between activities is described under accounting policies

Leukaemia & Myeloma Research UK Ltd

Detailed analysis of income and expenditure for the year ended 31 March 2023 as required by the SORP 2015

Prior Year	Current year Unrestricted Funds 2023 £	Current year Restricted Funds 2023 £	Prior Year Total Funds 2022 £
Premises Expenses			
Rates and water charges	249	-	**249**
Rent and rates	23,206	-	**23,206**
Light heat and power	414	-	**414**
Cleaning and waste management	216	-	**216**
Premises repairs, renewals and maintenance	4,098	-	**4,098**
Property insurance	428	-	**428**
Administrative overheads			
Telephone, fax and internet	2,042	323	**2,365**
Postage	483	99	**582**
Stationery and printing	416	-	**416**
Shipping, freight and delivery	840	-	**840**
Membership subscriptions	7,381	-	**7,381**
Equipment expenses	3,167	-	**3,167**
Hire of equipment	1,058	-	**1,058**
Software licences and expenses	1,426	906	**2,332**
Advertising and marketing	12,433	1,069	**13,502**
Equipment repairs,expenses and maintenance	325	-	**325**
Professional fees paid to advisors other than the auditor or examiner			
Accountancy fees other than examination or audit fees	1,080	-	**1,080**
Management fees	21,528	-	**21,528**
Financial costs			
Bank charges	24	-	**24**
Depreciation & Amortisation in total for the period	625	-	**625**
Support costs before reallocation	**81,439**	**2,397**	**83,836**
Total support costs - Prior Year	**81,439**	**2,397**	**83,836**

The basis of allocation of costs between activities is described under accounting policies

Detailed analysis of income and expenditure for the year ended 31 March 2023 as required by the SORP 2015

26 Other Expenditure - Governance costs

Current Year	Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
	2023	2023	2023	2022
	£	£	£	£
Independent Examiner's fees	-	-	**-**	**420**
Total Governance costs	**-**	**-**	**-**	**420**

All the expenditure in the prior year was unrestricted.

27 Total Charitable expenditure

Current Year		Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
		2023	2023	2023	2022
		£	£	£	£
Total direct spending	**B2a**	46,402	25,102	**71,504**	**47,250**
Total charitable trading costs	**B2b**	7,874	-	**7,874**	**11,198**
Total grantmaking costs	**B2c**	25,000	-	**25,000**	**24,251**
Total support costs	**B2d**	83,172	3,132	**86,304**	**83,836**
Total Governance costs	**B2e**	-	-	**-**	**420**
Total charitable expenditure	**B2**	**162,448**	**28,234**	**190,682**	**166,955**

Prior Year		Prior Year Unrestricted Funds	Prior Year Restricted Funds	Prior Year Total Funds
		2022	2022	2022
		£	£	£
Total direct spending	**B2a**	36,665	10,585	**47,250**
Total charitable trading costs	**B2b**	11,198	-	**11,198**
Total grantmaking costs	**B2c**	24,251	-	**24,251**
Total support costs	**B2d**	81,439	2,397	**83,836**
Total Governance costs	**B2e**	420	-	**420**
Total charitable expenditure	**B2**	**153,973**	**12,982**	**166,955**

Detailed analysis of income and expenditure for the year ended 31 March 2023 as required by the SORP 2015

28 Expenditure on raising funds and costs of investment management

Current Year		Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
		2023	2023	2023	2022
		£	£	£	£
Agent's costs for fundraising		6,450	-	**6,450**	**4,945**
Fundraising publicity & marketing		-	-	**-**	**480**
Cost of fundraising activities		11,996	-	**11,996**	**2,764**
Fundraising trading costs		654	-	**654**	**906**
Total fundraising costs	**B1**	**19,100**	**-**	**19,100**	**9,095**

All the expenditure in the prior year was unrestricted.

LEUKAEMIA & MYELOMA RESEARCH UK LTD

England & Wales - Charity number 1161622

Accounts

Leukaemia & Myeloma Research UK

Report and Accounts

31 March 2022

Research That Saves Lives

leukaemiamyelomaresearchuk.org
Registered charity number 1161622 (England & Wales), SC046106 (Scotland),
Leukaemia and Myeloma Research UK Ltd
Company Limited by guarantee Registered number 09481278

Leukaemia & Myeloma Research UK

Research That Saves Lives

Leukaemia and Myeloma Research UK Ltd
Unit 127,
North Mersey Business Centre,
Woodward Rd,
Knowsley Industrial Park,
Liverpool,
Merseyside,
L33 7UY

Tel: 0800 368 7309

Web: www.leukaemiamyelomaresearchuk.org

Email: cs@leukaemiamyelomaresearchuk.org

Charity Number 1161622
Company Number 09481278



Follow us on Twitter: **https://twitter.com/lmruk_org**

Facebook: **https://www.facebook.com/leukaemiamyelomaresearchuk.org**

MODEL CELL BIOBANK
research that saves lives

Together we can beat cancer

Annual Report 2022

Table of contents

About Us 3

Stem Cells 4

Charitable Activities..... 5

Chairman's Report 6

Operation Director's Report 7

MCB Service..... 9

Overview 9

Case Study..... 11

Research Priorities..... 12

Fundraising and Volunteers..... 13

Thanks..... 14

Trustees and Staff 14

Accounts 15



About Us

Leukaemia & Myeloma Research UK Ltd wants to prevent people dying from blood cancer through more effective treatment in the future. We are willing to fight blood cancer regardless of how long it might take.

Founded in 2015, our mission is to prevent people dying from blood cancer through prevention, research and more effective treatment.

Unfortunately, blood cancer affects a large number of people. Every 13 minutes, someone in the UK is told they have a blood cancer. That's around 110 people per day, 40,000 people per year. There are an estimated 4,700 leukaemia deaths every year, that's 13 every day!

We are aiming to become the UK's leading charity in supporting efforts to combat the three major types of blood cancer. The work we do helps fund vital stem cell research, raises awareness of stem cell therapies and helps families protect their children's future health by storing their cord blood stem cells at the time of birth.

There are 3 main types of cancers of the blood; they are lymphoma, leukaemia and myeloma. The blood is made up of three different types of cells:

- Red blood cells which carry the oxygen around the body
- White blood cells which fight and stop infections
- Platelets which help the blood to clot

The course of treatment given will depend on the type of cancer. The most common treatments are chemotherapy, radiotherapy and in some instances, a stem cell transplant.

In essence, the Charity wants to eradicate blood cancer once and for all. One of the ways we are aiming to achieve that is through advancing our understanding of stem cells and how we can use them to treat patients with blood cancer, particularly through stem cell transplants. We do this by:

- Actively supporting stem cell research into blood cancers
- Raising awareness of stem cell therapies
- Provide information about blood cancers and treatment options
- Protecting the vulnerable by offering qualifying expectant mothers, with a family history of cancer, the opportunity to store their baby's umbilical cord blood stem cells at the time of birth, in case they are needed in the future to treat that child or another member of the family if they're a suitable match. This service is called Model Cell Biobank (MCB).

Stem Cells

In humans, there are two types of stem cells: embryonic stem cells and adult stem cells, which are found in various tissues.

Adult stem cells are the primary focus of the research that the Charity supports. They typically generate the cell types of the tissue in which they reside.

For example, a blood-forming adult stem cell in the bone marrow normally gives rise to the many types of blood cells. It is generally accepted that a blood-forming cell in the bone marrow—which is called a hematopoietic stem cell—cannot give rise to the cells of a very different tissue, such as nerve cells in the brain.

Where are stem cells found?
There are four known accessible sources of autologous adult stem cells in humans:

• Bone marrow which requires harvesting by drilling into bone (typically the femur or iliac crest). This is done under a general anesthetic.
• Blood, which requires extraction through apheresis, wherein blood is drawn from the donor (similar to a blood donation), and passed through a machine that extracts the stem cells and then returns the blood to the donor.
• Adipose tissue (lipid cells), which requires extraction by liposuction
• Umbilical cord blood - these stem cells can be collected from the umbilical cord blood just after birth.

What can stem cells be used for today?
There are treatments where Hematopoietic Stem Cell Transplants (HSCT) - the transplantation of blood forming stem cells - is a standard treatment. For some diseases they are the only therapy, and in other diseases they are only employed when front-line therapies have failed or the disease is very aggressive.

There are other blood disorders that can be treated with stem cells that aren't cancers, such as sickle cell anaemia and aplastic anaemia.

For most types of blood cancers, for example: leukaemia, lymphoma and various anaemia's, the treatments use allogeneic stem cell transplants (someone else's stem cells). The reason for this is that the person may have a genetic predisposition to the disease; their genes have a defect that predisposes them to that disease.

However there are various types of cancers (some myelomas, plasma cell leukaemia, some anaemia's and solid tumours) that are treated using autologous stem cells (using your own stem cells).

Charitable Activities

Providing Information

Throughout the year we have shared facts about blood cancer, including the signs, symptoms and treatments. We have achieved this through our regular newsletter, social media channels, website, and our blood cancer booklet. This provides patients with clear and informative advice that would answer their questions, explain terminology, discuss treatments so they are better prepared and able to make informed choices.

We produce a quarterly newsletter that shines a spotlight on our inspirational fundraisers and their stories; highlights our exciting plans for the future and provides information relating to blood cancer. It is available from our website free of charge.

Medical Research

Leukaemia & Myeloma Research UK allocate research grants to those who uphold our primary objectives. These are to benefit the public, in particular by research into the nature, causes, diagnosis, prevention, treatment and cure of leukaemia and myeloma.

Our current funding priorities are to advance understanding of stem cells and how they can be used to treat blood cancer patients. All grant applications are reviewed by the Charity's Research and Review Committee, an independent panel of experts. The Charity is a member of the Association of Medical Research Charities, the AMRC.



Fundraising Activities

Over the last year, the Charity expanded its textile recycling project so it now includes local schools to the Merseyside and Greater Manchester areas. This is with the aim of raising awareness of both blood cancer and of the environmental benefits of recycling. It also continues to raise valuable funds for the charities work.

In conjunction with this, our fundraisers have been busy running events from cake sales to sky dives. This has secured £68,806 of funding to support our services and help in the fight against cancer.

Model Cell Biobank Service

This service was established to support families who are on low income, have a history of cancer in the family, to store their babies cord blood stem cells at the time of birth. These cells are stored for 25 years in case that child, or another member of the family, needs them in the future to treat a disease.

The cord blood stem cells can be used today instead of bone marrow stem cells to treat blood cancer and genetic disorders. In fact, recent studies show that over 80 diseases could be treated using cord blood stem cells.

This is the first funded stem-cell storage service to promote 'biological insurance' - where a child's cord-blood stem cells are stored at the time of birth. The service is offered free of charge to families on benefits, and a part funded service is offered to low income families.

Chairman's Report

One of our key focuses over the last year has been to widen awareness of blood cancer. We have achieved this in a number of ways.

In May, the Charity engaged in the World Blood Cancer Day sharing blood cancer statistics and highlighting how people support us.

Combined with this, in June we marked National Myeloma Awareness week, during which the Charity highlighted common signs and symptoms to look out for.

In November, we celebrated World Cord Blood Day. We collated 80 facts about cord blood and produced a special edition of our E-newsletter.

UK Charity Week was celebrated in December for which we became an official partner. The charity now has a regular section in the organisers Charity Today E-magazine where we highlight facts about blood cancer , the MCB service, and celebrate our amazing fundraisers.

In January, we launched the School Textile Recycling Scheme in the Liverpool and Greater Manchester areas. The team have been working hard to engage with schools and spread the message.

The end of the financial year was marked by Myeloma Awareness Month. The Charity promoted its annual March for Myeloma campaign and shared quotes from the West Lancashire and Merseyside Myeloma Support Group about living with the disease. It also shared facts and statistics about myeloma.

Finally, I would like to take this opportunity to thank all our volunteers and fundraisers for all the amazing work they have done throughout the year. Without their support we wouldn't be able to continue to offer the services that we do.

Sergey Vinogradov
Chair, Leukaemia and Myeloma Research UK Ltd

Operation Director's Report



It has been a challenging year as the country emerges from the pandemic. However, we are truly grateful to our fantastic fundraisers who have ventured out to challenge themselves whilst raising vital funds for the Charity.

To give a few examples, we have had a father and son run 300 kilometres in memory of their wife and mum, who sadly passed away from leukaemia.

Students have held a Turkish buffet in college. Other fundraisers have done events such as: Man Versus Coast Challenge, cycling Lands End to John O'Groats, running the virtual London Marathon, and taking part in the Snowdonia Trail Marathon.

We welcomed three new members to the Research and Review Committee this year: Dr John Jones, Dr Ceri Bygrave, and Dr Salvatore Papa. Dr Rhys Morgan was the recipient of research grant to support his work into Cell Signalling Abnormalities in Leukaemia Cells.

We were fortunate to be awarded our first corporate funding from Aviva 'Pennies for Good' who donated £17,000 towards our work. Following this in December, the Charity received £10,000 from Box Power - the UK's first philanthropic energy consultancy firm. We were overwhelmed by the generousity of Aviva and Box Power with their significant funding, which will help us to make a huge difference in finding better treatments to fight blood cancer.

In November, the Charity produced a webinar with the help of one of our fundraisers, one of our ambassadors and members of the Research and Review Committee. This was designed to inform the public about the important work we do, protecting the next generation and the vital stem cell research we invest in to prevent people dying from blood cancer.

One of our new fundraising ventures was to secure places for riders to participate in the 2022 London to Brighton Ride. This was launched in September 2021 and I am pleased to report we had filled all the places by March 22. We are pleased to be working with Lister Wilder Agriculture team of over 50 riders who



are joining us for this epic challenge.

Our cord blood banking service continues to grow from strength to strength. We experienced a 50% increase in enquiries and hope that this will continue over the the next year ensuring we can help more families in our fight against blood cancer.

We are extremely grateful to the generous funding received from Fundraising Support who have helped this service support even more families. I would like to say a huge 'thank you' to our fundraisers for their hard work and to our hard working staff and partners who have pulled together to make 2021-22 such a huge success. All of our fundraisers are important from cake sales to sky dives - we simply would not be able to run these services without their help.



Dr Joanna Tilley
Operations Director,
Leukaemia and Myeloma Research UK Ltd

MCB Service

Overview

The Model Cell Biobank (MCB) service allows the storage of a child's umbilical cord blood stem cells at the time of birth, in case they or another member of the family needs them in the future to help in the treatment of a disease. It may be possible to use the stem cells to treat blood cancers or in emerging therapies to treat diseases such as diabetes, cerebral palsy and Parkinson's disease. Clinical trials are being performed all over the world looking at the potential use of stem cells to treat new diseases and hopefully further breakthroughs.

When a baby is born and the umbilical cord is cut, the placenta and umbilical cord are normally thrown away. The blood that remains in the cord and the placenta contains stem cells. The Charity offers a service to collect these stem cells without any risk to the mother and baby, and to store them in case that child or another member of the family needs them in the future.

The cord blood stem cells are stored on behalf of the child for 25 years. The mother is the legal guardian of the cells until the child reaches the age of majority, at which point, ownership transfers to the child. After 25 years, the cells can be privately stored, donated for research, offered to a public bank, or destroyed. Consent from the child will be sought at this point and we would strongly encourage the donation of any remaining cells to public banks.

The cord blood banking service is available to qualifying expectant mothers who live in the UK. They must be in receipt of Housing Benefit, Council tax or Universal Credit (at least one of these) and must meet the following criteria:

- The stem cells will be used to treat the child, or another member of the family, for a medically attested treatment;
- There is a history of cancer in the immediate family.

We recently extended the project to support low-income families by implementing a part funded service for those who have medical history, but are not on benefits.

Biovault Technical is our chosen partner to procure; process and store cord stem cells under its Human Tissue Authority licence.

Biovault has a strong reputation for standards it applies to the storage and processing of stem cells derived from umbilical cord and peripheral blood, bone marrow, now extending to many types of tissues for human application or transplant.

Biovault not only works to the highest standards, it also has an ethical approach, which aligns with our charity, something we are proud of.

MODEL CELL BIOBANK
research that saves lives





Advantages of Cord Blood Stem Cells

Today, cord blood banking is changing lives and there have already been more than one million stem cell transplants around the world since the 1980s.

The stem cells in your baby's cord blood are fully developed adult stem cells, which are the building blocks of the blood immune system. These stem cells can be used instead of bone marrow stem cells to treat blood cancers and genetic disorders.

Cord blood stem cells have many advantages including:

• They are easily available, having already been harvested and stored;
• A new born baby has been exposed to fewer viruses and infections and so the stem cells are less likely to transmit infection and react with the patient;
• Cord blood stem cells offer the life-saving option of a transplant and avoids the invasive, painful and expensive procedures of other stem-cell collection, such as bone marrow;
• Cord blood stem cells can be stored for many years - the longevity of these cells has proved they are as good 30 years later as on as the day they were first extracted and stored.

Client feedback

"The team at LMRUK were so helpful andknowledgeable – they talked me through the whole process and advised me that as a sibling, there was a 25% chance that Alice's stem cells would be a match for Lara's. Craig and I read through all the information on the LMRUK website and decided to apply.
(Client)

"Ever since my diagnosis I have felt an enormous sense of guilt about the chance of any of my children getting cancer – it is a mother's worst nightmare. I am incredibly grateful to have found out about this potentially lifesaving service, and even if we don't use the stored cord blood stem cells, it is reassuring to know that they will not go to waste."
(Client)

Case Study – Elaine's Story

Restaurant owners, Elaine and Peter Kinsella have raised an impressive £15,000 in three months for Leukaemia & Myeloma Research UK (LMRUK), West Lancs and Merseyside Myeloma Support Group (WL&M Myeloma) and the Liverpool Haematology Patient Support Group following Elaine's myeloma diagnosis last year.

Elaine, 57, was diagnosed with myeloma following a routine blood test after undergoing treatment less than a year before for thyroid cancer.

Following initial treatment at Arrowe Park Hospital in Wirral, Elaine had a stem cell transplant at The Clatterbridge Cancer Centre in Liverpool. To support her recovery, she was encouraged to join the WL&M Myeloma Support Group and whilst recovering, she started planning ways she could fundraise to give back to those who helped her throughout her treatment.

From October to January 2022, Elaine and Peter who have jointly run the Lunya restaurant in Hanover Street, and Lunyalita on the Albert Docks for over 12 years, invited customers to add an extra pound onto their bill which went into a charity donation pot with the promise of the final fundraising total being matched by the couple.

Over the three months, £7,500 was raised from generous donations and with their personally matched donation, bought the final figure to £15,000. This fantastic sum has been split and donated to LMRUK, WL&M Myeloma and the Liverpool Haematology Patient Support Group.

Elaine Kinsella said: "We are so thankful to all our customers and friends who have donated money. Now that I am in remission and on the road to recovery, I can't wait to get back into the restaurants and see everyone again.

Dr Joanna Tilley, Operations Director at LMRUK said: "We are incredibly thankful to Elaine, Peter and their customers who have raised a significant amount of money to support the potentially lifesaving stem cell research to find better treatments to fight blood cancer once and for all. We work closely with the WL&M Myeloma Support Group and know how important donations like these are so that they can continue providing vital support to their members."

Research Priorities

Leukaemia & Myeloma Research UK Ltd offer research grants to those who uphold our primary objectives: to protect and promote the health of the public, in particular by research into the nature, causes, diagnosis, prevention, treatment and cure of leukaemia and myeloma.

The Trustees' current funding priorities are to advance understanding of stem cells and how they can be used to treat blood cancer patients, particularly through stem cell transplants.

Dr Rhys Morgan, a leukaemia researcher and lecturer in Biomedical Science, was awarded a grant for novel research into cell signalling abnormalities in leukaemia cells.

"These funds have allowed us to perform an expensive, but highly informative, technique called RNA sequencing (RNAseq) to understand how the cancer promoting protein β-catenin causes inappropriate gene activation in leukaemia cells, an analysis not previously undertaken before.

The research will be undertaken at the University of Sussex. Dr Joanna Tilley, Operations Director at LMRUK said: "Our charity focuses on investing in vital research into the nature, causes, prevention, diagnosis, treatment and cure of blood cancer in the hope of protecting the next generation from this disease.

"We're thrilled to be able to fund Dr Rhys Morgan on the first and most crucial first phase of his fascinating research and we wish him all the best in developing his findings, which will support our work in finding more effective treatments to fight blood cancer."

Dr Paul Spencer Hole
Senior Research Scientist. Has been engaged in academic research at Cardiff University and extends his experience in a clinical-stage biopharmaceutical company.

Dr Claire Seedhouse
Associate Professor within Division of Cancer and Stem Cells, University of Nottingham. She is Principle Investigator and research group leader in Blood Cancer at the University of Nottingham.

Dr John Jones
Senior Clinical Lecturer – Brighton and Sussex Medical School, Honorary Consultant Haematologist – Kings College Hospital NHS Trust, London and Eastbourne District General Hospital.

Dr Rhys Morgan
Lecturer in Biomedical Sciences in Department of Biochemistry and Biomedicine, at the University of Sussex.

Professor Joseph R. Slupsky
Reader in Department of Molecular and Clinical Cancer Medicine, University of Liverpool. He is Principal Investigator of the Liverpool Blood Disease Biobank and Academic Lead University of Liverpool Technology Directorate Cell Sorting and Flow/Mass Cytometry Facility.

Dr Ceri Bygrave
A Consultant Haematologist and Myeloma Lead at the University Hospital of Wales and a member of the UK Myeloma Forum Executive Committee and the UK Myeloma Research Alliance.

Dr Salvatore Papa
An Associate Professor at Leeds University whose research speciality is in lymphoma and myeloma.

Fundraising and Volunteers

With two half marathons under his belt, Daz Martin from Whittington in Shropshire has decided to lace up his running shoes once again and take on his biggest challenge yet.

This July, Daz will be running the epic Xterra Snowdonia Trail Marathon to raise money for Leukaemia & Myeloma Research UK (LMRUK) after his mum, Sue, passed away from Acute Myeloid Leukaemia (AML).

After initially going into hospital from suffering with months of getting water infections in April 2021, doctors diagnosed Sue with AML and she was immediately given medication. At first, she responded well but unfortunately, she was fighting infection after infection and the doctors decided to stop the treatment. Soon after, she was moved into a hospice for palliative care.

Three weeks after her diagnosis and just two days before her 69th birthday, Sue passed away leaving behind her husband, John, two sons Daz and Kev, and six grandchildren.

"Before my mum's diagnosis, I wasn't aware of Acute Myeloid Leukaemia and as a family we were all learning and reading up as much as possible together. "Leukaemia was a form of blood cancer I was familiar with as back in secondary school my best friend, Paul Dart, was diagnosed with it and passed away at the young age of 17, which was devastating", said Daz.

To raise awareness of the different forms of blood cancer and gather vital funds for charity, Daz will be ascending almost 1,700 metres over 27 miles while navigating himself across Wales' highest peak – Snowdon, as part of the Xterra Trail Marathon on 10th July 2022.

"The event takes place over one day and starts and finishes in Llanberis village at the foot of Snowdon. The route will take us through all different terrains as we reach the summit to take in the spectacular views – fingers crossed for a clear day! – and then we'll descend towards the finish line to meet our family and friends", explained Daz.

Over 2,000 runners will be taking part and all hoping to raise money for worthy causes. Daz is aiming to raise over £300 for LMRUK, he explained: "I wanted to fundraise for a charity that was related to my mum's illness to help raise awareness of the signs and symptoms of blood cancer, as well as help fund the work being done on finding more effective treatments for patients".

Having previously taken on the Three Peaks Challenge over 24 hours with friends, Daz is no stranger to the gruelling hours of training. "This will be the longest and toughest distance I've run in one go, but having already completed the Three Peaks Challenge, half marathons and regularly running 5-10k, and with the amazing support from my partner, Sharon, friends and family, I'm positive I'll beable to make it to the finish line in a good time.

Thanks to Funders

- Arnold Clark Community Fund
- The Hobson Charity Ltd
- The Constance Paterson Foundation
- Aviva Pennies for Good
- Lillie Johnson Charitable Trust
- Thomas Sivewright Catto Charitable Trust
- Speke Operations
- Caron Keating Foundation
- Box Power
- The Hospital Saturday Fund
- The Cliff Richard Charitable Trust
- L and R Gilley Charitable Trust
- Ian Askew Charitable Trust

Staff and Committee Members

Trustees 2021-2022

- Sergejs Vinogradov (Chair)
- Tatjana Vinogradova
- Victoria Kieran
- Julija Sidorika

Staff Team

- Dr Joanna Tilley - Interim Operations Director
- Lucy Heron - Office Manager / Senior MCB Call Centre Manager
- Richard Thompson - Call Centre
- Kate Williams - PT Fundraiser

Thanks to Individuals and supporters

- Best Freelance Design Ltd
- Biovault Technical Ltd
- Dr Hannah Hunter – Consultant Haematologist
- Fundraising Support Ltd
- KOR Communications
- Phlebotomy UK Ltd
- Research Review Committee

Leukaemia & Myeloma Research UK

leukaemiamyelomaresearchuk.org

Registered charity number 1161622 (England & Wales), SC046106 (Scotland),
Company Limited by guarantee Registered number 09481278

Accounts 31 March 2022



Leukaemia & Myeloma Research UK Ltd

Report and accounts for the year ended 31 March 2022

Contents

	Page
Charity information	1
Trustees' Annual Report	1
Statement of directors' responsibilities	5
Independent Examiner's Report	7
Funds Statements:-	
Statement of Financial Activities	9
Statement of Financial Activities - Prior Year statement	10
Movements in funds	12
Income and Expenditure account	13
Balance sheet	14
Notes to the accounts	15

Leukaemia & Myeloma Research UK Ltd

Company Registration Number - 09481278

Trustees' Annual Report for the year ended 31 March 2022

The Trustees present their Report and Accounts for the year ended 31 March 2022, which also comprises the Directors' Report required by the Companies Act 2006.

Reference and administrative details

The charity name.

The legal name of the charity is:- Leukaemia & Myeloma Research UK Ltd.

The charity is also known by its operating name, LMR UK Ltd.

The charity's areas operation and UK charitable registration.

The charity is registered in England & Wales with the Charity Commission in England & Wales (CCEW) with charity number 1161622.

The charity is also registered in Scotland, with charity number SC046106 as it has operations in Scotland.

The charity does not operate in any overseas jurisdictions.

Legal structure of the charity

The charity is constituted as a company limited by guarantee, registered under the Companies Acts . The governing document of the charity is the Memorandum and Articles of Association establishing the company under company legislation.
The governing document is dated 10 March 2015
There are no restrictions in the governing documents on the operation of the Charity or on its investment powers other than those imposed by Charity Law.

By operation of law all, trustees are directors under the Companies Act 2006 and all directors are trustees under Charities legislation and have responsibilities, as such, under both company and charity legislation.

The trustees are all individuals.

Leukaemia & Myeloma Research UK Ltd

Company Registration Number - 09481278

Trustees' Annual Report for the year ended 31 March 2022

The principal operating address, telephone number, email and web addresses of the charity

Room 127, North Mersey Business Centre
Woodward Road, Liverpool
Merseyside, L33 7UY
Telephone 08003687309

Email Address info@leukaemiamyelomaresearchuk.org Web address https://www.leukaemiamyelomaresearchuk.org/

The registered office of the charity for Companies Act purposes is the same as the operating

The Trustees in office on the date the report was approved were:-

Sergejs Vinogradovs
Tatjana Vinogradova
Julija Sidorika
Victoria Kieran

The following persons served as Trustees during the year ended 31 March 2022 :-

The trustees who served as a trustee in the reporting period were as shown above, and there were no changes during the year, or in the period between the year end and the approval of the accounts.

All the trustees are also members of the charity.

Objects and activities of the charity

The purposes of the charity as set out in its governing document.

The objectives of the charity are set out in the Memorandum of Association of 14 July 2015. They are:
1. to protect and promote the health of the public in particular by research into the nature, causes, diagnosis, prevention, treatment and cure of leukaemia and myeloma.
2. development of research into practical applications for the prevention. Treatment and cure leukaemia and myeloma and raise public understanding of such matters.

Trustees' Annual Report for the year ended 31 March 2022

Structure, governance and management of the charity

The methods used to recruit and appoint new charity trustees.

Proposals for new Trustees are made by the Chair after making appropriate enquiries. Appointments are then made by election by the existing board of Trustees.

Accountants	KBH Accountants Ltd - 255 Poulton Road, Wallasey, CH44 4BT

Leukaemia & Myeloma Research UK Ltd

Company Registration Number - 09481278

Trustees' Annual Report for the year ended 31 March 2022

Financial review

	2022	2021
	£	£
Net income	30,559	49,918
Unrestricted Revenue Funds available for the general purposes of the charity	285,330	258,527
Restricted Revenue Funds	31,517	27,761
Total Funds	316,847	286,288

Financial review of the position at the reporting date, 31 March 2022 .

Overall surpplus stands at £316,847 and will be distributed in following way: £50,000 for the Reserves; £20,000 for the E-Shop development; £60,000 for Research grants and 186,847 for the charity and MCB development.
The trustees consider the financial performance by the charity during the year to have been satisfactory.

Policies on reserves.

All the trustees aim to maintain free reserves in unrestricted funds at a level which equates to between two and four months of unrestricted charitable expenditure. The trustees consider that this level will ensure that there are sufficient funds available to cover support and governance costs. Reserves policy will be reviewed annually based on the charity's annual accounts. Based on the results of past year, the Reserves amount is £50,000.

Availability and adequacy of assets of each of the funds

The board of trustees is satisfied that the charity's assets in each fund are available and adequate to fulfil its obligations in respect of each fund.

Details of The Independent Examiner

Olivia Higgins

Member of Chartered Certified Accountants

255 Poulton Road
Wallasey
Wirral
CH44 4BT

Trustees' Annual Report for the year ended 31 March 2022

Statement of the Directors Trustees' Responsibilities

The charity's trustees are responsible for the preparation of the accounts in accordance with the terms of the Companies Act 2006, the Charities Act 2011 and the Charities (Accounts and Reports) Regulations 2008. Notwithstanding the explicit requirement in the extant statutory regulations,the Charities (Accounts and Reports) Regulations 2008, to prepare the financial statements in accordance with the SORP 2005, in view of the fact that the SORP 2005 has been withdrawn, the Trustees determined to interpret this responsibility as requiring them to follow current best practice and prepare the accounts according to the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), .

In particular, the Companies Act 2006 and charity law require the Board of Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity as at the end of the financial year and of the surplus or deficit of the charity. In preparing those financial statements the Board is required to :-

- to prepare the accounts in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law).
- select suitable accounting policies and apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business;
- state whether applicable accounting standards and statements of recommended practice have been followed, subject to any material departures disclosed and explained in the financial statements;

The law requires that the trustees must not approve the accounts unless they are satisfied that they give a true and fair view of the state of affairs of the charity and of the surplus or deficit of the charity for the year.
The Trustees are also responsible for maintaining adequate accounting records which disclose with reasonable accuracy at any time the financial position of the charity and which are sufficient to show and explain the charity's transactions and enable them to ensure that the financial statements comply with the Companies Act 2006 and comply with regulations made under the Charities Act. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Trustees are also responsible for the contents of the Trustees' report, and the statutory responsibility of the Independent Examiner in relation to the Trustees' report is limited to examining the report and ensuring that , on the face of the report, there are no material inconsistencies with the figures disclosed in the financial statements.

Leukaemia & Myeloma Research UK Ltd

Company Registration Number - 09481278

Trustees' Annual Report for the year ended 31 March 2022

Method of preparation of accounts - Small company provisions

The financial statements are set out on pages 9 to 33.
The financial statements have been prepared implementing the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), and in accordance with the Financial Reporting Standard 102, (effective 1st January 2016)
These financial statements have been prepared in accordance with the provisions in Part 15 of the Companies Act 2006. applicable to companies subject to the small companies regime.

This report was approved by the board of trustees on 19 December 2022.

TATJANA VINOGRADOVA
Director and Trustee

Leukaemia & Myeloma Research UK Ltd

Report of the Independent Examiner to the Trustees of the charitable company on the accounts for the year ended 31 March 2022

I report to the Trustees on my examination of the financial statements of the charitable company on pages 9 to 33 for the year ended 31 March 2022 which have been prepared in accordance with the Charities Act 2011 (the Act) and with the Financial Reporting Standard 102, (effective 1st January 2016) as modified by FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), published by the Charity Commission in England & Wales (CCEW) , and under the historical cost convention and the accounting policies set out on page 15.

Respective responsibilities of the Trustees and the Independent Examiner and the basis of the report

As described on page 5, you, the charitable company's Trustees, who are also the Directors of the Company for the purposes of Company law, are responsible for the preparation of the financial statements in accordance with the Companies Act 2006, the Charities Act 2011 and all other applicable law and with United Kingdom Generally Accepted Accounting Practice, applicable to smaller entities, and for being satisfied that the financial statements give a true and fair view.

The Trustees consider that the audit requirement of Section 144(1) of the Charities Act 2011 (the Act) does not apply, and that there is no requirement in the memorandum and articles of the charity for the conducting of an audit, and that the accounts do not require an audit in accordance with Part 16 of the Companies Act 2006 and that no member or members have requested an audit pursuant to Section 476 of the Companies Act 2006. As a consequence, the Trustees have elected that the financial statements be subject to independent examination.

Having satisfied myself that the financial statements are not required to be audited under any legal provision, or otherwise, and are eligible for independent examination, it is my responsibility to:-

a) examine the financial statements of the charity under Section 145 of the Act;

b) follow the applicable procedures in the Directions given by the Charity Commission under section 145(5)(b) of the Act.

Basis of Independent Examiner's Statement and scope of work undertaken

Since the charitable company's gross income exceeded £250,000, the charitable company's examiner must be a member of a body listed in section 145 of the Act. I confirm that I am qualified to undertake the examination because I am an authorised member of Chartered Certified Accountants , which is one of the listed bodies.

I report in respect of my examination of the charity's financial statements carried out under s145 of the Act. In carrying out my examination, I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act setting out the duties of an independent examiner in relation to the conducting of an independent examination. An independent examination includes a review of the accounting records kept by the charitable company and of the accounting systems employed by the charitable company and a comparison of the financial statements presented with those records. It also includes consideration of any unusual items or disclosures in the financial statements, and seeking explanations from you, as Trustees, concerning such matters. The purpose of the examination is to establish as far as possible that there have been no breaches of charity legislation and that, on a test basis of evidence relevant to the amounts and disclosures made, the financial statements comply with the SORP.

The procedures undertaken do not provide all the evidence that would be required in an audit, and information supplied by the Trustees in the course of the examination is not subjected to audit tests or enquiries and does not cover all the matters that an auditor would consider in arriving at an opinion. The planning and conduct of an audit goes beyond the limited assurance that an independent examination can provide

Consequently, I do not express an audit opinion on the view given by the financial statements, and in particular, I express no opinion as to whether the financial statements give a true and fair view of the affairs of the charity, and my report is limited to the matters set out in the statement below.

I planned and performed my examination so as to satisfy myself that the objectives of the independent examination are achieved and before finalising the report I obtained written assurances from the Trustees of all material matters.

Leukaemia & Myeloma Research UK Ltd

Independent Examiner's Statement, Report and Opinion

Subject to the limitations upon the scope of my work as detailed above, I have completed my examination: and can confirm that:-

The accounts of this charitable company are not required to be audited under Part 16 of the Companies Act 2006;

This is a report in respect of an examination carried out under 145 of the Act and in accordance with Directions given by the Charity Commission under section 145(5)(b) of the Act which may be applicable;

and that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:-

accounting records were not kept in respect of the charity as required by Section 386 of the Companies Act 2006 and Section 130 of The Charities Act 2011;

the financial statements do not accord with those records; or

the financial statements do not comply with the applicable requirements concerning the form and content of accounts set out in section 396 of the Companies Act 2006 other than any requirement that the accounts give a 'true and fair' view, which is not a matter considered as part of an independent examination;

have not been prepared in accordance with the methods and principles set out in the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.

Signed:-

O. Higgins

Olivia Higgins - Independent Examiner

KBH Accountants Ltd

Chartered Certified Accountants

255 Poulton Road
Wallasey
Wirral
CH44 4BT

This report was signed on 19 / 12 / 2022

Leukaemia & Myeloma Research UK Ltd - Statement of Financial Activities for the year ended 31 March 2022

Statement of Financial Activities (including the Income and Expenditure Account for the year ended 31 March 2022, as required by the Companies Act 2006)

	SORP Ref	Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
		2022	2022	2022	2021
		£	£	£	£
Income & Endowments from:					
Donations & Legacies	A1	122,209	16,418	**138,627**	128,400
Charitable activities	A2	17,526	320	**17,846**	7,241
Investments	A4	27	-	**27**	187
Other	A5	50,109	-	**50,109**	52,476
Total income	**A**	**189,871**	**16,738**	**206,609**	**188,304**
Expenditure on:					
Raising funds	B1	9,095	-	**9,095**	3,527
Charitable activities	B2	153,973	12,982	**166,955**	134,859
Total expenditure	**B**	**163,068**	**12,982**	**176,050**	**138,386**
Net income for the year		**26,803**	**3,756**	**30,559**	**49,918**
Transfers between funds	**C**	-	-	**-**	-
Net income after transfers	**A-B-C**	**26,803**	**3,756**	**30,559**	**49,918**
Net movement in funds		**26,803**	**3,756**	**30,559**	**49,918**
Reconciliation of funds:-	**E**				
Total funds brought forward		258,527	27,761	**286,288**	236,370
Total funds carried forward		**285,330**	**31,517**	**316,847**	**286,288**

The 'SORP Ref' indicated above is the classification of income set out in the formal SORP documents. As required by paragraph 4.60 of the SORP, the brought forward and carried forward funds above have been agreed to the Balance Sheet.

A separate Statement of Total Recognised Gains and Losses is not required as this statement includes all recognised gains and losses.

All activities derive from continuing operations

The notes attached on pages 15 to 33 form an integral part of these accounts.

Leukaemia & Myeloma Research UK Ltd - Statement of Financial Activities for the year ended 31 March 2022

Leukaemia & Myeloma Research UK Ltd - Analysis of prior year total funds, as required by paragraph 4.2 of the SORP

	SORP Ref	Prior Year Unrestricted Funds 2021 £	Prior Year Restricted Funds 2021 £		Prior Year Total Funds 2021 £
Income & Endowments from:					
Donations & Legacies	A1	120,119	8,281		**128,400**
Charitable activities	A2	7,241	-		**7,241**
Investments	A4	187	-		**187**
Other	A5	52,476	-	-	**52,476**
Total income	**A**	180,023	8,281		**188,304**
Expenditure on:					
Raising funds	B1	3,527	-		**3,527**
Charitable activities	B2	131,594	3,265		**134,859**
Total expenditure	**B**	**135,121**	**3,265**		**138,386**
Net income for the year		44,902	5,016		49,918
Net income after transfers		44,902	5,016		49,918
Net movement in funds		**44,902**	**5,016**		**49,918**
Reconciliation of funds:-	**E**				
Total funds brought forward		213,625	22,745		**236,370**
Total funds carried forward		**258,527**	**27,761**		**286,288**

All activities derive from continuing operations

A separate Statement of Total Recognised Gains and Losses is not required as this statement includes all recognised gains and losses.'

The notes attached on pages 15 to 33 form an integral part of these accounts.

Leukaemia & Myeloma Research UK Ltd - Statement of Financial Activities for the year ended 31 March 2022

Leukaemia & Myeloma Research UK Ltd - Resources applied in the year ended 31 March 2022 towards fixed assets for Charity use:-

	2022 £	2021 £
Funds generated in the year as detailed in the SOFA	30,559	49,918
Net resources available to fund charitable activities	**30,559**	**47,418**

The resources applied on fixed assets for charity use represents the cost of additions less proceeds of any disposals.

The notes attached on pages 15 to 33 form an integral part of these accounts.

Leukaemia & Myeloma Research UK Ltd - Statement of Financial Activities for the year ended 31 March 2022

Movements in revenue and capital funds for the year ended 31 March 2022

Revenue accumulated funds

	Unrestricted Funds 2022 £	Restricted Funds 2022 £	Total Funds 2022 £	Last year Total Funds 2021 £
Accumulated funds brought forward	258,527	27,761	286,288	**236,370**
Recognised gains and losses before transfers	26,803	3,756	30,559	49,918
	285,330	**31,517**	**316,847**	**286,288**
(From)/To unrestricted revenue funds	-	-	-	-
Closing revenue funds	**285,330**	**31,517**	**316,847**	**286,288**

Summary of funds	Unrestricted and Designated funds 2022 £	Restricted Funds 2022 £	Total Funds 2022 £	Last Year Total Funds 2021 £
Revenue accumulated funds	285,330	31,517	**316,847**	286,288

The notes attached on pages 15 to 33 form an integral part of these accounts.

Leukaemia & Myeloma Research UK Ltd - Statement of Financial Activities for the year ended 31 March 2022

Leukaemia & Myeloma Research UK Ltd
Income and Expenditure Account for the year ended 31 March 2022 as required by the Companies Act 2006

	2022 £	2021 £
Income		
Income from operations	156,405	135,641
Interest receivable	27	187
Other operating income	50,109	52,476
Gross income in the year before exceptional items	**206,609**	**188,304**
Gross income in the year including exceptional items	**206,609**	**188,304**
Expenditure		
Charitable expenditure, excluding depreciation and amortisation	165,910	133,814
Depreciation and amortisation	625	625
Fundraising costs	9,095	3,527
Governance costs	420	420
Total expenditure in the year	**176,050**	**138,386**
Net income before tax in the financial year	**30,559**	**49,918**
Tax on surplus on ordinary activities	-	-
Net income after tax in the financial year	**30,559**	**49,918**
Retained surplus for the financial year	**30,559**	**49,918**

All activities derive from continuing operations

In accordance with the provisions of the Companies Act 2006, the headings and subheadings used in the Income and Expenditure account have been adapted to reflect the special nature of the charity's activities.

The notes attached on pages 15 to 33 form an integral part of these accounts.

Leukaemia & Myeloma Research UK Ltd - Balance Sheet as at 31 March 2022

	Note	SORP Ref		2022 £		2021 £
Fixed assets		A				
Tangible assets	7	A2		1,250		1,875
Total fixed assets				1,250		1,875
Current assets		B				
Stocks		B1	17,507		16,361	
Debtors	9	B2	4,432		1,660	
Cash at bank and in hand		B4	299,864		270,732	
Total current assets			321,803		288,753	
Creditors: amounts falling due within one year	10	C1	(6,206)		(4,340)	
Net current assets				315,597		284,413
The total net assets of the charity				**316,847**		**286,288**
The total net assets of the charity are funded by the funds of the charity, as follows:-						
Restricted funds						
Restricted Revenue Funds	13	D2	31,517		27,761	
				31,517		27,761
Unrestricted Funds						
Unrestricted Revenue Funds	13	D3	285,330		258,527	
				285,330		258,527
Designated Funds						
Total charity funds				**316,847**		**286,288**

The 'SORP Ref' indicated above is the classification of Balance Sheet items as set out in the formal SORP documents. As required by paragraph 4.60 of the SORP, the brought forward and carried forward funds above have been agreed to the SOFA..

The directors are satisfied that the company is entitled to exemption from the requirement to obtain an audit under section 477 of the Companies Act 2006.

The members have not required the company to obtain an audit in accordance with section 476 of the Act.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.

The charity is subject to Independent Examination under charity legislation, and the report of the Independent Examiner is on page 8.

The financial statements have been prepared in accordance with the provisions in Part 15 of the Companies Act 2006. applicable to companies subject to the small companies regime.

TATJANA VINOGRADOVA
Trustee
Approved by the board of trustees on 19 December 2022

The notes attached on pages 15 to 33 form an integral part of these accounts.

Leukaemia & Myeloma Research UK Ltd

Notes to the Accounts for the year ended 31 March 2022

1 Accounting policies

Policies relating to the production of the accounts.

Basis of preparation and accounting convention

The accounts have been prepared on the accruals basis, under the historical cost convention, and in accordance with the Financial Reporting Standard 102, (effective 1st January 2016) and 'FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), published by the Charity Commission in England & Wales (CCEW) , effective January 2016, , and in accordance with all applicable law in the charity's jurisdiction of registration, except that the charity has prepared the financial statements in accordance with the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), in preference to the previous SORP, the SORP 2005, which has been withdrawn, notwithstanding the fact that the extant statutory regulations, the Charities (Accounts and Reports) Regulations 2008 refer explicitly to the SORP 2005. This has been done to accord with current best practice.

Risks and future assumptions

The charity is a public benefit entity.
This policy is a formal acknowledgement that LMRUK is committed to maintaining a strong risk management framework and making every effort to manage risk appropriately by maximising potential opportunities whilst minimising the adverse effects of risks. It should be used to support the internal control systems of the charity, enabling LMRUK to respond to operational, strategic and financial risks regardless of whether they are internally or externally driven.

Policies relating to categories of income and income recognition.

Nature of income

Gross income represents the value, net of value added tax and discounts, of goods provided to customers and work carried out in respect of services provided to customers.

Categories of Income

Income is categorised as income from exchange transactions (contract income) and income from non-exchange transactions (gifts), investment income and other income.

Income from exchange transactions is received by the charity for goods or services supplied under contract or where entitlement is subject to fulfilling performance related conditions. The income the charity receives is approximately equal in value to the goods or services supplied by the charity to the purchaser.

Income from a non-exchange transaction is where the charity receives value from the donor without providing equal value in exchange, and includes donations of money, goods and services freely given without giving equal value in exchange.

Income recognition

Income, whether from exchange or non exchange transactions, is recognised in the statement of financial activities (SOFA) on a receivable basis, when a transaction or other event results in an increase in the charity's assets or a reduction in its liabilities and only when the charity has legal entitlement, the income is probable and can be measured reliably.

Dividends are accrued when the shareholder's right to receive payment is established.

Income subject to terms and conditions which must be met before the charity is entitled to the resources is not recognised until the conditions have been met.

All income is accounted for gross, before deducting any related fees or costs.

Income from legacies

Income from legacies is recognised when the charity has sufficient evidence that a gift has been left to them, that where required, probate has been granted, the executor is satisfied that the property in question will not be required to satisfy claims in the estate, that it is probable that the amount will be received by the charity, and the amount to be received can be estimated with sufficient accuracy, and that any conditions attached to the legacy are either within the control of the charity or have been met.

Where a payment is received from an estate or is notified as receivable by the executors after the reporting date and before the accounts are authorised for issue but it is clear that the payment had been agreed by the executors prior to the end of the reporting period, then the amount concerned is treated as an adjusting event and accrued as income in the accounting period if receipt is probable.

Where the charity has established entitlement to a legacy but there is uncertainty as to the amount of the payment, details of the legacy are disclosed as a contingent asset until the criteria for income recognition are met. Where a legacy is subject to the interest of a life tenant, the legacy is not recognised as income until the death of the life tenant.

If it is doubtful that full settlement of a legacy debtor will be received, then an adjustment is made to reduce the amount of the legacy debtor and legacy income rather than charging the adjustment as expenditure in the Statement of Financial Activities

Notes to the Accounts for the year ended 31 March 2022

Donated goods, facilities and services

Donated fixed assets are recognised at the current fair value. All such donations are recognised as donation income, and debited to fixed assets.

Donated goods that are not fixed assets are accounted for at a fair value, unless it is impractical to reliably measure the value of the donated items.

In the absence of any direct evidence of fair value of donated goods, then a value is derived from the cost of the item to the donor or, in the case of goods that are expected to be sold, the estimated resale value after deducting any anticipated costs of sales.

If it is impracticable to measure the fair value of goods donated for resale, or the costs of valuation outweigh the benefits, the donated goods are recognised as income when sold, with an equivalent amount being recognised as an expense.

The costs of goods donated for distribution to beneficiaries is deemed to be the fair value of those goods upon receipt. When the goods are distributed freely or for a nominal consideration, then the carrying amount is adjusted at the time of sale, to the value at the point of distribution and the adjustment is shown as a cost of donations made.

The carrying amount of any stock held for distribution is assessed for impairment at the reporting date. All donated goods are recognised as donation income, and debited to trading stock.When trading stock is subsequently sold, or appropriated to meet an expense, then the carrying value of the stock is recognised as an expense. In accordance with the SORP, goods donated for distribution to beneficiaries, or for consumption by the charity are included in *'legacies and donations'*. Goods donated for resale are included in *'Income from other trading activities'*

The cost of any stock of goods donated for distribution to beneficiaries is deemed to be the fair value of those gifts at the time of their receipt. If the goods held are to be distributed freely or for a nominal consideration, then the carrying amount is subsequently adjusted to reflect the lower of deemed cost adjusted for any loss of service potential and replacement cost. Replacement cost is the economic cost incurred if the charity was to replace the service potential of the donated goods at its own expense in the most economic manner.

Donated services and facilities (including seconded staff and use of property) are included in the accounts on the basis of the value of the gift to the charity.

All donated services and facilities are recognised as donation income when received,(provided the value of the gift can be measured reliably) and recognised as an expense with an equivalent value.

Policies relating to expenditure on goods and services provided to the charity.

Allocating costs to activities

Direct costs that are specifically related to an activity are allocated to that activity. Shared direct costs and support costs are apportioned between activities.

The basis for apportionment, which is consistently applied, and proportionate to the circumstances, is :-

Staffing - on the basis of time spent in connection with any particular activity.
Staffing - on a per capita basis, based on the number of of people employed within any partiular activity.
Premises related costs - on the proportion of floor area occupied by a particular activity.
Non specific support costs - on the basis of the usage of resources, in terms of time taken, capacity used, request made or other measures
Estimation techniques used in apportioning costs - give details

Notes to the Accounts for the year ended 31 March 2022

Policies relating to assets, liabilities and provisions and other matters.

Stocks and work in progress

Stock is valued at the lower of cost and net realisable value.

Debtors

Debtors are measured at their recoverable amounts at the balance sheet date.

Creditors and provisions

Liabilities are measured at their settlement amount. A liability is recognised for the the amount the Charity anticpates it will pay to settle the deb or the amount it has received as an advance payment for goods or services it must provide.

2 Liability to taxation

The Trustees consider that the charity satisfies the tests set out in Paragraph 1 Schedule 6 of the Finance Act 2010 for UK corporation tax purposes. Accordingly, the Charity is potentially exempt from taxation in respect of income or capital gains received within categories covered by chapter 3 part 11 of the Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992, to the extent that such income or gains are applied exclusively on the specific charitable objects of the charity and for no other purpose. Value Added Tax is not recoverable by the charity, and is therefore included in the relevant costs in the Statement of Financial Activities.

3 Winding up or dissolution of the charity

If upon winding up or dissolution of the charity there remain any assets, after the satisfaction of all debts and liabilities, the assets represented by the accumulated fund shall be transferred to some other charitable body or bodies having similar objects to the charity.

No employees received emoluments (excluding pension costs) in excess of £60,000 per annum.

4 Defined contribution pension schemes

Any liabilites and assets associated with the scheme are shown under debtors and creditors.

5 Remuneration and payments to Trustees and persons connected with them

No trustees or persons connected with them received any remuneration from the charity, or any related entity.

6 Trustees' expenses

There were no Trustees' expenses in the year and in the prior year.

7 Tangible fixed assets

Current Year	Land and Buildings	Plant & Machinery	Motor Vehicles	Total	Total
	£	£	£	£	£
Cost					
At 1 April 2021	-	2,500	-	2,500	2,500
Additions	-	-	-	-	-
At 31 March 2022	**-**	**2,500**	**-**	**2,500**	**2,500**
Depreciation					
At 1 April 2021	-	625	-	625	625
Charge for the year	-	625	-	625	625
At 31 March 2022	**-**	**1,250**	**-**	**1,250**	**1,250**
Net book value					
At 31 March 2022	**-**	**1,250**	**-**	**1,250**	**1,250**
At 31 March 2021	**-**	**1,875**	**-**	**1,875**	**1,875**

8 Stocks & Work in Progress

	2022	2021
	£	£
Stocks before write downs	17,507	16,361
	17,507	16,361

9 Debtors

	2022	2021
	£	£
Prepayments and accrued income	485	1,660
Other debtors	3,947	-
	4,432	**1,660**

Notes to the Accounts for the year ended 31 March 2022

10 Creditors: amounts falling due within one year

	2022	2021
	£	£
Trade creditors	3,916	2,470
Accruals	2,290	1,870
	6,206	**4,340**

11 Income and Expenditure account summary

	2022	2021
	£	£
At 1 April 2021	286,288	236,370
Surplus after tax for the year	30,559	49,918
At 31 March 2022	**316,847**	**286,288**

12 Particulars of how particular funds are represented by assets and liabilities

At 31 March 2022	**Unrestricted funds**	**Designated funds**	**Restricted funds**	**Total Funds**	**Total Funds**
	£	**£**	**£**	**£**	**£**
Tangible Fixed Assets	1,250	-	-	**1,250**	**1,250**
Current Assets	290,286		31,517	**321,803**	**321,803**
Current Liabilities	(6,206)	-	-	**(6,206)**	**(6,206)**
	285,330	**-**	**31,517**	**316,847**	**316,847**

At 1 April 2021	**Unrestricted funds**	**Designated funds**	**Restricted funds**	**Total Funds**	**Total Funds**
	£	**£**	**£**	**£**	**£**
Tangible Fixed Assets	1,875	-	-	**1,875**	**1,875**
Current Assets	260,992	-	27,761	**288,753**	**288,753**
Current Liabilities	(4,340)	-	-	**(4,340)**	**(4,340)**
	258,527	**-**	**27,761**	**286,288**	**286,288**

Leukaemia & Myeloma Research UK Ltd

Notes to the Accounts for the year ended 31 March 2022

13 Change in total funds over the year as shown in Note 12 , analysed by individual funds

	Funds brought forward from 2021	Movement in funds in 2022	Transfers between funds in 2022	Funds carried forward to 2023	Funds carried forward to 2023
		See Note 14			
	£	£	£	£	£
Unrestricted and designated funds:-					
Unrestricted Revenue Funds	258,527	26,803	-	**285,330**	**285,330**
Total unrestricted and designated funds	**258,527**	**26,803**	**-**	**285,330**	**285,330**
Restricted funds:-					
Model Cell Biobank	27,761	3,756	-	**31,517**	**31,517**
Total restricted funds	**27,761**	**3,756**	**-**	**31,517**	**31,517**
Total charity funds	**286,288**	**30,559**	**-**	**316,847**	**316,847**

14 Analysis of movements in funds over the year as shown in Note 13

	Income	Expenditure	Gains & Losses	Movement in funds	Movement in funds
	2022	2022	2022	2022	2022
	£	£	£	£	£
Unrestricted and designated funds:-					
Unrestricted Revenue Funds	189,871	(163,068)	-	**26,803**	**26,803**
Restricted funds:-					
Model Cell Biobank	16,738	(12,982)	-	**3,756**	**3,756**
	206,609	**(176,050)**	**-**	**30,559**	**30,559**

Notes to the Accounts for the year ended 31 March 2022

15 The purposes for which the funds

Unrestricted and designated funds:-

Unrestricted Revenue Funds	These funds are held for the meeting the objectives of the charity, and to provide reserves for future activities, research grants, and, subject to charity legislation, are free from all restrictions on their use.

Restricted funds:-

Model Cell Biobank	The purpose of these funds is described under the accounting policy.

16 Ultimate controlling party

The charity is under the control of its legal members.
Every member of the charity is obliged to contribute such amount as may be required not exceeding £10 to the assets of the company in the event of its being wound up while he or she is a member, or within one year after he or she ceases to be a member.

Leukaemia & Myeloma Research UK Ltd

Detailed analysis of income and expenditure for the year ended 31 March 2022 as required by the SORP 2015

This analysis is classsified by conventional nominal descriptions and not by activity.

17 Donations, Grants and Legacies

	Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
	2022	2022	2022	2021
	£	£	£	£
Donations and gifts from individuals				
Small donations individually less than £1000	7,410	-	**7,410**	5,274
Refunds from HMRC on gift aided donations	68	-	**68**	-
Stripe direct donations	7,995	-	**7,995**	6,061
Briggs Equipment Ltd	-	-	**-**	1,000
Facebook	3,782	-	**3,782**	6,378
Just Giving	17,827	-	**17,827**	11,847
Kiltwalk	1,193	-	**1,193**	-
In Memory	9,028	-	**9,028**	9,135
Fundraising Support	-	-	**-**	1,731
Muchloved	3,545	-	**3,545**	2,522
Virgin Money Giving	2,453	-	**2,453**	2,880
Giving.com	2,379	-	**2,379**	-
Paypal Giving	1,066	-	**1,066**	-
Total donations and gifts from individuals	**56,746**	**-**	**56,746**	**46,828**

All the donations and gifts in the prior year were unrestricted.

Donations and gifts from individuals (Include HMRC refunds on gift aided donations) - Prior Year analysis

	Prior Year Unrestricted Funds	Prior Year Restricted Funds	Prior Year Total Funds
	2021	2021	2021
	£	£	£
Prior year	**45,097**	**1,731**	**46,828**

Leukaemia & Myeloma Research UK Ltd

Detailed analysis of income and expenditure for the year ended 31 March 2022 as required by the SORP 2015

Legacies receivable

	Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
	2022	2022	2022	2021
	£	£	£	£
Legacies receivable				
Small legacies individually less than £1000	-	-	**-**	-
Mrs Mary Dallas	100	-	**100**	-
Mrs Beryl Mary Round	40,784	-	**40,784**	-
Mayo Wynne Baxter Solicitors	64	-	**64**	9,771
Withers LLP	-	-	**-**	25,165
Macmillans Solicitors LLP	-	-	**-**	6,820
Total legacies receivable	**40,948**	**-**	**40,948**	**41,756**

Legacies receivable - Prior Year analysis

	Prior Year Unrestricted Funds	Prior Year Restricted Funds	Prior Year Total Funds
	2021	2021	2021
	£	£	£
Prior year	41,756	-	**41,756**

Leukaemia & Myeloma Research UK Ltd

Detailed analysis of income and expenditure for the year ended 31 March 2022 as required by the SORP 2015

Revenue grants from government and public bodies

	Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
	2022	2022	2022	2021
	£	£	£	£
Revenue grants from government and public bodies				
Small grants individually less than £1000	-	1,240	**1,240**	1,350
M&G Plc Charities Trust	-	-	**-**	1,900
Arcobaleno Cancer Trust	-	-	**-**	3,000
LCVS Community Impact Fund	-	-	**-**	1,000
Albert Hunt Trust	-	-	**-**	1,000
The Grace Trust	-	-	**-**	1,500
L&R Gilley Charitable Trust	-	2,500	**2,500**	-
Tesco/Groundwork UK	-	-	**-**	1,000
The Constance Paterson Charitable Trust	-	2,500	**2,500**	-
The Ian Askew Charitable Trust	1,000	-	**1,000**	-
Charities Trust AVIVA	3,268	-	**3,268**	12,066
Crowdfunder	247	-	**247**	5,000
The Caron Keating Foundation	-	3,000	**3,000**	-
The Hospital Saturday Fund	-	2,000	**2,000**	-
CAF/Box Power Foundation	10,000	-	**10,000**	-
The Thomas Sivewright Catto Charitable Trust	-	1,000	**1,000**	-
Sir Cliff Richard	1,000	-	**1,000**	-
Arnold Clark	1,000	-	**1,000**	-
Total public sector revenue grants	**16,515**	**12,240**	**28,755**	**27,816**

Revenue grants from government and public bodies - Prior Year analysis

	Prior Year Unrestricted Funds	Prior Year Restricted Funds	Prior Year Total Funds
	2021	2021	2021
	£	£	£
Prior Year	21,266	6,550	**27,816**

Leukaemia & Myeloma Research UK Ltd

Detailed analysis of income and expenditure for the year ended 31 March 2022 as required by the SORP 2015

	Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
	2022	2022	2022	2021
	£	£	£	£
Revenue grants and donations from non public bodies				
Lunya Limited	8,000	-	**8,000**	-
Fundraising Support Ltd	-	4,178	**4,178**	-
Total private sector revenue grants	**8,000**	**4,178**	**12,178**	**-**

Donated goods and services

	Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
	2022	2022	2022	2021
	£	£	£	£
Donated goods and services				
Small gifts individually less than £1000	-	-	**-**	12,000
Total donated goods and services	**-**	**-**	**-**	**12,000**

Donated goods and services - Prior Year analysis

	Prior Year Unrestricted Funds	Prior Year Restricted Funds	Prior Year Total Funds
	2021	2021	2021
	£	£	£
Prior Year	12,000	-	**12,000**

Total Donations, Grants and Legacies

Current year		Unrestricted Funds	Restricted Funds	Current Year Total Funds	Prior Year Total Funds
		2022	2022	2022	2021
		£	£	£	£
Total Donations, Grants and Legacies	**A1**	**122,209**	**16,418**	**138,627**	**128,400**

All the donations and gifts in the prior year were unrestricted.

Prior year		Unrestricted Funds 2021	Restricted Funds 2021	Prior Year Total Funds 2021
		£	£	£
Total Donations, Grants and Legacies	**A1**	**120,119**	**8,281**	**128,400**

Leukaemia & Myeloma Research UK Ltd

Detailed analysis of income and expenditure for the year ended 31 March 2022 as required by the SORP 2015

18 Income from charitable activities - Trading Activities

Current year

	Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total funds
	2022	2022	2022	2021
	£	£	£	£
Primary purpose and ancillary trading				
Sale of goods and services in accordance with the charity's objects	17,526	320	**17,846**	7,241
Total Primary purpose and ancillary trading	**17,526**	**320**	**17,846**	**7,241**

19 Total Income from charitable activities

Current year

		Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
		2022	2022	2022	2021
		£	£	£	£
Total income from charitable trading		17,526	320	**17,846**	7,241
Total from charitable activities	**A2**	**17,526**	**320**	**17,846**	**7,241**

Income from charitable activities - Prior Year analysis

Prior year

	Prior Year Unrestricted Funds	Prior Year Restricted Funds	Prior Year Total Funds
	2021	2021	2021
	£	£	£
Total income from charitable trading	7,241	-	7,241
	7,241	**-**	**7,241**

20 Investment income

		Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
		2022	2022	2022	2021
		£	£	£	£
Bank Interest Receivable		27	-	**27**	187
Total investment income	**A4**	**27**	**-**	**27**	**187**

Detailed analysis of income and expenditure for the year ended 31 March 2022 as required by the SORP 2015

21 Other income and gains

Current year		Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
		2022	2022	2022	2021
		£	£	£	£
Royalties from the exploitation of intellectual property rights		50,000	-	**50,000**	50,085
Sundry other income		109	-	**109**	2,391
Total other income	**A5**	**50,109**	**-**	**50,109**	**52,476**

Other income and gains - Prior year analysis

Prior Year		Prior Year Unrestricted Funds	Prior Year Restricted Funds	Prior Year Total Funds
		2021	2021	2021
		£	£	£
Royalties from the exploitation of intellectual property rights		50,085	-	**50,085**
Sundry other income		2,391	-	**2,391**
Total other income	**A5**	**52,476**	**-**	**52,476**

Detailed analysis of income and expenditure for the year ended 31 March 2022 as required by the SORP 2015

22 Expenditure on charitable activities - Direct spending

Current Year		Current year Unrestricted Funds 2022 £	Current year Restricted Funds 2022 £	Current year Total Funds 2022 £	Prior Year Total Funds 2021 £
Travel and Subsistence - Charitable Activities		1,930	-	**1,930**	**2,150**
Costs of activities and events		10,098	10,585	**20,683**	**9,814**
Consultancy and professional support		24,636	-	**24,636**	**22,180**
Total direct spending	**B2a**	**36,664**	**10,585**	**47,249**	**34,144**

Prior Year		Prior Year Unrestricted Funds 2021 £	Prior Year Restricted Funds 2021 £	Prior Year Total Funds 2021 £
Travel and Subsistence - Charitable Activities		2,150	-	**2,150**
Costs of activities and events		7,991	1,823	**9,814**
Consultancy and professional support		22,180	-	**22,180**
Total direct spending	**B2a**	**32,321**	**1,823**	**34,144**

23 Expenditure on charitable activities - Charitable trading

Current Year		Current year Unrestricted Funds 2022 £	Current year Restricted Funds 2022 £	Current year Total Funds 2022 £	Prior Year Total Funds 2021 £
Cost of goods for primary purpose trading - Including movement in stock for goods made by beneficiaries		**11,198**	**-**	**11,198**	**3,179**
Total charitable trading costs	**B2b**	**11,198**	**-**	**11,198**	**3,179**

24 Expenditure on charitable activities- Grant funding of activities

Current Year		Current year Unrestricted Funds 2022 £	Current year Restricted Funds 2022 £	Current year Total Funds 2022 £	Prior Year Total Funds 2021 £
Grants made to organisations		24,251	-	**24,251**	**35,000**
Total grantmaking costs	**B2c**	**24,251**	**-**	**24,251**	**35,000**

Detailed analysis of income and expenditure for the year ended 31 March 2022 as required by the SORP 2015

25 Support costs for charitable activities

Current Year	Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
	2022	2022	2022	2021
	£	£	£	£
Premises Expenses				
Rates and water charges	249	-	**249**	**-**
Rent and rates	23,206	-	**23,206**	**17,050**
Light heat and power	414	-	**414**	**522**
Cleaning and waste management	216	-	**216**	**690**
Premises repairs, renewals and maintenance	4,098	-	**4,098**	**423**
Property insurance	428	-	**428**	**-**
Administrative overheads				
Telephone, fax and internet	2,042	323	**2,365**	**2,222**
Postage	483	99	**582**	**635**
Stationery and printing	416	-	**416**	**949**
Shipping, freight and delivery	840	-	**840**	**-**
Membership subscriptions	7,381	-	**7,381**	**5,564**
Equipment expenses	3,168	-	**3,168**	**2,670**
Hire of equipment	1,058	-	**1,058**	**1,031**
Software licences and expenses	1,426	906	**2,332**	**1,409**
Advertising and marketing	12,433	1,069	**13,502**	**10,798**
Equipment,repairs,expenses and maintenance	325	-	**325**	**-**
Professional fees paid to advisors other than the auditor or examiner				
Accountancy fees other than examination or audit fees	1,080	-	**1,080**	**1,080**
Management fees	21,528	-	**21,528**	**16,210**
Other legal and professional	-	-	**-**	**104**
Financial costs				
Bank charges	24	-	**24**	**134**
Depreciation & Amortisation in total for	625	-	**625**	**625**
Support costs before reallocation	**81,440**	**2,397**	**83,837**	**62,116**
Total support costs - Current Year	**81,440**	**2,397**	**83,837**	**62,116**

The basis of allocation of costs between activities is described under accounting policies

Leukaemia & Myeloma Research UK Ltd

Detailed analysis of income and expenditure for the year ended 31 March 2022 as required by the SORP 2015

Prior Year	Current year Unrestricted Funds 2022 £	Current year Restricted Funds 2022 £	Prior Year Total Funds 2021 £
Premises Expenses			
Rent and rates	17,050	-	**17,050**
Light heat and power	522	-	**522**
Cleaning and waste management	690	-	**690**
Premises repairs, renewals and maintenance	423	-	**423**
Administrative overheads			
Telephone, fax and internet	1,899	323	**2,222**
Postage	635	-	**635**
Stationery and printing	949	-	**949**
Membership subscriptions	5,564	-	**5,564**
Equipment expenses	2,670	-	**2,670**
Hire of equipment	1,031	-	**1,031**
Software licences and expenses	496	913	**1,409**
Advertising and marketing	10,592	206	**10,798**
Professional fees paid to advisors other than the auditor or examiner			
Accountancy fees other than examination or audit fees	1,080	-	**1,080**
Management fees	16,210	-	**16,210**
Other legal and professional	104	-	**104**
Financial costs			
Bank charges	134	-	**134**
Depreciation & Amortisation in	625	-	**625**
Support costs before	**60,674**	**1,442**	**62,116**
Total support costs - Prior Year	**60,674**	**1,442**	**62,116**

The basis of allocation of costs between activities is described under accounting policies

Detailed analysis of income and expenditure for the year ended 31 March 2022 as required by the SORP 2015

26 Other Expenditure - Governance costs

Current Year	Current year Unrestricted Funds 2022 £	Current year Restricted Funds 2022 £	Current year Total Funds 2022 £	Prior Year Total Funds 2021 £
Independent Examiner's fees	420	-	**420**	**420**
Total Governance costs	**420**	**-**	**420**	**420**

All the expenditure in the prior year was unrestricted.

27 Total Charitable expenditure

Current Year		Current year Unrestricted Funds 2022 £	Current year Restricted Funds 2022 £	Current year Total Funds 2022 £	Prior Year Total Funds 2021 £
Total direct spending	**B2a**	36,664	10,585	**47,249**	**34,144**
Total charitable trading costs	**B2b**	11,198	-	**11,198**	**3,179**
Total grantmaking costs	**B2c**	24,251	-	**24,251**	**35,000**
Total support costs	**B2d**	81,440	2,397	**83,837**	**62,116**
Total Governance costs	**B2e**	420	-	**420**	**420**
Total charitable expenditure	**B2**	**153,973**	**12,982**	**166,955**	**134,859**

Prior Year		Prior Year Unrestricted Funds 2021 £	Prior Year Restricted Funds 2021 £	Prior Year Total Funds 2021 £
Total direct spending	**B2a**	32,321	1,823	**34,144**
Total charitable trading costs	**B2b**	3,179	-	**3,179**
Total grantmaking costs	**B2c**	35,000	-	**35,000**
Total support costs	**B2d**	60,674	1,442	**62,116**
Total Governance costs	**B2e**	420	-	**420**
Total charitable expenditure	**B2**	**131,594**	**3,265**	**134,859**

Detailed analysis of income and expenditure for the year ended 31 March 2022 as required by the SORP 2015

28 Expenditure on raising funds and costs of investment management

Current Year		Current year Unrestricted Funds 2022 £	Current year Restricted Funds 2022 £	Current year Total Funds 2022 £	Prior Year Total Funds 2021 £
Agent's costs for fundraising		4,945	-	**4,945**	**3,000**
Fundraising publicity & marketing		480	-	**480**	**-**
Cost of fundraising activities		2,764	-	**2,764**	**250**
Fundraising trading costs		906	-	**906**	**277**
Total fundraising costs	**B1**	**9,095**	**-**	**9,095**	**3,527**

All the expenditure in the prior year was unrestricted.

LEUKAEMIA & MYELOMA RESEARCH UK LTD

England & Wales - Charity number 1161622

Accounts

Leukaemia & Myeloma Research UK

Report and Accounts

31 March 2021

Research That Saves Lives

leukaemiamyelomaresearchuk.org
Registered charity number 1161622
(England & Wales), SC046106 (Scotland),
Leukaemia and Myeloma Research UK Ltd
Company Limited by guarantee Registered number 09481278

Leukaemia & Myeloma Research UK

Research That Saves Lives

Leukaemia and Myeloma Research UK Ltd
Unit 127,
North Mersey Business Centre,
Woodward Rd,
Knowsley Industrial Park,
Liverpool,
Merseyside,
L33 7UY

Tel: 0800 368 7309

Web: www.leukaemiamyelomaresearchuk.org

Email: cs@leukaemiamyelomaresearchuk.org

Charity Number 1161622
Company Number 09481278

Facebook: **https://www.facebook.com/leukaemiamyelomaresearchuk.org/**

Follow us on Twitter: **https://twitter.com/lmruk_org**

MODEL CELL BIOBANK
research that saves lives

Stem cell treatments are now available to even more families

Table of contents

About Us 3

Stem Cells 4

Charitable Activities..... 5

Chairman's Report 6

Operation Director's Report 7

MCB Service..... 9

Overview 9

Case Study..... 11

Research Priorities..... 12

Fundraising and Volunteers..... 13

Thanks..... 14

Trustees and Staff 14

Accounts 15



About Us

Leukaemia & Myeloma Research UK Ltd wants to prevent people dying from blood cancer through more effective treatment in the future. We are willing to fight blood cancer regardless of how long it might take.

Founded in 2015, our mission is to prevent people dying from blood cancer through prevention, research and more effective treatment.

Blood cancer is the 3rd most common type of cancer in the UK and the most common type of cancer in children and young people. There are currently more than 250,000 patients living with the condition – in fact, every year in the UK around 40,000 people are diagnosed with blood cancer and an estimated 4,700 leukaemia deaths every year, that's 13 every day!

We are aiming to become the UK's leading charity in supporting efforts to combat the three major types of blood cancer. The work we do helps fund vital stem cell research, raises awareness of stem cell therapies and helps families protect their children's future health by storing their cord blood stem cells at the time of birth.

There are 3 main types of cancers of the blood; they are lymphoma, leukaemia and myeloma. The blood is made up of three different types of cells:

• Red blood cells which carry the oxygen around the body
• White blood cells which fight and stop infections
• Platelets which help the blood to clot

The course of treatment given will depend on the type of cancer. The most common treatments are chemotherapy, radiotherapy and in some instances, a stem cell transplant.

In essence, the Charity want to eradicate blood cancer once and for all. One of the ways we are aiming to achieve that is through advancing our understanding of stem cells and how we can use them to treat patients with blood cancer, particularly through stem cell transplants. We do this by:

• Actively supporting stem cell research into blood cancers
• Raising awareness of stem cell therapies
• Provide information about blood cancers and treatment options
• Protecting the vulnerable by offering qualifying expectant mothers, with a family history of cancer, the opportunity to store their baby's umbilical cord blood stem cells at the time of birth, in case they are needed in the future to treat that child or another member of the family if they're a suitable match. This service is called Model Cell Biobank (MCB).

Stem Cells

In humans, there are two types of stem cells: embryonic stem cells and adult stem cells, which are found in various tissues.

Adult stem cells are the primary focus of the research that the Charity supports. They typically generate the cell types of the tissue in which they reside.

For example, a blood-forming adult stem cell in the bone marrow normally gives rise to the many types of blood cells. It is generally accepted that a blood-forming cell in the bone marrow—which is called a hematopoietic stem cell—cannot give rise to the cells of a very different tissue, such as nerve cells in the brain.

Where are stem cells found?
There are four known accessible sources of autologous adult stem cells in humans:

• Bone marrow which requires harvesting by drilling into bone (typically the femur or iliac crest). This is done under a general anesthetic.
• Blood, which requires extraction through apheresis, wherein blood is drawn from the donor (similar to a blood donation), and passed through a machine that extracts the stem cells and then returns the blood to the donor.
• Adipose tissue (lipid cells), which requires extraction by liposuction
• Umbilical cord blood - these stem cells can be collected from the umbilical cord blood just after birth.

What can stem cells be used for today?
There are treatments where Hematopoietic Stem Cell Transplants (HSCT) - the transplantation of blood forming stem cells - is a standard treatment. For some diseases they are the only therapy, and in other diseases they are only employed when front-line therapies have failed or the disease is very aggressive.

There are other blood disorders that can be treated with stem cells that aren't cancers, such as sickle cell anaemia and aplastic anaemia.

For most types of blood cancers, for example: leukaemia, lymphoma and various anaemia's, the treatments use allogeneic stem cell transplants (someone else's stem cells). The reason for this is that the person may have a genetic predisposition to the disease; their genes have a defect that predisposes them to that disease.

However there are various types of cancers (some myelomas, plasma cell leukaemia, some anaemia's and solid tumours) that are treated using autologous stem cells (using your own stem cells).

Charitable Activities

Providing Information

March was the month that we shone a light on Myeloma and hosted a Myeloma Awareness Month. We joined forces with West Lancs and Merseyside Myeloma Support Group, a local group close to our Head Office in Liverpool, that engages with people who have been diagnosed with myeloma or know of someone close to them with myeloma who need extra support and guidance. During the month we shared facts about myeloma across our social media channels and encouraged our supporters to take part in March for Myeloma, running, walking or cycling 5.7 miles. 5,700 people in the UK are diagnosed each year with Myeloma.

We produce a quarterly newsletter that shines a spotlight on our inspirational fundraisers and their stories; highlights our exciting plans for the future and provides information relating to blood cancer. It is available from our website free of charge.

Medical Research

Leukaemia & Myeloma Research UK allocate research grants to those who uphold our primary objectives. These are to benefit the public, to protect and promote the health of the public, in particular by research into the nature, causes, diagnosis, prevention, treatment and cure of leukaemia and myeloma. The trustees recognise that a limited amount of funds are available to distribute each year.

Our current funding priorities are to advance understanding of stem cells and how they can be used to treat blood cancer patients. All grant applications are reviewed by the Charity's Research and Review Committee, an independent panel of experts. The Charity is very proud to have been approved this year as a member of the Association of Medical Research Charities the AMRC.

Fundraising Activities

The Charity has been supported by our volunteers, this year their activities have been limited by the COVID-19 pandemic, however that hasn't stopped them finding different ways to fundraise for us. The Charity produced a fundraising brochure to offer suggestions to fundraisers of how to set up virtual events, such as our online quiz.

There are over 100,000 types of blood cancer making it the 5th most common cancer in the UK. Current figures show that there are more than 240,000 patients living with blood cancer. The 3 main types are: leukaemia, myeloma and lymphoma.

In addition to this we receive funding from grant making foundations and trusts and have recently launched a corporate fundraising page.

Model Cell Biobank Service

The service that the Charity offers to collect the umbilical cord blood stem cells at the time of birth, was affected by the COVID-19 pandemic this year. The plan had been to continue to raise awareness of the Model Cell Biobank Service with GP surgeries and hospitals. These plans however had to be put on hold due the the pressures on the NHS and healthcare professionals. Despite this we have had a busy year focusing on raising our profile and of stem cell treatments and therapies in other ways. The full force of our work will resume as soon as possible.

Chairman's Report

During the lockdown we produced a brochure to support our brilliant fundraisers with ideas of how they could continue their work for us, particularly during the lockdown period.

In November, we supported World Cord Blood Day, where we shared facts on the uses of cord blood stem cells, raising awareness of current treatments and their potential use in the future. Following this, we took part in World Cancer Day using our social media to publish facts about blood cancer and how people can get involved and support us.

One of our innovative young fundraisers, Jacob (aged 8), raised money for the Charity through a click and collect cake sale raising over £3,000!

We also made the headlines when Britain's oldest married couple (pictured above) celebrated their oak wedding anniversary with a donation to Leukaemia & Myeloma Research UK.

In conjunction with this, we are proud to be partnering Aviva who selected us for their Pennies for Good scheme. To date they have donated over £12,000 towards our vital work fighting blood cancer.

At the beginning of the lockdown, Leukaemia & Myeloma Research UK gave a generous grant of £20,000 to R Charity to help support medical staff (pictured above) during the COVID-19 outbreak. R Charity raises vital funds to enable Liverpool University Hospitals NHS Foundation Trust, to provide the best possible healthcare through our 3 local hospitals.

Finally we would like to thank all our volunteers and fundraisers for all the amazing work they have done throughout the year. Without their support we would not be able to continue to offer the services that we do.

It has been a challenging time both for the Charity and for our many fundraisers. Our thoughts go out to everyone who has been affected.

Sergey Vinogradov
Chair, Leukaemia and Myeloma Research UK Ltd

Operation Director's Report

2020 has been a difficult for everybody. Despite this, our fundraisers have done some amazing things from running virtual marathons and virtual quizzes to ebay sales and birthday fundraisers. The Charity produced a brochure to offer various fundraising ideas to our supporters and we produced a quiz for them to do with family and friends online.

There have been some big changes in how we fund our research programme. This year the Charity formed the Research and Review Committee (RRC). We are honoured to have experts in their fields join the RRC. The list of members is on our website. The role of the RRC is to review research grant applications received. Its funding priorities are to advance understanding of stem cells and how they can be used to treat blood cancer patients, particularly through stem cell transplants.

The first meeting of the committee took place in July 2020. We are excited to announce the Research Grant has been awarded to Dr Salvatore Papa, an Assistant Professor in Cancer Research at the University of Leeds to support a new method of research into blood cancer. Following this, in December a new funding round was opened to researchers which closed at the end of the financial year.

We are pleased to announce that we've been approved as a member of the Association of Medical Research Charities (AMRC) an organisation dedicated to supporting charities that focus on medical research intending to save and improve lives.

Carol Bewick, Director of Membership Engagement and Communications at the AMRC said: "We are very excited to welcome Leukaemia

and Myeloma Research UK as new members to AMRC showing they meet the highest standards for funding research.

Towards the end of the year, Leukaemia & Myeloma Research UK worked in partnership with the West Lancs and Merseyside Myeloma Support Group for Myeloma Awareness Month. The group provide a friendly and understanding service for people affected by myeloma and hold informal meetings to discuss the latest news and research findings, share their personal experiences, and raise money for charity.

Special thanks to our ambassador, Zoe Gillings-Brier the four time winter Olympian, who recorded two special messages on behalf of the Charity. The first in aid of Blood Cancer Awareness Month and the second a special fundraising message.

Our clothes recycling service resumed in March after the easing of the lockdown. This continues to be a consistent source of income for the Charity and helps us to fund many of the services we run.

The Charity turned 5 in October and we marked the occasion by producing the Big 5 Checklist. 5 challenges for our fundraisers to do to help us mark the occasion.

I would like to say a huge 'thank you' to our fundraisers for their hard work under such difficult circumstances and to our hard working staff and partners who have pulled together to make 2020 a success.



Dr Joanna Tilley
Operations Director,
Leukaemia and Myeloma Research UK Ltd

MCB Service

Overview

The Model Cell Biobank (MCB) service allows the storage of a child's umbilical cord blood stem cells at the time of birth, in case they or another member of the family needs them in the future to help in the treatment of a disease. It may be possible to use the stem cells to treat blood cancers or in emerging therapies to treat diseases such as diabetes, cerebral palsy and Parkinson's disease. Clinical trials are being performed all over the world looking at the potential use of stem cells to treat new diseases and hopefully further breakthroughs.

When a baby is born and the umbilical cord is cut, the placenta and umbilical cord are normally thrown away. The blood that remains in the cord and the placenta contains stem cells. The Charity offers a service to collect these stem cells without any risk to the mother and baby, and to store them in case that child or another member of the family needs them in the future.

The cord blood stem cells are stored on behalf of the child for 25 years. The mother is the legal guardian of the cells until the child reaches the age of majority, at which point, ownership transfers to the child. After 25 years, the cells can be privately stored, donated for research, offered to a public bank, or destroyed. Consent from the child will be sought at this point and we would strongly encourage the donation of any remaining cells to public banks.

The cord blood banking service is available to qualifying expectant mothers who live in the UK. They must be in receipt of Housing Benefit, Council tax or Universal Credit (at least one of these) and must meet the following criteria:

• The stem cells will be used to treat the child, or another member of the family, for a medically attested treatment;
• There is a history of cancer in the immediate family.

Last financial year, we extended the project to support low-income families by implementing a part funded service for those who have medical history, but are not on benefits.

Our partner
We have chosen Biovault Technical as our partner to procure; process and store cord stem cells under its Human Tissue Authority licence. Biovault has a strong reputation for standards it applies to the storage and processing of stem cells derived from umbilical cord and peripheral blood, bone marrow, now extending to many types of tissues for human application or transplant.

Biovault not only works to the highest standards, it also has an ethical approach, which aligns with our charity, something we are proud of.

MODEL CELL BIOBANK
research that saves lives



Advantages of Cord Blood Stem Cells

Today, cord blood banking is changing lives and there have already been more than one million stem cell transplants around the world since the 1980s.

The stem cells in your baby's cord blood are fully developed adult stem cells, which are the building blocks of the blood immune system. These stem cells can be used instead of bone marrow stem cells to treat blood cancers and genetic disorders.

Cord blood stem cells have many advantages including:

• They are easily available, having already been harvested and stored;
• A new born baby has been exposed to fewer viruses and infections and so the stem cells are less likely to transmit infection and react with the patient;
• Cord blood stem cells offer the life-saving option of a transplant and avoids the invasive, painful and expensive procedures of other stem-cell collection, such as bone marrow;
• Cord blood stem cells can be stored for many years - the longevity of these cells has proved they are as good 30 years later as on as the day they were first extracted and stored.

Client feedback

"When I was induced at the hospital we called the phlebotomist who arrived shortly after to take our baby daughter's cord blood stem cells. The collection was very quick – and within two hours of birth her cord blood stem cells had been collected and taken to be stored." (Client)

"When I went into labour, a phlebotomist came to the hospital and waited until the baby was delivered. Then they took a sample of cord blood to collect the stem cells, which caused no harm or pain to our baby or myself, and packaged it safely and securely." (Client)

Case Study – Lara's Story

The moment baby Alice was born, parents Sam and Craig had a phlebotomist on hand to harvest potentially lifesaving stem cells from her umbilical cord, which were frozen and banked as a charity-funded health insurance for the little girl and her older sister.

Just weeks before Alice's birth, her sister Lara, 3, was given her final dose of chemotherapy after two long, hard years of treatment for leukaemia, which was diagnosed when she was just a year old. During her pregnancy with Alice, Sam discovered the Charity's Model Cell Biobank service and contacted the Charity to find out about the potential ways she could protect her daughters in the future by using stem cell treatments.

"My dad came across the Charity's website and sent me a link, which is how I first learnt about cord blood banking. I started reading up about their Model Cell Biobank service, which enables parents to store their baby's umbilical cord blood stem cells for future use, and found it really interesting," said Sam.

The Model Cell Biobank is the first fully-funded service for eligible families, offering parents the opportunity to store their baby's cord blood for 25 years in case the child, or another member of the family, needs them in the future.

"If Lara was to relapse, we want to ensure that we have done everything possible to give her the best treatment options available, which Lara's consultant has advised us could potentially include a stem cell transplant if a suitable match could be found. The team at Model Cell Biobank were so helpful and knowledgeable – they talked me through the whole process ...we were so grateful to the Charity for their support and advice. They made the process straightforward from start to finish.

"The process went really smoothly – it had no impact on the birth or bonding experience, and it happened out of sight so we could still have our privacy. It caused no harm or stress to either Alice or me.

"Although it is still a worrying time for us, it helps us to know that we have this extra 'safety net' to call upon should Lara's leukaemia ever return. We'd recommend expectant parents to look into this as an option to protect their family and future generations".

Research Priorities

Leukaemia & Myeloma Research UK Ltd offer research grants to those who uphold our primary objectives: to protect and promote the health of the public, in particular by research into the nature, causes, diagnosis, prevention, treatment and cure of leukaemia and myeloma.

The Trustees' current funding priorities are to advance understanding of stem cells and how they can be used to treat blood cancer patients, particularly through stem cell transplants.

During the summer, Dr Salvatore Papa, an Assistant Professor in Cancer Research at the University of Leeds, was awarded the Charity's research grant to continue his specialist studies, into examining how the accumulation of mutated proteins in certain blood cancer cells allow them to multiply repeatedly. These findings can then be used to investigate how to prevent these mutations from occurring by blocking the process. Dr Joanna Tilley, Operations Director, said: "We're really pleased to award this grant to support crucial work into targeting protein stability in multiple myeloma, which will complement our work in finding more effective treatments to fight blood cancer in the future and to protect the next generation."

We joined the Association of Medical Research Charities (AMRC) in March, who are dedicated to supporting charities that focus on funding medical research intending to save and improve lives. All grant applications received are reviewed by the Research Review Committee. The members of the RRC are volunteers appointed for a three-year term. The current scientist members of the RRC are:

Dr Paul Spencer Hole
Senior Research Scientist. Has been engaged in academic research at Cardiff University and extends his experience in a clinical-stage biopharmaceutical company

Dr Claire Seedhouse
Associate Professor within Division of Cancer and Stem Cells, University of Nottingham. She is Principle Investigator and research group leader in Blood Cancer at the University of Nottingham.

Dr John Jones
Senior Clinical Lecturer – Brighton and Sussex Medical School, Honorary Consultant Haematologist – Kings College Hospital NHS Trust, London and Eastbourne District General Hospital.

Dr Rhys Morgan
Lecturer in Biomedical Sciences in Department of Biochemistry and Biomedicine, at the University of Sussex.

Professor Joseph R. Slupsky
Reader in Department of Molecular and Clinical Cancer Medicine, University of Liverpool. He is Principal Investigator of the Liverpool Blood Disease Biobank and Academic Lead University of Liverpool Technology Directorate Cell Sorting and Flow/Mass Cytometry Facility.

Dr Ceri Bygrave
A Consultant Haematologist and Myeloma Lead at the University Hospital of Wales and a member of the UK Myeloma Forum Executive Committee and the UK Myeloma Research Alliance.

Fundraising and Volunteers

Damian Basey, 38, from Hertfordshire is running his first Half Marathon this June to raise money for Leukaemia & Myeloma Research UK after a close family member was diagnosed with myeloma.

Damian's cousin Lorna, a healthy mother of two young boys, was diagnosed with monoclonal gammopathy of undetermined significance (MGUS) in 2011, a non-cancerous condition, which in 2018, shortly after her 40th birthday, developed into Multiple Myeloma.

"Lorna has remarkable courage and the way she's dealt with everything is incredibly inspiring – we're all so proud of her. Since her diagnosis, Lorna has undergone chemotherapy and a stem cell transplant and is now in remission doing well. Our whole family is keen to raise money and awareness of Myeloma by supporting research into finding an effective treatment to beat blood cancer once and for all. So now it's my turn to take on a challenge and raise vital funds for charity," said Damian.

On 6th June 2021, Damian is taking on the Hertfordshire Half Marathon, a 13.1-mile race starting and finishing at Knebworth House. The route takes runners through the grounds of Knebworth Park before heading out to the surrounding country lanes.

"I work as an Area Manager in retail, so during most of the lockdown I've been on furlough, which has given me lots of time to improve my fitness levels. I started slowly, but now I'm loving running. I wanted to keep pushing myself and have something to work towards, so I looked at running events nearby which I could take part in and that's when I found the Herts Half Marathon. I spoke with the event organisers about raising money for a charity supporting myeloma research, and that's when they put me in touch with Leukaemia & Myeloma Research UK.

"The Charity is a perfect fit for me with their focus on finding effective treatments to fight leukaemia and myeloma, so I registered to run representing the Charity and raising money for them. I haven't set a huge fundraising target as I appreciate times are tricky for a lot of people at the moment, so I initially set out to raise £250, which I'm really pleased to say has now been hit.

My family have been incredibly supportive. My wife Lizzie has done a few training runs with me and I'm hoping to persuade my two children; Jacob, 10, and Alice, 7, to get their running shoes on when the weather starts to brighten. Who knows, maybe next year they'll be wanting to join me in some races! I'm holding out hope that there will be a cure for myeloma within our lifetimes, and the money I raise will go towards finding a cure for Lorna and other myeloma patients," added Damian.

Thanks to Funders

- Albert Hunt Trust
- Grace Trust
- Tesco Groundworks
- Warburtons
- LCVS - Community Impact Fund
- M & G Plc. Community Fund
- Aviva - Pennies for Good
- Aviva Community Fund
- JP Jacobs Charitable Trust
- Tory Family Foundation
- Groundwork - Jacks Stores

Staff and Committee Members

Trustees 2020-21

- Sergejs Vinogradov (Chair)
- Tatjana Vinogradova
- Victoria Kieran
- Julija Sidorika

Staff Team

- Dr Joanna Tilley - Interim Operations Director
- Lucy Heron - Office Manager / Senior MCB Call Centre Manager
- Richard Thompson - Call Centre
- Kate Williams - PT Fundraiser

Thanks to Individuals and supporters

- Best Freelance Design Ltd
- Biovault Technical Ltd
- Dr Hannah Hunter – Consultant Haematologist
- Fundraising Support Ltd
- KOR Communications
- Phlebotomy UK Ltd
- Research Review Committee

Leukaemia & Myeloma Research UK

leukaemiamyelomaresearchuk.org

Registered charity number 1161622 (England & Wales), SC046106 (Scotland),
Company Limited by guarantee Registered number 09481278

Accounts 31 March 2021





Leukaemia & Myeloma Research UK Ltd

Report and accounts for the year ended 31 March 2021

Contents

	Page
Charity information	1
Trustees' Annual Report	1
Statement of directors' responsibilities	5
Independent Examiner's Report	7
Funds Statements:-	
Statement of Financial Activities	9
Statement of Financial Activities - Prior Year statement	10
Movements in funds	12
Income and Expenditure account	13
Balance sheet	14
Notes to the accounts	15

Leukaemia & Myeloma Research UK Ltd

Company Registration Number - 09481278

Trustees' Annual Report for the year ended 31 March 2021

The Trustees present their Report and Accounts for the year ended 31 March 2021, which also comprises the Directors' Report required by the Companies Act 2006.

Reference and administrative details

The charity name.

The legal name of the charity is:- Leukaemia & Myeloma Research UK Ltd.

The charity is also known by its operating name, LMR UK Ltd.

The charity's areas operation and UK charitable registration.

The charity is registered in England & Wales with the Charity Commission in England & Wales (CCEW) with charity number 1161622.

The charity is also registered in Scotland, with charity number SC046106 as it has operations in Scotland.

The charity does not operate in any overseas jurisdictions.

Legal structure of the charity

The charity is constituted as x Data not entered in Step 5. The governing document of the charity is You have entered insufficient data to determine if the data is correct

The governing document is dated 10 March 2015
There are no restrictions in the governing documents on the operation of the Charity or on its investment powers other than those imposed by Charity Law.

By operation of law all, trustees are directors under the Companies Act 2006 and all directors are trustees under Charities legislation and have responsibilities, as such, under both company and charity legislation.

The trustees are all individuals.

Leukaemia & Myeloma Research UK Ltd

Company Registration Number - 09481278

Trustees' Annual Report for the year ended 31 March 2021

The principal operating address, telephone number, email and web addresses of the charity

Room 127, North Mersey Business Centre
Woodward Road, Liverpool
Merseyside, L33 7UY
Telephone 08003687309

Email Address info@leukaemiamyelomaresearchuk.org Web address https://www.leukaemiamyelomaresearchuk.org/

The registered office of the charity for Companies Act purposes is the same as the operating

The Trustees in office on the date the report was approved were:-

Sergejs Vinogradovs
Tatjana Vinogradova
Julija Sidorika
Victoria Kieran

The following persons served as Trustees during the year ended 31 March 2021 :-

The trustees who served as a trustee in the reporting period were as shown above, and there were no changes during the year, or in the period between the year end and the approval of the accounts.

All the trustees are also members of the charity.

Objects and activities of the charity

The purposes of the charity as set out in its governing document.

The objectives of the charity are set out in the Memorandum of Association of 14 July 2015. They are:
1. to protect and promote the health of the public in particular by research into the nature, causes, diagnosis, prevention, treatment and cure of leukaemia and myeloma.
2. development of research into practical applications for the prevention. Treatment and cure leukaemia and myeloma and raise public understanding of such matters.

Trustees' Annual Report for the year ended 31 March 2021

Structure, governance and management of the charity

The methods used to recruit and appoint new charity trustees.

Proposals for new Trustees are made by the Chair after making appropriate enquiries. Appointments are then made by election by the existing board of Trustees.

Accountants	KBH Accountants Ltd - 255 Poulton Road, Wallasey, CH44 4BT

Leukaemia & Myeloma Research UK Ltd

Company Registration Number - 09481278

Trustees' Annual Report for the year ended 31 March 2021

Financial review

	2021	2020
	£	£
Net income	49,918	174,410
Unrestricted Revenue Funds available for the general purposes of the charity	258,527	213,625
Restricted Revenue Funds	27,761	22,745
Total Funds	286,288	236,370

Financial review of the position at the reporting date, 31 March 2021 .

Overall surpplus stands at £286,288 and will be distributed in following way: £50,000 for the Reserves; £20,000 for the E-Shop developement; £50,000 for Research grants and £166,288 for the charity and MCB development.
The trustees consider the financial performance by the charity during the year to have been satisfactory.

Policies on reserves.

All the trustees aim to maintain free reserves in unrestricted funds at a level which equates to between two and four months of unrestricted charitable expenditure. The trustees consider that this level will ensure that there are sufficient funds available to cover support and governance costs. Reserves policy will be reviewed annually based on the charity's annual accounts. Based on the results of past year, the Reserves amount is £50,000.

Availability and adequacy of assets of each of the funds

The board of trustees is satisfied that the charity's assets in each fund are available and adequate to fulfil its obligations in respect of each fund.

Details of The Independent Examiner

Olivia Higgins
Member of Chartered Certified Accountants
255 Poulton Road
Wallasey
Wirral
CH44 4BT

Trustees' Annual Report for the year ended 31 March 2021

Statement of the Directors Trustees' Responsibilities

The charity's trustees are responsible for the preparation of the accounts in accordance with the terms of the Companies Act 2006, the Charities Act 2011 and the Charities (Accounts and Reports) Regulations 2008. Notwithstanding the explicit requirement in the extant statutory regulations,the Charities (Accounts and Reports) Regulations 2008, to prepare the financial statements in accordance with the SORP 2005, in view of the fact that the SORP 2005 has been withdrawn, the Trustees determined to interpret this responsibility as requiring them to follow current best practice and prepare the accounts according to the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019). (The SORP). .

In particular, the Companies Act 2006 and charity law require the Board of Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity as at the end of the financial year and of the surplus or deficit of the charity. In preparing those financial statements the Board is required to :-

- to prepare the accounts in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law).
- select suitable accounting policies and apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business;
- state whether applicable accounting standards and statements of recommended practice have been followed, subject to any material departures disclosed and explained in the financial statements;

The law requires that the trustees must not approve the accounts unless they are satisfied that they give a true and fair view of the state of affairs of the charity and of the surplus or deficit of the charity for the year.
The Trustees are also responsible for maintaining adequate accounting records which disclose with reasonable accuracy at any time the financial position of the charity and which are sufficient to show and explain the charity's transactions and enable them to ensure that the financial statements comply with the Companies Act 2006 and comply with regulations made under the Charities Act. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Trustees are also responsible for the contents of the Trustees' report, and the statutory responsibility of the Independent Examiner in relation to the Trustees' report is limited to examining the report and ensuring that , on the face of the report, there are no material inconsistencies with the figures disclosed in the financial statements.

Leukaemia & Myeloma Research UK Ltd

Company Registration Number - 09481278

Trustees' Annual Report for the year ended 31 March 2021

Method of preparation of accounts - Small company provisions

The financial statements are set out on pages 9 to 33.
The financial statements have been prepared implementing the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), and in accordance with the Financial Reporting Standard 102, (effective 1st January 2016)
These financial statements have been prepared in accordance with the provisions in Part 15 of the Companies Act 2006. applicable to companies subject to the small companies regime.

This report was approved by the board of trustees on 12 November 2021.

TATJANA VINOGRADOVA
Director and Trustee

Leukaemia & Myeloma Research UK Ltd

Report of the Independent Examiner to the Trustees of the charitable company on the accounts for the year ended 31 March 2021

I report to the Trustees on my examination of the financial statements of the charitable company on pages 9 to 33 for the year ended 31 March 2021 which have been prepared in accordance with the Charities Act 2011 (the Act) and with the Financial Reporting Standard 102, (effective 1st January 2016) as modified by FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), published by the Charity Commission in England & Wales (CCEW) , and under the historical cost convention and the accounting policies set out on page 15.

Respective responsibilities of the Trustees and the Independent Examiner and the basis of the report

As described on page 5, you, the charitable company's Trustees, who are also the Directors of the Company for the purposes of Company law, are responsible for the preparation of the financial statements in accordance with the Companies Act 2006, the Charities Act 2011 and all other applicable law and with United Kingdom Generally Accepted Accounting Practice, applicable to smaller entities, and for being satisfied that the financial statements give a true and fair view.

The Trustees consider that the audit requirement of Section 144(1) of the Charities Act 2011 (the Act) does not apply, and that there is no requirement in the memorandum and articles of the charity for the conducting of an audit, and that the accounts do not require an audit in accordance with Part 16 of the Companies Act 2006 and that no member or members have requested an audit pursuant to Section 476 of the Companies Act 2006. As a consequence, the Trustees have elected that the financial statements be subject to independent examination.

Having satisfied myself that the financial statements are not required to be audited under any legal provision, or otherwise, and are eligible for independent examination, it is my responsibility to:-

a) examine the financial statements of the charity under Section 145 of the Act;

b) follow the applicable procedures in the Directions given by the Charity Commission under section 145(5)(b) of the Act.

Basis of Independent Examiner's Statement and scope of work undertaken

Since the charitable company's gross income exceeded £250,000, the charitable company's examiner must be a member of a body listed in section 145 of the Act. I confirm that I am qualified to undertake the examination because I am an authorised member of Chartered Certified Accountants , which is one of the listed bodies.

I report in respect of my examination of the charity's financial statements carried out under s145 of the Act. In carrying out my examination, I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act setting out the duties of an independent examiner in relation to the conducting of an independent examination. An independent examination includes a review of the accounting records kept by the charitable company and of the accounting systems employed by the charitable company and a comparison of the financial statements presented with those records. It also includes consideration of any unusual items or disclosures in the financial statements, and seeking explanations from you, as Trustees, concerning such matters. The purpose of the examination is to establish as far as possible that there have been no breaches of charity legislation and that, on a test basis of evidence relevant to the amounts and disclosures made, the financial statements comply with the SORP.

The procedures undertaken do not provide all the evidence that would be required in an audit, and information supplied by the Trustees in the course of the examination is not subjected to audit tests or enquiries and does not cover all the matters that an auditor would consider in arriving at an opinion. The planning and conduct of an audit goes beyond the limited assurance that an independent examination can provide

Consequently, I do not express an audit opinion on the view given by the financial statements, and in particular, I express no opinion as to whether the financial statements give a true and fair view of the affairs of the charity, and my report is limited to the matters set out in the statement below.

I planned and performed my examination so as to satisfy myself that the objectives of the independent examination are achieved and before finalising the report I obtained written assurances from the Trustees of all material matters.

Leukaemia & Myeloma Research UK Ltd

Independent Examiner's Statement, Report and Opinion

Subject to the limitations upon the scope of my work as detailed above, I have completed my examination: and can confirm that:-

The accounts of this charitable company are not required to be audited under Part 16 of the Companies Act 2006;

This is a report in respect of an examination carried out under 145 of the Act and in accordance with Directions given by the Charity Commission under section 145(5)(b) of the Act which may be applicable;

and that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:-

accounting records were not kept in respect of the charity as required by Section 386 of the Companies Act 2006 and Section 130 of The Charities Act 2011;

the financial statements do not accord with those records; or

the financial statements do not comply with the applicable requirements concerning the form and content of accounts set out in section 396 of the Companies Act 2006 other than any requirement that the accounts give a 'true and fair' view, which is not a matter considered as part of an independent examination;

have not been prepared in accordance with the methods and principles set out in the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.

Signed:- O. Higgins

Olivia Higgins - Independent Examiner

Chartered Certified Accountants

255 Poulton Road
Wallasey
Wirral
CH44 4BT

This report was signed on 12 November 2021

Leukaemia & Myeloma Research UK Ltd - Statement of Financial Activities for the year ended 31 March 2021

Statement of Financial Activities (including the Income and Expenditure Account for the year ended 31 March 2021, as required by the Companies Act 2006)

	SORP Ref	Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
		2021	2021	2021	2020
		£	£	£	£
Income & Endowments from:					
Donations & Legacies	A1	120,119	8,281	**128,400**	211,478
Charitable activities	A2	7,241	-	**7,241**	73
Investments	A4	187	-	**187**	64
Other	A5	52,476	-	**52,476**	52,722
Total income	**A**	**180,023**	**8,281**	**188,304**	**264,337**
Expenditure on:					
Raising funds	B1	3,527	-	**3,527**	7,576
Charitable activities	B2	131,594	3,265	**134,859**	82,351
Total expenditure	**B**	**135,121**	**3,265**	**138,386**	**89,927**
Net income for the year		**44,902**	**5,016**	**49,918**	**174,410**
Transfers between funds	**C**	-	-	**-**	-
Net income after transfers	**A-B-C**	**44,902**	**5,016**	**49,918**	**174,410**
Net movement in funds		**44,902**	**5,016**	**49,918**	**174,410**
Reconciliation of funds:-	**E**				
Total funds brought forward		213,625	22,745	**236,370**	61,960
Total funds carried forward		**258,527**	**27,761**	**286,288**	**236,370**

The 'SORP Ref' indicated above is the classification of income set out in the formal SORP documents. As required by paragraph 4.60 of the SORP, the brought forward and carried forward funds above have been agreed to the Balance Sheet.

A separate Statement of Total Recognised Gains and Losses is not required as this statement includes all recognised gains and losses.

All activities derive from continuing operations

The notes attached on pages 15 to 33 form an integral part of these accounts.

Leukaemia & Myeloma Research UK Ltd - Statement of Financial Activities for the year ended 31 March 2021

Leukaemia & Myeloma Research UK Ltd - Analysis of prior year total funds, as required by paragraph 4.2 of the SORP

	SORP Ref	Prior Year Unrestricted Funds 2020 £	Prior Year Restricted Funds 2020 £		Prior Year Total Funds 2020 £
Income & Endowments from:					
Donations & Legacies	A1	202,488	8,990		**211,478**
Charitable activities	A2	73	-		**73**
Investments	A4	64	-		**64**
Other	A5	51,283	1,439	-	**52,722**
Total income	**A**	253,908	10,429		**264,337**
Expenditure on:					
Raising funds	B1	7,576	-		**7,576**
Charitable activities	B2	71,069	11,282		**82,351**
Total expenditure	**B**	**78,645**	**11,282**		**89,927**
Net income for the year		175,263	(853)		174,410
Transfers between funds	**C**	-	-		**-**
Net income after transfers		175,263	(853)		174,410
Net movement in funds		**175,263**	**(853)**		**174,410**
Reconciliation of funds:-	**E**				
Total funds brought forward		44,669	17,291		**61,960**
Total funds carried forward		**219,932**	**16,438**		**236,370**

All activities derive from continuing operations

A separate Statement of Total Recognised Gains and Losses is not required as this statement includes all recognised gains and losses.'

The notes attached on pages 15 to 33 form an integral part of these accounts.

Leukaemia & Myeloma Research UK Ltd - Statement of Financial Activities for the year ended 31 March 2021

Leukaemia & Myeloma Research UK Ltd - Resources applied in the year ended 31 March 2021 towards fixed assets for Charity use:-

	2021 £	2020 £
Funds generated in the year as detailed in the SOFA	49,918	174,410
Net resources available to fund charitable activities	**47,418**	**174,410**

The resources applied on fixed assets for charity use represents the cost of additions less proceeds of any disposals.

The notes attached on pages 15 to 33 form an integral part of these accounts.

Leukaemia & Myeloma Research UK Ltd - Statement of Financial Activities for the year ended 31 March 2021

Movements in revenue and capital funds for the year ended 31 March 2021

Revenue accumulated funds

	Unrestricted Funds 2021 £	Restricted Funds 2021 £	Total Funds 2021 £	Last year Total Funds 2020 £
Accumulated funds brought forward	213,625	22,745	236,370	**61,960**
Recognised gains and losses before transfers	44,902	5,016	49,918	174,410
	258,527	**27,761**	**286,288**	**236,370**
(From)/To unrestricted revenue funds	-	-	-	-
Closing revenue funds	**258,527**	**27,761**	**286,288**	**236,370**

Summary of funds	Unrestricted and Designated funds 2021 £	Restricted Funds 2021 £	Total Funds 2021 £	Last Year Total Funds 2020 £
Revenue accumulated funds	258,527	27,761	**286,288**	236,370

The notes attached on pages 15 to 33 form an integral part of these accounts.

Leukaemia & Myeloma Research UK Ltd - Statement of Financial Activities for the year ended 31 March 2021

Leukaemia & Myeloma Research UK Ltd
Income and Expenditure Account for the year ended 31 March 2021 as required by the Companies Act 2006

	2021 £	2020 £
Income		
Income from operations	135,641	211,551
Investment income		
Interest receivable	187	64
Other operating income	52,476	52,722
Gross income in the year before exceptional items	**188,304**	**264,337**
Gross income in the year including exceptional items	**188,304**	**264,337**
Expenditure		
Charitable expenditure, excluding depreciation and amortisation	133,814	81,931
Depreciation and amortisation	625	-
Fundraising costs	3,527	7,576
Governance costs	420	420
Total expenditure in the year	**138,386**	**89,927**
Net income before tax in the financial year	**49,918**	**174,410**
Tax on surplus on ordinary activities	-	-
Net income after tax in the financial year	**49,918**	**174,410**
Retained surplus for the financial year	**49,918**	**174,410**

All activities derive from continuing operations

In accordance with the provisions of the Companies Act 2006, the headings and subheadings used in the Income and Expenditure account have been adapted to reflect the special nature of the charity's activities.

The notes attached on pages 15 to 33 form an integral part of these accounts.

Leukaemia & Myeloma Research UK Ltd - Balance Sheet as at 31 March 2021

	Note	SORP Ref		2021		2020
				£		£
Fixed assets		A				
Tangible assets	7	A2		1,875		-
Total fixed assets				1,875		-
Current assets		B				
Stocks		B1	16,361		1,628	
Debtors	9	B2	1,660		5,695	
Cash at bank and in hand		B4	270,732		233,523	
Total current assets			288,753		240,846	
Creditors: amounts falling due within one year	10	C1	(4,340)		(4,476)	
Net current assets				284,413		236,370
The total net assets of the charity				**286,288**		**236,370**
The total net assets of the charity are funded by the funds of the charity, as follows:-						
Restricted funds						
Restricted Revenue Funds	13	D2	27,761		22,745	
				27,761		22,745
Unrestricted Funds						
Unrestricted Revenue Funds	13	D3	258,527		213,625	
				258,527		213,625
Designated Funds						
Total charity funds				**286,288**		**236,370**

The 'SORP Ref' indicated above is the classification of Balance Sheet items as set out in the formal SORP documents. As required by paragraph 4.60 of the SORP, the brought forward and carried forward funds above have been agreed to the SOFA..

The directors are satisfied that the company is entitled to exemption from the requirement to obtain an audit under section 477 of the Companies Act 2006.

The members have not required the company to obtain an audit in accordance with section 476 of the Act.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.

The charity is subject to Independent Examination under charity legislation, and the report of the Independent Examiner is on page 8.

The financial statements have been prepared in accordance with the provisions in Part 15 of the Companies Act 2006. applicable to companies subject to the small companies regime.

TATJANA VINOGRADOVA
Trustee
Approved by the board of trustees on 12 November 2021

The notes attached on pages 15 to 33 form an integral part of these accounts.

Leukaemia & Myeloma Research UK Ltd

Notes to the Accounts for the year ended 31 March 2021

1 Accounting policies

Policies relating to the production of the accounts.

Basis of preparation and accounting convention

The accounts have been prepared on the accruals basis, under the historical cost convention, and in accordance with the Financial Reporting Standard 102, (effective 1st January 2016) and 'FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), published by the Charity Commission in England & Wales (CCEW) , effective January 2016, , and in accordance with all applicable law in the charity's jurisdiction of registration, except that the charity has prepared the financial statements in accordance with the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities) 2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), in preference to the previous SORP, the SORP 2005, which has been withdrawn, notwithstanding the fact that the extant statutory regulations, the Charities (Accounts and Reports) Regulations 2008 refer explicitly to the SORP 2005. This has been done to accord with current best practice.

Risks and future assumptions

The charity is a public benefit entity.
This policy is a formal acknowledgement that LMRUK is committed to maintaining a strong risk management framework and making every effort to manage risk appropriately by maximising potential opportunities whilst minimising the adverse effects of risks. It should be used to support the internal control systems of the charity, enabling LMRUK to respond to operational, strategic and financial risks regardless of whether they are internally or externally driven.

Policies relating to categories of income and income recognition.

Nature of income

Gross income represents the value, net of value added tax and discounts, of goods provided to customers and work carried out in respect of services provided to customers.

Categories of Income

Income is categorised as income from exchange transactions (contract income) and income from non-exchange transactions (gifts), investment income and other income.

Income from exchange transactions is received by the charity for goods or services supplied under contract or where entitlement is subject to fulfilling performance related conditions. The income the charity receives is approximately equal in value to the goods or services supplied by the charity to the purchaser.

Income from a non-exchange transaction is where the charity receives value from the donor without providing equal value in exchange, and includes donations of money, goods and services freely given without giving equal value in exchange.

Notes to the Accounts for the year ended 31 March 2021

Income recognition

Income, whether from exchange or non exchange transactions, is recognised in the statement of financial activities (SOFA) on a receivable basis, when a transaction or other event results in an increase in the charity's assets or a reduction in its liabilities and only when the charity has legal entitlement, the income is probable and can be measured reliably.

Dividends are accrued when the shareholder's right to receive payment is established.

Income subject to terms and conditions which must be met before the charity is entitled to the resources is not recognised until the conditions have been met.

All income is accounted for gross, before deducting any related fees or costs.

Income from legacies

Income from legacies is recognised when the charity has sufficient evidence that a gift has been left to them, that where required, probate has been granted, the executor is satisfied that the property in question will not be required to satisfy claims in the estate, that it is probable that the amount will be received by the charity, and the amount to be received can be estimated with sufficient accuracy, and that any conditions attached to the legacy are either within the control of the charity or have been met.

Where a payment is received from an estate or is notified as receivable by the executors after the reporting date and before the accounts are authorised for issue but it is clear that the payment had been agreed by the executors prior to the end of the reporting period, then the amount concerned is treated as an adjusting event and accrued as income in the accounting period if receipt is probable.

Where the charity has established entitlement to a legacy but there is uncertainty as to the amount of the payment, details of the legacy arediscloseed as a contingent asset until the criteria for income recognition are met. Where a legacy is subject to the interest of a life tenant, the legacy is not recognised as income until the death of the life tenant.

If it is doubtful that full settlement of a legacy debtor will be received, then an adjustment is made to reduce the amount of the legacy debtor and legacy income rather than charging the adjustment as expenditure in the Statement of Financial Activities

Notes to the Accounts for the year ended 31 March 2021

Donated goods, facilities and services

Donated fixed assets are recognised at the current fair value. All such donations are recognised as donation income, and debited to fixed assets.

Donated goods that are not fixed assets are accounted for at a fair value, unless it is impractical to reliably measure the value of the donated items.

In the absence of any direct evidence of fair value of donated goods, then a value is derived from the cost of the item to the donor or, in the case of goods that are expected to be sold, the estimated resale value after deducting any anticipated costs of sales.

If it is impracticable to measure the fair value of goods donated for resale, or the costs of valuation outweigh the benefits, the donated goods are recognised as income when sold, with an equivalent amount being recognised as an expense.

The costs of goods donated for distribution to beneficiaries is deemed to be the fair value of those goods upon receipt. When the goods are distributed freely or for a nominal consideration, then the carrying amount is adjusted at the time of sale, to the value at the point of distribution and the adjustment is shown as a cost of donations made.

The carrying amount of any stock held for distribution is assessed for impairment at the reporting date. All donated goods are recognised as donation income, and debited to trading stock.When trading stock is subsequently sold, or appropriated to meet an expense, then the carrying value of the stock is recognised as an expense. In accordance with the SORP, goods donated for distribution to beneficiaries, or for consumption by the charity are included in *'legacies and donations'*. Goods donated for resale are included in *'Income from other trading activities'*

The cost of any stock of goods donated for distribution to beneficiaries is deemed to be the fair value of those gifts at the time of their receipt. If the goods held are to be distributed freely or for a nominal consideration, then the carrying amount is subsequently adjusted to reflect the lower of deemed cost adjusted for any loss of service potential and replacement cost. Replacement cost is the economic cost incurred if the charity was to replace the service potential of the donated goods at its own expense in the most economic manner.

Donated services and facilities (including seconded staff and use of property) are included in the accounts on the basis of the value of the gift to the charity.

All donated services and facilities are recognised as donation income when received,(provided the value of the gift can be measured reliably) and recognised as an expense with an equivalent value.

Policies relating to expenditure on goods and services provided to the charity.

Allocating costs to activities

Direct costs that are specifically related to an activity are allocated to that activity. Shared direct costs and support costs are apportioned between activities.

The basis for apportionment, which is consistently applied, and proportionate to the circumstances, is :-

Staffing - on the basis of time spent in connection with any particular activity.
Staffing - on a per capita basis, based on the number of of people employed within any partiular activity.
Premises related costs - on the proportion of floor area occupied by a particular activity.
Non specific support costs - on the basis of the usage of resources, in terms of time taken, capacity used, request made or other measures
Estimation techniques used in apportioning costs - give details

Notes to the Accounts for the year ended 31 March 2021

Policies relating to assets, liabilities and provisions and other matters.

Stocks and work in progress

Stock is valued at the lower of cost and net realisable value.

Debtors

Debtors are measured at their recoverable amounts at the balance sheet date.

Creditors and provisions

Liabilities are measured at their settlement amount. A liability is regonised for the the amount the Charity anticpates it will pay to settle the deb or the amount it has received as an advance payment for goods or services it must provide.

2 Liability to taxation

The Trustees consider that the charity satisfies the tests set out in Paragraph 1 Schedule 6 of the Finance Act 2010 for UK corporation tax purposes. Accordingly, the Charity is potentially exempt from taxation in respect of income or capital gains received within categories covered by chapter 3 part 11 of the Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992, to the extent that such income or gains are applied exclusively on the specific charitable objects of the charity and for no other purpose. Value Added Tax is not recoverable by the charity, and is therefore included in the relevant costs in the Statement of Financial Activities.

3 Winding up or dissolution of the charity

If upon winding up or dissolution of the charity there remain any assets, after the satisfaction of all debts and liabilities, the assets represented by the accumulated fund shall be transferred to some other charitable body or bodies having similar objects to the charity.

No employees received emoluments (excluding pension costs) in excess of £60,000 per annum.

4 Defined contribution pension schemes

Any liabilites and assets associated with the scheme are shown under debtors and creditors.

5 Remuneration and payments to Trustees and persons connected with them

No trustees or persons connected with them received any remuneration from the charity, or any related entity.

6 Trustees' expenses

There were no Trustees' expenses in the year and in the prior year.

Notes to the Accounts for the year ended 31 March 2021

7 Tangible fixed assets

Current Year	Land and Buildings	Plant & Machinery	Motor Vehicles	Total
	£	£	£	£
Cost				
At 1 April 2020	-	-	-	-
Additions	-	2,500	-	2,500
At 31 March 2021	**-**	**2,500**	**-**	**2,500**
Depreciation				
At 1 April 2020	-	-	-	-
Charge for the year	-	625	-	625
At 31 March 2021	**-**	**625**	**-**	**625**
Net book value				
At 31 March 2021	**-**	**1,875**	**-**	**1,875**
At 31 March 2020	**-**	**-**	**-**	**-**

8 Stocks & Work in Progress

	2021	2020
	£	£
Stocks before write downs	16,361	1,628
	16,361	1,628

Analysis of the carrying value of stocks and work in progress by activities

	Work in Progress		*Stocks*	
	2021	2020	2021	2020
	£	£	£	£
Activity				
Charitable activity	-	-	4,361	1,628
	-	-	4,361	1,628

9 Debtors

	2021	2020
	£	£
Prepayments and accrued income	1,660	5,695
	1,660	**5,695**

Notes to the Accounts for the year ended 31 March 2021

10 Creditors: amounts falling due within one year

	2021	2020
	£	£
Trade creditors	2,470	3,026
Accruals	1,870	1,450
	4,340	**4,476**

11 Income and Expenditure account summary

	2021	2020
	£	£
At 1 April 2020	236,370	61,960
Surplus after tax for the year	49,918	174,410
At 31 March 2021	**286,288**	**236,370**

12 Particulars of how particular funds are represented by assets and liabilities

At 31 March 2021	**Unrestricted funds**	**Designated funds**	**Restricted funds**	**Total Funds**
	£	£	£	£
Tangible Fixed Assets	1,875	-	-	**1,875**
Current Assets	260,992		27,761	**288,753**
Current Liabilities	(4,340)	-	-	**(4,340)**
	258,527	**-**	**27,761**	**286,288**

At 1 April 2020	**Unrestricted funds**	**Designated funds**	**Restricted funds**	**Total Funds**
	£	£	£	£
Current Assets	218,101	-	22,745	**240,846**
Current Liabilities	(4,476)	-	-	**(4,476)**
	213,625	**-**	**22,745**	**236,370**

Leukaemia & Myeloma Research UK Ltd

Notes to the Accounts for the year ended 31 March 2021

13 Change in total funds over the year as shown in Note 12 , analysed by individual funds

	Funds brought forward from 2020	Movement in funds in 2021	Transfers between funds in 2021	Funds carried forward to 2022
		See Note 14		
	£	£	£	£
Unrestricted and designated funds:-				
Unrestricted Revenue Funds	213,625	44,902	-	**258,527**
Total unrestricted and designated funds	**213,625**	**44,902**	**-**	**258,527**
Restricted funds:-				
Model Cell Biobank	22,745	5,016	-	**27,761**
Total restricted funds	**22,745**	**5,016**	**-**	**27,761**
Total charity funds	**236,370**	**49,918**	**-**	**286,288**

14 Analysis of movements in funds over the year as shown in Note 13

	Income	Expenditure	Gains & Losses	Movement in funds
	2021	2021	2021	2021
	£	£	£	£
Unrestricted and designated funds:-				
Unrestricted Revenue Funds	180,023	(135,121)	-	**44,902**
Restricted funds:-				
Model Cell Biobank	8,281	(3,265)	-	**5,016**
	188,304	**(138,386)**	**-**	**49,918**

Leukaemia & Myeloma Research UK Ltd

Notes to the Accounts for the year ended 31 March 2021

15 The purposes for which the funds as

Unrestricted and designated funds:-

Unrestricted Revenue Funds	These funds are held for the meeting the objectives of the charity, and to provide reserves for future activities, and , subject to charity legislation, are free from all restrictions on their use.

Restricted funds:-

Model Cell Biobank	The purpose of these funds is described under the accounting policy.

16 Ultimate controlling party

The charity is under the control of its legal members.
Every member of the charity is obliged to contribute such amount as may be required not exceeding £10 to the assets of the company in the event of its being wound up while he or she is a member, or within one year after he or she ceases to be a member.

Leukaemia & Myeloma Research UK Ltd

Detailed analysis of income and expenditure for the year ended 31 March 2021 as required by the SORP 2015

This analysis is classsified by conventional nominal descriptions and not by activity.

17 Donations, Grants and Legacies

	Current year Unrestricted Funds 2021 £	Current year Restricted Funds 2021 £	Current year Total Funds 2021 £	Prior Year Total Funds 2020 £
Donations and gifts from individuals				
Small donations individually less than £1000	5,274	-	**5,274**	13,835
Stripe direct donations	6,061	-	**6,061**	-
Briggs Equipment Ltd	1,000	-	**1,000**	-
Facebook	6,378	-	**6,378**	8,296
Just Giving	11,847	-	**11,847**	8,969
Kiltwalk	-	-	**-**	2,459
In Memory	9,135	-	**9,135**	9,839
Fundraising Support	-	1,731	**1,731**	-
Muchloved	2,522	-	**2,522**	-
Virgin Money Giving	2,880	-	**2,880**	-
Total donations and gifts from individuals	**45,097**	**1,731**	**46,828**	**43,398**

Donations and gifts from individuals (Include HMRC refunds on gift aided donations) - Prior Year analysis

	Prior Year Unrestricted Funds 2020 £	Prior Year Restricted Funds 2020 £	Prior Year Total Funds 2020 £
Prior year	**43,398**	**-**	**43,398**

Leukaemia & Myeloma Research UK Ltd

Detailed analysis of income and expenditure for the year ended 31 March 2021 as required by the SORP 2015

Legacies receivable

	Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
	2021	2021	2021	2020
	£	£	£	£
Legacies receivable				
Small legacies individually less than £1000	-	-	-	1,000
Mrs Mary Dallas	-	-	-	8,910
Bower Cotton Hamilton	-	-	-	70,844
Mayo Wynne Baxter Solicitors	9,771	-	**9,771**	78,336
Withers LLP	25,165	-	**25,165**	-
Macmillans Solicitors LLP	6,820	-	**6,820**	-
Total legacies receivable	**41,756**	**-**	**41,756**	**159,090**

Legacies receivable - Prior Year analysis

	Prior Year Unrestricted Funds	Prior Year Restricted Funds	Prior Year Total Funds
	2020	2020	2020
	£	£	£
Prior year	159,090	-	**159,090**

Leukaemia & Myeloma Research UK Ltd

Detailed analysis of income and expenditure for the year ended 31 March 2021 as required by the SORP 2015

Revenue grants from government and public bodies

	Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
	2021	2021	2021	2020
	£	£	£	£
Revenue grants from government and public bodies				
Small grants individually less than £1000	300	1,050	**1,350**	2,990
M&G Plc Charities Trust	1,900	-	**1,900**	-
Arcobaleno Cancer Trust	-	3,000	**3,000**	-
LCVS Community Impact Fund	1,000	-	**1,000**	-
Albert Hunt Trust	-	1,000	**1,000**	-
The Grace Trust	-	1,500	**1,500**	-
Medicash	-	-	**-**	-
Tesco/Groundwork UK	1,000	-	**1,000**	1,000
The Constance Paterson Charitable Trust	-	-	**-**	3,000
Hemby Charitable Trust	-	-	**-**	2,000
Charities Trust AVIVA	12,066	-	**12,066**	-
Crowdfunder	5,000	-	**5,000**	-
Total public sector revenue grants	**21,266**	**6,550**	**27,816**	**8,990**

Revenue grants from government and public bodies - Prior Year analysis

	Prior Year Unrestricted Funds	Prior Year Restricted Funds	Prior Year Total Funds
	2020	2020	2020
	£	£	£
Prior Year	-	8,990	**8,990**

Leukaemia & Myeloma Research UK Ltd

Detailed analysis of income and expenditure for the year ended 31 March 2021 as required by the SORP 2015

Donated goods and services

	Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
	2021	2021	2021	2020
	£	£	£	£
Donated goods and services				
Small gifts individually less than £1000	12,000	-	**12,000**	-
Total donated goods and services	**12,000**	**-**	**12,000**	**-**

Total Donations, Grants and Legacies

Current year		Unrestricted Funds	Restricted Funds	Current Year Total Funds	Prior Year Total Funds
		2021	2021	2021	2020
		£	£	£	£
Total Donations, Grants and Legacies	**A1**	**120,119**	**8,281**	**128,400**	**211,478**

All the donations and gifts in the prior year were unrestricted.

Prior year		Unrestricted Funds 2020	Restricted Funds 2020	Prior Year Total Funds 2020
		£	£	£
Total Donations, Grants and Legacies	**A1**	**202,488**	**8,990**	**211,478**

Leukaemia & Myeloma Research UK Ltd

Detailed analysis of income and expenditure for the year ended 31 March 2021 as required by the SORP 2015

18 Income from charitable activities - Trading Activities

Current year

	Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total funds
	2021	2021	2021	2020
	£	£	£	£
Primary purpose and ancillary trading				
Sale of goods and services in accordance with the charity's objects	7,241	-	**7,241**	73
Total Primary purpose and ancillary trading	**7,241**	**-**	**7,241**	**73**

19 Total Income from charitable activities

Current year

		Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
		2021	2021	2021	2020
		£	£	£	£
Total income from charitable trading		7,241	-	**7,241**	73
Total from charitable activities	**A2**	**7,241**	**-**	**7,241**	**73**

Income from charitable activities - Prior Year analysis

Prior year

	Prior Year Unrestricted Funds	Prior Year Restricted Funds	Prior Year Total Funds
	2020	2020	2020
	£	£	£
Total income from charitable trading	73	-	73
	73	**-**	**73**

Detailed analysis of income and expenditure for the year ended 31 March 2021 as required by the SORP 2015

20 Investment income

		Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
		2021	2021	2021	2020
		£	£	£	£
Bank Interest Receivable		187	-	**187**	64
Total investment income	**A4**	**187**	**-**	**187**	**64**

21 Other income and gains

Current year		Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
		2021	2021	2021	2020
		£	£	£	£
Royalties from the exploitation of intellectual property rights		50,085	-	**50,085**	50,000
Sundry other income		2,391	-	**2,391**	2,722
Total other income	**A5**	**52,476**	**-**	**52,476**	**52,722**

All the income in the prior year was unrestricted.

Other income and gains - Prior year analysis

Prior Year		Prior Year Unrestricted Funds	Prior Year Restricted Funds	Prior Year Total Funds
		2020	2020	2020
		£	£	£
Royalties from the exploitation of intellectual property rights		50,000	-	**50,000**
Sundry other income		1,283	1,439	**2,722**
Total other income	**A5**	**51,283**	**1,439**	**52,722**

Detailed analysis of income and expenditure for the year ended 31 March 2021 as required by the SORP 2015

22 Expenditure on charitable activities - Direct spending

Current Year		Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
		2021	2021	2021	2020
		£	£	£	£
Travel and Subsistence - Charitable Activities		2,150	-	**2,150**	**1,811**
Costs of activities and events		7,991	1,823	**9,814**	**9,814**
Consultancy and professional support		22,180	-	**22,180**	**18,575**
Total direct spending	**B2a**	**32,321**	**1,823**	**34,144**	**30,200**

Prior Year		Prior Year Unrestricted Funds	Prior Year Restricted Funds	Prior Year Total Funds
		2020	2020	2020
		£	£	£
Travel and Subsistence - Charitable Activities		1,811	-	**1,811**
Costs of activities and events		2,837	6,977	**9,814**
Consultancy and professional support		16,335	2,240	**18,575**
Total direct spending	**B2a**	**20,983**	**9,217**	**30,200**

23 Expenditure on charitable activities - Charitable trading

Current Year		Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
		2021	2021	2021	2020
		£	£	£	£
Cost of goods for primary purpose trading - Including movement in stock		**3,179**	**-**	**3,179**	**-**
Total charitable trading costs	**B2b**	**3,179**	**-**	**3,179**	**-**

Leukaemia & Myeloma Research UK Ltd

Detailed analysis of income and expenditure for the year ended 31 March 2021 as required by the SORP 2015

24 Expenditure on charitable activities- Grant funding of activities

Current Year		Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
		2021	2021	2021	2020
		£	£	£	£
Grants made to organisations		35,000	-	**35,000**	**-**
Total grantmaking costs	**B2c**	**35,000**	**-**	**35,000**	**-**

25 Support costs for charitable activities

Current Year	Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
	2021	2021	2021	2020
	£	£	£	£
Rent and rates	17,050	-	**17,050**	**10,737**
Light heat and power	522	-	**522**	**-**
Cleaning and waste management	690	-	**690**	**-**
Premises repairs, renewals and maintenance	423	-	**423**	**614**
Administrative overheads				
Telephone, fax and internet	1,899	323	**2,222**	**2,738**
Postage	635	-	**635**	**275**
Stationery and printing	949	-	**949**	**887**
Membership subscriptions	5,564	-	**5,564**	**4,313**
Equipment expenses	2,670	-	**2,670**	**2,675**
Hire of equipment	1,031	-	**1,031**	**1,129**
Software licences and expenses	496	913	**1,409**	**1,633**
Advertising and marketing	10,592	206	**10,798**	**6,164**
Professional fees paid to advisors other than the auditor or examiner				
Accountancy fees other than examination or audit fees	1,080	-	**1,080**	**1,000**
Management fees	16,210	-	**16,210**	**16,105**
Other legal and professional	104	-	**104**	**3,202**
Financial costs				
Bank charges	134	-	**134**	**259**
Depreciation & Amortisation in total for	625	-	**625**	**-**
Support costs before reallocation	**60,674**	**1,442**	**62,116**	**51,731**
Total support costs - Current Year	**60,674**	**1,442**	**62,116**	**51,731**

The basis of allocation of costs between activities is described under accounting policies

Leukaemia & Myeloma Research UK Ltd

Detailed analysis of income and expenditure for the year ended 31 March 2021 as required by the SORP 2015

Prior Year	Current year Unrestricted Funds	Current year Restricted Funds	Prior Year Total Funds
	2021	2021	2020
	£	£	£
Premises Expenses			
Rent and rates	10,737	-	**10,737**
Premises repairs, renewals and maintenance	614	-	**614**
Administrative overheads			
Telephone, fax and internet	2,416	322	**2,738**
Postage	275	-	**275**
Stationery and printing	887	-	**887**
Membership subscriptions	4,252	61	**4,313**
Equipment expenses	2,675	-	**2,675**
Hire of equipment	1,129	-	**1,129**
Software licences and expenses	941	692	**1,633**
Advertising and marketing	5,234	930	**6,164**
Professional fees paid to advisors			
Accountancy fees other than examination or audit fees	1,000	-	**1,000**
Management fees	16,105	-	**16,105**
Other legal and professional	3,202	-	**3,202**
Financial costs			
Bank charges	199	60	**259**
Support costs before reallocation	**49,666**	**2,065**	**51,731**
Total support costs - Prior Year	**49,666**	**2,065**	**51,731**

The basis of allocation of costs between activities is described under accounting policies

Detailed analysis of income and expenditure for the year ended 31 March 2021 as required by the SORP 2015

26 Other Expenditure - Governance costs

Current Year	Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
	2021	2021	2021	2020
	£	£	£	£
Independent Examiner's fees	420	-	**420**	**420**
Total Governance costs	**420**	**-**	**420**	**420**

All the expenditure in the prior year was unrestricted.

27 Total Charitable expenditure

Current Year		Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
		2021	2021	2021	2020
		£	£	£	£
Total direct spending	**B2a**	32,321	1,823	**34,144**	**30,200**
Total charitable trading costs	**B2b**	3,179	-	**3,179**	**-**
Total grantmaking costs	**B2c**	35,000	-	**35,000**	**-**
Total support costs	**B2d**	60,674	1,442	**62,116**	**51,731**
Total Governance costs	**B2e**	420	-	**420**	**420**
Total charitable expenditure	**B2**	**131,594**	**3,265**	**134,859**	**82,351**

Prior Year		Prior Year Unrestricted Funds	Prior Year Restricted Funds	Prior Year Total Funds
		2020	2020	2020
		£	£	£
Total direct spending	**B2a**	20,983	9,217	**30,200**
Total grantmaking costs	**B2c**	-	-	**-**
Total support costs	**B2d**	49,666	2,065	**51,731**
Total Governance costs	**B2e**	420	-	**420**
Total charitable expenditure	**B2**	**71,069**	**11,282**	**82,351**

Leukaemia & Myeloma Research UK Ltd

Detailed analysis of income and expenditure for the year ended 31 March 2021 as required by the SORP 2015

28 Expenditure on raising funds and costs of investment management

Current Year		Current year Unrestricted Funds	Current year Restricted Funds	Current year Total Funds	Prior Year Total Funds
		2021	2021	2021	2020
		£	£	£	£
Agent's costs for fundraising		3,000	-	**3,000**	**5,280**
Cost of fundraising activities		250	-	**250**	**764**
Fundraising trading costs		277	-	**277**	**937**
Marketing & advertising of fundraising		-	-	**-**	**595**
Total fundraising costs	**B1**	**3,527**	**-**	**3,527**	**7,576**

All the expenditure in the prior year was unrestricted.